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Abstract 
Allergic asthma is a chronic inflammatory disease of the lower airways resulting, in many 
cases, from dysregulated Th2 CD4
+
 T-cell responses to inhaled environmental allergens. Allergic 
sensitisation, defined as the induction of Th2 mediated allergen-specific responses for the clinical 
disease, is a key risk factor for asthma. Although current therapies are relatively safe and effective 
at controlling symptoms they do not alter the chronic course of disease. Additionally, there are 
complications associated with chronic use of pharmacologic disease modifiers. Current allergen-
specific immunotherapy aims to reintroduce immune-regulation, in an immune environment where 
regulation has failed. We propose an alternative approach to ‘turn off’ the ‘reservoir’ of pathogenic 
allergen-sensitised effector and memory T cells in established allergic asthma. Previously, it has 
been shown that antigen targeted genetically to be expressed in resting dendritic cells (DC) 
inactivates naïve, memory and effector CD4
+
 and CD8
+
 T cells and this could provide a therapeutic 
approach.  
In this study, I will investigate, using the model allergen ovalbumin (OVA), whether 
genetically-targeting antigen to DC can prevent allergic sensitisation and allergen-induced airway 
inflammation. In addition, the project will determine whether antigen-encoding bone marrow cell 
(BM) transfer under non-myeloablative conditions terminates the established allergic airway 
disease. I also develop a robust murine model of airway inflammation elicited by the major ryegrass 
pollen allergen Lol p 1 in which therapeutic strategies could be tested. In addition, I produce a 
lentivirus vector encoding Lol p 1 which can be used to test therapeutic strategies in conjunction 
with the model developed. 
Transgenic (Tg) mice genetically-engineered to express OVA in DC under control of the 
CD11c promoter (11c.OVA mice) were sensitised with OVA323-339/alum intraperitoneally and 
intranasally challenged with OVA. When splenocytes and mediastinal lymph nodes (MLNs) of 
OVA323-339-sensitised and OVA challenged mice were restimulated in vitro with OVA323-339 peptide, 
IL-4, IL-5, IL-13 levels were significantly decreased in OVA-expressing 11c.OVA transgenic 
relative to control mice. Also little or no inflammatory cell infiltrate was present in bronchoalveolar 
lavage fluid (BALF) in OVA-expressing mice after sensitisation and i.n. challenge. Next, using 
non-myeloablative conditions, OVA-encoding or non-Tg BM was transferred to OVA323-339/alum-
sensitised and OVA-intranasally challenged BALB/c mice. Production of IL-4, IL-5 and IL-13 by 
OVA323-339 restimulated spleen cells and MLN cells was dramatically reduced in recipients of 
OVA-encoding, but not non-Tg, BM. Eosinophil content in BALF and histological evidence of 
mucus hypersecretion were also reduced indicating reversal of pathogenic processes associated with 
dysregulated T-cell responses. 
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For Lol p 1, BALB/c mice were sensitised with crude ryegrass pollen extract (containing Lol p 
1)/alum intraperitoneally. When splenocytes of the sensitised mice were restimulated in vitro with 
ryegrass pollen extract, IL-4, IL-5, IL-13 levels were significantly increased in sensitised vs sham-
sensitised mice. Ryegrass pollen extract/alum-sensitised BALB/c mice also showed significant 
airway inflammation when challenged intranasally with Lol p 1 compared to mice challenged with 
PBS.  
Significantly, when fused with the transmembrane portion of the human transferrin receptor the 
plant allergen Lol p 1 was successfully expressed and targeted to the membrane of mammalian 
cells. When lentiviral vectors encoding Lol p 1 under control of a truncated DC-specific (11c960) 
promoter were generated and tested these effectively transduced hematopoietic progenitor cells 
based on reported gene expression. This indicated that lentiviral vectors encoding a plant allergen 
targeted to DC could be could be successfully engineered. 
From the findings of my studies I conclude that expression of OVA in DC prevents allergic 
priming and consequently respiratory immune responses to respiratory antigen challenge. Allergen-
encoding BM transfer under non-myeloablative conditions terminates established allergic T-cell 
responses and reduces allergen-induced airway inflammation. Lol p 1 is a good model for clinically 
relevant allergic responses and the lentiviral approach could provide a potential robust method for 
the induction of tolerance to terminate allergen-induced airway inflammation.  
  
iii 
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my research higher degree 
candidature and does not include a substantial part of work that has been submitted to qualify for 
the award of any other degree or diploma in any university or other tertiary institution. I have 
clearly stated which parts of my thesis, if any, have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the policy and procedures of The University of Queensland, the thesis be made available 
for research and study in accordance with the Copyright Act 1968 unless a period of embargo has 
been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
  
iv 
 
Publications during candidature 
Research papers 
Anne-Sophie Bergot, Nastasia Monnet, Le Son Tran, Deepak Mittal, Jane Al-Kouba, Raymond J. 
Steptoe, Michele A. Grimbaldeston, Ian H. Frazer and James W. Wells. HPV16-E7 Expression in 
Squamous Epithelium induces TSLP-1 secretion, type 2 ILC infiltration, and the development of 
atopic dermatitis-like lesions. Immunology and Cell biology. (2015) 
Jane AL-Kouba, Andrew Wilkinson, Malcolm Starkey, Jay Horvat, Chantelle Reid, Tracy Doan, 
Ryan Galea,  Janet Davies, Philip M. Hansbro, Raymond J. Steptoe. Allergen-encoding 
hematopoietic progenitor transfer reverses established allergic T-cell responses and treats allergen-
induced airways inflammation. (Manuscript in preparation) 
Poster presentations 
‘Expression of OVA in DC prevents allergic sensitisation and allergen exposure-induced airway 
inflammation.’ 
 Brisbane Immunology Group 13th annual retreat (2012) 
‘Therapeutic induction of tolerance to reverse allergen-induced airway inflammation.’ 
 Brisbane Immunology Group 14th annual retreat (2013) 
‘Therapeutic induction of tolerance to reverse allergen-induced airway inflammation.’ 
 4th annual IMB-ECR symposium (2013) 
‘Therapeutic induction of tolerance to reverse allergen-induced airway inflammation.’ (an update) 
 Poster session for UQDI staff and students (2014) 
‘Therapeutic induction of tolerance to reverse allergen-induced airway inflammation.’ (an update) 
 Brisbane Immunology Group 15th annual retreat (2014) 
‘Therapeutic induction of tolerance to reverse allergen-induced airway inflammation.’ (an update) 
  PAH-Health-Symposium (2014) 
Publications included in this thesis 
No publications included. 
  
v 
 
Contributions by others to the thesis  
Associate Professor Raymond J Steptoe contributed to the design and analysis of all experiments as 
well as the written portion of this thesis. Dr. Janet Davies contributed to the design of some 
experiments and some written portions of this thesis. 
In Chapter 4, University of Newcastle collaborators, Professor Philip Hansbro, Dr. Jay Horvat, and 
Dr. Malcolm Starkey, performed airway hyper responsiveness measurements (Fig. 4.16). Ryan 
Galea assisted in staining BALF samples and their acquisition by flow cytometry in some 
experiments. In Chapter 4, Chantelle Reid performed and analysed experiment in Fig. 4.1. 
Victoria Timbrell purified the plant allergen Lol p 1 used in chapters 4 and 5. 
Statement of parts of the thesis submitted to qualify for the award of another degree 
None. 
  
vi 
 
Acknowledgements  
I would like to express my special thanks and gratitude to my supervisor, Associate Professor 
Raymond Steptoe for his academic guidance, supervision, encouragement, patience and infinite 
help throughout this project. I appreciate every minute you spent in helping me become a better 
scientist. I hope words are sincere enough to show how thankful I am. Special and warm thanks go 
to, my co-supervisor Dr. Janet Davies for guiding, teaching and supporting me.  
My thesis committee members, Professor John Upham, Dr James Wells and Associate 
Professor Simon Phipps, I thank you for the valuable feedback you provided during my PhD 
milestones.  
I would further like to thank The University of Queensland for awarding me the scholarship 
which gave me the opportunity to extend my scientific knowledge and skills. 
I would like to thank the staff of the flow cytometry and histology facility. My sincere thanks 
go to the BRF staff, especially to Michael Osborne for being an extremely helpful and patient 
animal technician. I also like to thank Sandrine Roy for her guidance in microscopy. 
Over the years my colleagues have provided continual scientific help and emotional support. 
My particular thanks to Ryan Galea, Peta Reeves, Michael Anderson, Rajeev Rudraraju, and Kunal 
Bhat. We shared lots of laughs and great times together. 
My sincere gratitude goes to Marilyne Awad, Diana Awad, Anthony Awad, and Justine 
Terrant for being there for me and encouraging me even in the most difficult moments. You are true 
friends and family. 
The warmest thanks goes to my entire beloved family, my father Elie, my mother Jwana, my 
sister Sami-Joe, and my two brothers Judy and Jose. I got this far in my achievements because of 
your support, love, and prayers. You are the most wonderful family anyone could ever hope to 
have. 
To my partner Joe Hanna who has been my rock, thank you so much for your endless love, 
continued support and understanding. I am blessed to have you in my life. 
I apologize if I missed anyone’s name from the list unknowingly. Last, but not least, I give 
thanks to you Lord Jesus for giving me the strength throughout this project and for being with me 
every step of the way. 
  
vii 
 
Keywords 
allergy and immunology, bone marrow transplantation, tolerance, T-cells, non-myeloablative stem 
cell transplantation, targeted gene- expression, lentivirus, gene-therapy 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 0110704, Cellular immunology, 40% 
ANZSRC code: 0110701, Allergy, 40% 
ANZSRC code: 0110708, Transplant immunology, 20% 
 
Fields of Research (FoR) Classification 
FoR code: 1107, Immunology, 100% 
  
viii 
 
TABLE OF CONTENTS 
ABSTRACT........................................................................................................................... i 
DECLARATION BY AUTHOR......................................................................................... iii 
PUBLICATIONS DURING CANDIDATURE.................................................................. iv 
CONTRIBUTION BY OTHERS TO THE THESIS......................................................... v 
ACKNOWLEDGMENTS.................................................................................................... vi 
KEYWORDS......................................................................................................................... vii 
TABLE OF CONTENTS..................................................................................................... viii 
LIST OF FIGURES.............................................................................................................. xii 
LIST OF TABLES................................................................................................................ xvi 
LIST OF ABBREVIATIONS.............................................................................................. xvii 
CHAPTER 1: LITERATURE REVIEW........................................................................... 1 
1.1 Introduction....................................................................................................................... 2 
1.2 Allergic Sensitisation........................................................................................................ 2 
1.2.1 Effect of allergens on airway epithelium........................................................... 3 
1.2.2 Allergen processing and presentation by dendritic cells................................... 4 
1.2.3 Non-airway routes of allergic sensitisation....................................................... 5 
1.2.3.1 Maternal antigen transfer.................................................................... 5 
1.3 Pathogenic immunity in allergic asthma........................................................................... 6 
1.3.1 T cells and cytokine production......................................................................... 6 
1.3.1.1 IL-4..................................................................................................... 6 
1.3.1.2 IL-13................................................................................................... 6 
1.3.1.3 IL-5..................................................................................................... 7 
1.3.1.4 IL-9..................................................................................................... 7 
1.3.2 B cells, IgE production and their role in airway pathology in asthma.............. 7 
1.4 Current therapies for asthma............................................................................................. 8 
1.4.1 Avoidance and drugs......................................................................................... 8 
1.4.2 Specific immunotherapy (SIT).......................................................................... 9 
1.4.2.1 SIT disadvantages and limitations of current therapies...................... 10 
1.5 Immunological tolerance.................................................................................................. 11 
1.5.1 Definition........................................................................................................... 11 
1.5.2 Central tolerance................................................................................................ 11 
1.5.3 Peripheral tolerance........................................................................................... 12 
1.5.3.1 Anergy................................................................................................ 12 
ix 
 
1.5.3.2 Deletion............................................................................................... 13 
1.5.3.3 Regulatory T cells............................................................................... 13 
1.6 BM and HSC transplantation............................................................................................ 14 
1.7 HSCT and autoimmune diseases...................................................................................... 15 
1.8 Gene therapy..................................................................................................................... 16 
1.8.1 Retroviral vectors a limited tool for gene transfer............................................. 16 
1.8.2 Lentiviral vectors as a better tool for gene transfer........................................... 17 
1.8.3 HSCs as a target for gene transfer..................................................................... 18 
1.8.4 Targeted expression to DC to induce tolerance................................................. 19 
1.9 Hypothesis and aims......................................................................................................... 20 
CHAPTER 2: MATERIALS AND METHODS................................................................ 21 
2.1 Mice.................................................................................................................................. 22 
2.1.1 Inbred and congenic strains............................................................................... 22 
2.1.2 Transgenic strains.............................................................................................. 22 
2.2 Cell strains........................................................................................................................ 23 
2.3 Reagents............................................................................................................................ 23 
2.3.1 Peptides.............................................................................................................. 23 
2.3.2 Proteins.............................................................................................................. 23 
2.3.3 Chemicals.......................................................................................................... 24 
2.3.4 Buffers............................................................................................................... 26 
2.3.5 Adjuvants........................................................................................................... 29 
2.3.6 Tissue culture and bacterial culture media........................................................ 29 
2.3.7 Electrophoresis gels........................................................................................... 30 
2.3.8 Cytokines........................................................................................................... 30 
2.3.9 Plasmids............................................................................................................. 31 
2.3.10 Flow cytometry and western blot antibodies................................................... 32 
2.4 Cell culture and animal procedures.................................................................................. 34 
2.4.1 Lymph nodes and spleens.................................................................................. 34 
2.4.2 Bone marrow transplantation............................................................................. 35 
2.4.3 Sensitisations..................................................................................................... 35 
2.4.5 Intranasal challenges.......................................................................................... 35 
2.4.6 Bronchoalveolar lavage..................................................................................... 36 
2.4.7 Serum collection................................................................................................ 36 
2.5 Lentiviral vector design and production.......................................................................... 36 
x 
 
2.5.1 TfR-Lol p 1 and TfR-OVA construct design and plasmid preparation.............  36 
2.5.2 Restriction digests, DNA preparation, ligation, transformation........................ 37 
2.5.3 Ligation confirmation and sequencing.............................................................. 38 
2.5.4 Transient transfections....................................................................................... 39 
2.5.5 Lentivirus production and titration.................................................................... 40 
2.5.6 AUTOMACS enrichment of c-kit
+
 hematopoietic stem and progenitor cells... 41 
2.5.7 Lentiviral transduction of c-kit
+
 HSPC and in vitro DC differentiation............ 41 
2.6 Western blot...................................................................................................................... 42 
2.6.1 Sample preparation............................................................................................ 42 
2.6.2 Electrophoresis and blotting.............................................................................. 42 
2.7 Flow cytometry................................................................................................................. 43 
2.7.1 Surface staining................................................................................................. 43 
2.8 In vivo and in vitro assays................................................................................................. 44 
2.8.1 In vitro lymphocyte restimulation..................................................................... 44 
2.8.2 Cytokine enzyme-linked immunosorbent assay (ELISA)................................. 44 
2.8.3 Airway hyper responsiveness measurement...................................................... 45 
2.8.4 Lung histology................................................................................................... 45 
2.8.5 Histological analysis of respiratory tissues........................................................ 46 
2.9 Statistical analysis............................................................................................................. 46 
CHAPTER 3:TRANSGENIC EXPRESSION OF AN ALLERGEN IN DC 
PREVENTS SENSITISATION AND ALLERGEN-INDUCED 
AIRWAY INFLAMMATION..................................................................... 47 
3.1 Introduction....................................................................................................................... 48 
3.2 Results............................................................................................................................... 50 
3.2.1 OVA expression in DC prevents allergen-specific priming.............................. 50 
3.2.2 OVA323-339  induces a weak airway inflammatory response............................. 53 
3.2.3 OVA is superior to OVA323-339 for induction of airway inflammation in 
OVA/alum sensitised mice................................................................................ 56 
3.2.4 Sensitisation and challenging system optimization........................................... 58 
3.2.5 OVA expression in DC prevents OVA323-339 priming...................................... 63 
3.2.6 OVA expression in DC prevents OVA323-339 priming and OVA-elicited 
airways inflammation........................................................................................ 65 
3.3 Discussion......................................................................................................................... 72 
3.4 Future directions............................................................................................................... 77 
xi 
 
 
CHAPTER 4:TRANSFER OF ANTIGEN-ENCODING BONE MARROW 
REVERSES ESTABLISHED TH2 IMMUNITY AND REDUCES 
ALLERGEN-ELICITED AIRWAY INFLAMMATION.................... 78 
4.1 Introduction....................................................................................................................... 79 
4.2 Results............................................................................................................................... 81 
4.2.1 Transfer of OVA encoding BM reverses Th2 responses and prevents airway 
inflammation..................................................................................................... 81 
4.2.2 Tolerance induced by transfer of OVA-encoding BM is antigen-specific....... 92 
4.2.3 Transfer of OVA-encoding BM prevents exacerbation of established Th2 
responses and reduces airways inflammation................................................... 97 
4.2.4 Transfer of OVA-encoding BM Reverses airway hyper responsiveness.......... 105 
4.3 Discussion......................................................................................................................... 107 
4.4 Future directions............................................................................................................... 112 
CHAPTER 5:DEVELOPMENT OF A GRASS POLLEN ALLERGEN-ENCODING 
LENTIVIRAL VECTOR FOR GENETIC ENGINEERING OF 
HEMATOPOIETIC STEM AND PROGENITOR CELLS..................... 113 
5.1 Introduction....................................................................................................................... 114 
5.2 Results............................................................................................................................... 116 
5.2.1 Ryegrass extract is highly allergenic in BALB/c mice...................................... 116 
5.2.2 Intransal challenge with Lol p 1 induces airway inflammation in RGP-
sensitised mice................................................................................................... 118 
5.2.3 Optimization for the airway inflammatory response in sensitised mice............ 122 
5.2.4 Construction of grass pollen encoding plasmids............................................... 129 
5.2.5 TfR-Lol p 1 and TfR-OVA is expressed in mammalian cells........................... 134 
5.2.6 TfR-Lol p 1 and TfR-OVA is expressed on the membrane of mammalian 
cells.................................................................................................................... 137 
5.2.7 Lentivirus production......................................................................................... 141 
5.2.8 HSPC transduction and in vitro DC differentiation.......................................... 145 
5.3 Discussion......................................................................................................................... 152 
5.4 Future directions............................................................................................................... 158 
CHAPTER 6: CONCLUDING REMARKS...................................................................... 159 
CHAPTER 7: REFERENCES............................................................................................. 164 
APPENDIX I......................................................................................................................... 202 
xii 
 
LIST OF FIGURES 
Figure 2.1 OVA construct..................................................................................... 22 
Figure 3.1 T-cell tolerance specifically to a determinant within the expressed 
OVA transgene.................................................................................... 52 
Figure 3.2 Absence of strong airway inflammatory response when using 
OVA323-339 i.n challenge....................................................................... 54 
Figure 3.3 Different batches of OVA323-339 give similar results after intranasal 
challenges............................................................................................. 55 
Figure 3.4 OVA vs. OVA323-339 in intranasal challenges...................................... 57 
Figure 3.5 Different sensitisation and challenge regimes tested in BALB/c 
mice...................................................................................................... 59 
Figure 3.6 Comparison of different challenge regimes after OVA323-339 
sensitisation.......................................................................................... 60 
Figure 3.7 Analysis of cellular accumulation in BALF after different intranasal 
challenge regimes in 11c.OVA mice................................................... 61 
Figure 3.8 Cytokine production of the different challenge regimes in 11c.OVA 
mice..................................................................................................... 62 
Figure 3.9 In vitro induction of a Th2 response in cultures from OVA323-339 
sensitised non-transgenic mice after OVA323-339 stimulation............. 64 
Figure 3.10 In vitro stimulation of splenocytes with OVA323-339 or OVA induces 
Th2 cytokine production...................................................................... 67 
Figure 3.11 In vitro stimulation of MLNs with OVA323-339 or OVA induces an 
amplified Th2 response........................................................................ 68 
Figure 3.12 OVA intranasal challenges leads to profound eosinophil infiltrate in 
BALF of sensitised non-transgenic mice............................................. 69 
Figure 3.13 Transgenic mice protected from the effect of OVA intranasal 
challenges............................................................................................. 70 
Figure 3.14 Quantitative analysis of the stained lung sections showing 11c.OVA 
mice protected from OVA challenges................................................. 71 
Figure 4.1 High levels of engraftment are achieved with immune-preserving 
conditioning......................................................................................... 85 
Figure 4.2 Cytokine production by MLN cell cultures of OVA+ve BM 
recipients as an indication of the local response to OVA323-339 
stimulation............................................................................................ 86 
xiii 
 
Figure 4.3 Cytokine production by spleen cells of OVA-ve and OVA+ve BM 
recipients.............................................................................................. 87 
Figure 4.4 Cellular infiltrates in BALF after OVA intranasal challenge are 
reduced in OVA+ve BM recipients..................................................... 88 
Figure 4.5 Minimal effect of OVA intranasal challenge on alveolar 
macrophages and neutrophils in BALF............................................... 89 
Figure 4.6 Protective effect of 11c.OVA BM transfer on airway and lung 
inflammation in OVA challenged mice............................................... 90 
Figure 4.7 Quantitative analysis of lung histology reflects the protective effect 
of 11c.OVA BM.................................................................................. 91 
Figure 4.8 Preservation of Th2 responses to RGP after OVA+ve BM transfer.... 94 
Figure 4.9 Spontaneous production of IL-5 and IL-13 in unstimulated cultures 
of MLNs from RGP-challenged mice.................................................. 95 
Figure 4.10 Development of airway inflammatory response in RGP-challenged 
mice after transfer of OVA+ve BM..................................................... 96 
Figure 4.11 Cytokine production by MLNs of OVA+ve BM recipients as an 
indication of the reduced respiratory T-cell response to OVA323-339.... 100 
Figure 4.12 Reduced cytokine production by spleen cells of OVA+ve BM 
recipients indicates diminished systemic response to OVA323-339 
stimulation............................................................................................ 101 
Figure 4.13 Analysis of cellular recovery in BALF after OVA intranasal 
challenge.............................................................................................. 102 
Figure 4.14 Effect of 11c.OVA BM on airway and lung inflammation following 
OVA intranasal challenge.................................................................... 103 
Figure 4.15 Quantitative analysis of the stained lung sections reflects the trend 
of decreased inflammation observed in 11c.OVA recipients.............. 104 
Figure 4.16 Reduction of airway hyper responsiveness in 11c.OVA BM 
recipients.............................................................................................. 106 
Figure 5.1 Th2 cytokine production in response to RGP stimulation................... 117 
Figure 5.2 Lol p 1 intranasal challenge leads to substantial eosinophil infiltrate 
after RGP sensitisation......................................................................... 119 
Figure 5.3 Inflammatory cell infiltrate and mucus hyper secretion after Lol p 1 
intranasal challenge in RGP-sensitised mice....................................... 120 
Figure 5.4 Levels of IgE detected in serum of RGP-sensitised and Lol p 1 121 
xiv 
 
intranasally-challenged mice............................................................... 
Figure 5.5 Elevated production of Th2 cytokines in the site of local challenges 
with the allergen................................................................................... 124 
Figure 5.6 No difference in Th2 cytokine production in stimulated splenocytes 
regardless of number of Lol p1 challenges.......................................... 125 
Figure 5.7 Presence of Th2 cytokines in BALF of Lol p 1 challenged and RGP-
sensitised mice..................................................................................... 126 
Figure 5.8 A higher eosinophil proportion with 2x Lol p 1 intranasals than with 
1 x Lol p 1 intransals............................................................................ 127 
Figure 5.9 Robust mucus hyper secretion after 2x Lol p 1 intranasal challenge.. 128 
Figure 5.10 Agarose gels for restriction digests...................................................... 131 
Figure 5.11 Cloning strategy for pRRLsin.CMV.TfR-Lolp1.IRES.GFP............... 132 
Figure 5.12 Cloning strategy for pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1α-
tdTomato.............................................................................................. 133 
Figure 5.13 Western blots showing expression of Lol p 1 or OVA in mammalian 
cells...................................................................................................... 136 
Figure 5.14 Membrane expression of Lol p 1 or OVA in mammalian cells 
verified by flow cytometry................................................................... 139 
Figure 5.15 Not APC targeted, high- membrane expression of Lol p 1 not OVA 
is slightly toxic in mammalian cells..................................................... 140 
Figure 5.16 Length of plasmid, rather than length of insert, affects virus titer....... 143 
Figure 5.17 Increasing DNA amount does not lead to higher transfection rate...... 144 
Figure 5.18 Purity of c-kit-enriched HSPCs........................................................... 147 
Figure 5.19 GFP and td-Tomato expression day one post-transduction................. 148 
Figure 5.20 GFP expression a few days post-transduction..................................... 149 
Figure 5.21 td-Tomato expression and Lol p 1 membrane expression a few days 
post-transduction.................................................................................. 150 
Figure 5.22 td-Tomato expression and OVA membrane expression a few days 
post-transduction.................................................................................. 151 
Figure I.1 Annotated TfR-Lolp1 sequence........................................................... 203 
Figure I.2 Translated TfR-Lolp1 sequence........................................................... 204 
Figure I.3 Non-specific binding of streptavidin-APC to PI
+ve
 HEK293T cells.... 205 
Figure I.4 Sequencing analysis of pRRLsin.11c960.TfR-
OVA.IRES.GFP.Ef1α.td-Tomato........................................................ 209 
xv 
 
Figure I.5 Sequencing analysis of pRRLsin.11c960.TfR-
Lolp1.IRES.GFP.Ef1α.td-Tomato....................................................... 212 
Figure I.6 Sequencing analysis of pRRLsin.CMV.TfR-Lolp1.IRES.GFP........... 215 
Figure I.7 Sequencing analysis of pRRLsin.CMV.TfR-OVA.IRES.GFP............ 220 
Figure I.8 Total BAL counts……………………………………………………. 221 
Figure I.9 Summary of Th2 cytokine responses and BAL cell counts and 
percentages........................................................................................... 222 
 
  
xvi 
 
LIST OF TABLES 
Table 2.1 List of flow cytometry antibodies..................................................... 32 
Table 2.2 List of secondaries............................................................................. 34 
Table 2.3 List of western blot antibodies.......................................................... 34 
Table 2.4 ELISA Antibodies and Standards..................................................... 45 
Table 5.1 Effect of length of plasmid on virus titer.......................................... 143 
Table 5.2 Effect of length of insert on virus titer of 
pRRLsin11c960….IRES.GFP.EF1α.td-Tomato............................... 143 
Table 5.3 Rate of transfection and cell viability of the three different 
plasmids............................................................................................. 144 
Table 5.4 Amount of DNA effect on transfection............................................. 144 
Table I.1 Total BAL counts for Figure 3.12..................................................... 221 
Table I.2 Summary of results for Chapter 3..................................................... 222 
  
xvii 
 
LIST OF ABBREVIATIONS 
2-ME  2- mercaptoethanol 
AEC  airway epithelial cells 
Ag  antigen 
AHR  airway hyper responsiveness  
AICD  activation induced cell death 
APC  antigen presenting cell 
ASM  airway smooth muscle 
BALF  bronchoalveolar lavage fluid 
Bcl2  B-cell lymphoma/leukemia-2 
BCR  B cell receptor 
Bet v  birch pollen allergen 
BM  bone marrow 
BMDC bone marrow-derived DC 
BMT  bone marrow transplantation 
Breg  regulatory B-cell 
Ca  calcium 
CCR  chemokine receptor 
CD  cluster of differentiation 
cDC  conventional dendritic cell 
cDNA  complementary DNA 
CFA  complete Freud’s adjuvant 
CFSE  carboxyfluorescein diacetate succinimidyl ester 
CMV  cytomegalovirus 
CTL  cytotoxic T lymphocytes 
CTR  C-type lectin receptors 
DC  dendritic cell 
DNA  deoxyribonucleic acid 
DNA  Deoxyribonucleic acid 
EC  epithelial cell 
EDTA  Disodium ethylene diamine tetra-acetate 
Ef1α  elongation factor-1 alpha 
EGF  epidermal growth factor 
eGFP  enhanced green fluorescent protein 
ELISA  enzyme-linked immunosorbent assay 
xviii 
 
FACS  fluorescence-activated cell sorting 
FasL  TNF superfamily receptor 6 ligand 
FCεRI  high affinity IgE receptor 
FITC  fluorescein isothiocyanate 
FSC  forward scatter 
GATA  family of transcription factors 
GCH  goblet cell hyperplasia 
GM-CSF granulocyte macrophage colony stimulating factor 
Gr-1  myeloid differentiation antigen 
GVHD  graft-versus-host disease 
H&E  hematoxylin and eosin stain 
H-2
d
  MHC haplotype 
HDM  house dust mite 
HEK  human embryonic kidney cells 
HPC  hematopoietic progenitor cells  
HPLC  high performance liquid chromatography 
HRP  horseradish peroxidase 
HSC  hematopoietic stem cells 
HSPC  hematopoietic stem and progenitor cells 
i.n /IN  intranasal 
i.p.  intraperitoneally 
i.v.  intravenous 
ICAM  intracellular adhesion molecule 
ICS  inhaled corticosteroids 
IFN  interferon 
Ig  immunoglobulin 
IgE  immunoglobulin E 
IL  interleukin 
ILC  innate lymphoid cell 
IRES  internal ribosome entry site 
Kb  kilobases 
LFA-1  lymphocyte function-associated antigen 1 
LN  lymph node 
Lol p   Lolium perenne 
LPS  lipopolysaccharide  
xix 
 
LT  leukotriene  
LTR  long terminal repeat 
Lyn  a src family tyrosine-protein kinase 
MCC  moth cytochrome c 
MCP  monocyte chemotactic protein 
MD-2  myeloid differentiation protein-2 
MHC  Major histocompatibility complex 
MIP  macrophage inflammatory protein 
miRNA micro-RNA 
MLCK  myosin light chain kinase 
MLNs  mediastinal lymph nodes 
MMP  matrix metalloprotease 
MOG  myelin- oligodendrocyte glycoprotein 
mRNA  messenger RNA 
MS  multiple sclerosis 
MUC  mucin 
MyD88 myeloid differentiation factor 88 
NADPH nicotinamide adenine dinucleotide phosphate 
NLR  NOD-like receptor 
NOD  nucleotide oligomerization domain 
OVA  ovalbumin 
OVA323-339 MHC ClassII restricted epitope of OVA 
PAMP  pathogen associated molecular pathogens 
PAS  periodic acid schiff staining 
PBMC  peripheral blood mononuclear cell 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PD1  programmed death 1 
pDC  plasmacytoid dendritic cell 
PG  prostaglandin 
Phl p  Phleum pratense 
PI  propidium iodide 
PMA  phorbol myristate acetate 
pOVA  OVA peptide 
PRR  pathogen recognition receptors 
xx 
 
RGP  ryegrass pollen extract 
RNA  ribonucleic acid  
RNA  ribonucleic acid 
ROS  reactive oxygen species 
RT  room temperature 
SIGLEC-F a sialic acid-binding Ig superfamily receptor 
SIT  specific immunotherapy 
STAT  signal transducer and activator of transcription 
T-Bet  T-Box protein expressed in T cells 
TCR  T-cell receptor 
td-Tomato tandem tomato fluorescent protein 
TfR  transferrin receptor 
Tg  transgenic 
TGF  transforming growth factor 
Th  T-helper 
TLR  toll-like receptor 
TNF  tumour necrosis factor 
TNFR  Tumor necrosis factor receptor 
TRAIL TNF-related apoptosis-inducing ligand 
Treg  regulatory T-cell 
TSA  tissue specific antigen 
TSLP  thymic stromal lymphopoietin 
VCAM vascular cell adhesion molecule 
VEGF  vascular endothelial growth factor 
WT  wild type 
 
1 
 
 
 
 
 
CHAPTER 1: 
LITERATURE REVIEW 
  
2 
 
1.1  Introduction 
In developed countries, allergic diseases affect 25–40% of the population (Macaubas et al. 
2006). The prevalence of asthma in the adult population in developed countries is approximately 
10% (Australian Health and Welfare report November, 2011) and has increased dramatically 
worldwide by >20% every 10 years, especially in children (Umetsu et al. 2002, Brozek et al. 2015). 
Recently, between 2011 and 2014, the prevalence of asthma has increased by >40% (The Global 
Asthma Report 2014). The Global Initiative for Asthma defines asthma as a “chronic inflammatory 
disorder of the airways that causes recurrent episodes of wheezing, breathlessness, chest tightness, 
and coughing, particularly at night or in the early morning.” (http://www.ginasthma.org.) 
Asthma onset is most common during childhood, and in many cases the symptoms persist or 
appear again in adulthood. These patients are the ones most likely to be in need of therapy. 
(Locksley 2010). 
Asthma is known to be a heterogeneous disease with the subclassifaction of four distinct 
clinical phenotypes (Bradding et al. 2010) which can be divided broadly into two categories 
eosinophilic and non-eosinophilic. Atopic asthma (allergic asthma), which is the most common 
form (Court et al. 2002), is characterized by high levels of allergen-specific IgE and positive skin 
prick tests upon provocation by allergen (e.g. house-dust mite, cat, cockroach or pollen) and a 
preponderance towards eosinophilia in airway tissue (Amin et al. 2000). A Th2 cytokine milieu 
prevails in subjects with eosinophilic asthma (Quaedvlieg et al. 2006). The second broad category 
of asthma compromises disease where there is no clear association with atopy. In this group of 
asthmatic patients, no increase in allergen-specific or total IgE can be found in the blood (van 
Houwelingen et al. 2002) and neutrophilia predominates in the inflammatory infiltrates in lung and 
airways tissues. Higher levels of endotoxin increase pro-inflammatory cytokine production (IL-8 
and IL-1β) in non-eosinophilic subjects (Simpson et al. 2007). However, they do not have 
distinguished cytokine measurements compared to healthy controls (Quaedvlieg et al. 2006). As a 
result, despite similar clinical respiratory symptoms in both categories, they are associated with 
different pathological manifestations of airways inflammation (Amin et al. 2000). 
1.2  Allergic Sensitisation 
Atopic asthma is initiated at mucosal surfaces where epithelial barriers are breached by 
environmental aeroallergens sources, such as house dust mite (HDM), grass pollen and animal 
dander. This induces cytokine release (particularly TSLP, IL-25, IL-33 and GM-CSF) as a result of 
the interaction between innate pattern recognition receptors on epithelium and resident lung 
dendritic cells.  
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1.2.1 Effects of allergens on airway epithelium 
Many clinically-relevant allergens, such as ragweed pollen, possess nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase activity that leads to the generation of reactive oxygen 
species (ROS) that can act to disrupt airway epithelium (Boldogh et al. 2005). The dust mite protein 
Der p 1 and spores from Aspergillus spp. (Tai et al. 2006) possess serine and cysteine protease 
activity that cleaves tight junctions, such as those formed by occludin proteins in airway epithelia. 
Cleavage of tight junctions facilitates paracellular access of allergens to sub-epithelial cells. Other 
allergens, however, such as Phl p 1 do not appear to exert proteolytic activity, but can disrupt 
epithelial integrity by inducing expression of IL-8, IL-6 and TGF-β, mitogen-activated protein 
kinases (MAPK) p38 and extracellular signal-regulated kinases (Erk) activation in airway epithelia 
(Roschmann et al. 2009). Cockroach-derived allergens (e.g. Bla g 1 and Bla g 2), can also act 
indirectly to increase epithelial vascular permeability through the angiogenic cytokine vascular 
endothelial growth factor (VEGF) (Antony et al. 2002). This can lead to Th2-cell sensitisation to 
the allergens (Lee et al. 2004). Epithelial cells (ECs) express many pattern recognition receptors 
(PRRs) such as Toll-like receptors (TLRs) and can recognize pathogen-associated molecular 
patterns (PAMPs) present on allergens. Such interactions between PRRs and allergens can act to 
promote Th2 sensitisation (Van Rijt and Lambrecht 2005). In this way, ECs create a cross-talk 
between innate signals and adaptive immunity (Wan et al. 1999, Soumelis et al. 2002, Saenz et al. 
2008). LPS, for instance, induces Th2 responses through TLR-4 signalling only when administered 
with an allergen at low doses (Eisenbarth et al. 2002). However, high LPS doses tend to have a 
different effect by shifting the response to become Th1 focussed (Eisenbarth et al. 2002). HDM can 
trigger TLR4 and dectin-2 directly on DC to induce signalling through MyD88 (Lewkowich et al. 
2008, Barrett et al. 2009, Horner 2010, Marichal et al. 2010, Barrett et al. 2011, Page et al. 2011). In 
addition, Der p 2, an allergen from HDM, is able to trigger TLR4 signalling by mimicking the 
TRL4 co-receptor MD-2 (Trompette et al. 2009). Pollen extracts have also been shown to trigger 
TLR-4 on bone marrow-derived (BM)-DC (Kamijo et al. 2009).  
As a result of allergen interaction with epithelium a Th2-directing environment rich in 
innate ‘pro-Th2’ cytokines such as thymic stromal lymphopoietin cytokine (TSLP), IL-25, IL-33, 
and GM-CSF can be generated (Hammad et al. 2011). TSLP can also be secreted under 
inflammatory conditions by mast cells and DC (Willart et al. 2011). TSLP can upregulate 
expression of CD80, CD86, HLA-DR on human peripheral blood CD11c
+
 DC leading to the 
production of thymus- and activation-regulated chemokine (TARC) and macrophage-derived 
chemokine (MDC), both Th2-attracting chemokines (Soumelis et al. 2002). Moreover, TSLP-
treated DC upregulate OX40L (Ito et al. 2005, Seshasayee et al. 2007) and promote production of 
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Th2 cytokines by naïve human CD4
+
 T cells (Soumelis et al. 2002, Liu et al. 2007). In transgenic 
mouse models, overexpression of TSLP in lung tissues leads to spontaneous development of 
allergic inflammation (Zhou et al. 2005, Headley et al. 2009). IL-25 was initially thought to be 
produced only by differentiated Th2 cells (Fort et al. 2001, Wang et al. 2007). However, it is also a 
produced by activated eosinophils, mast cells, and most importantly, epithelial cells 
(Angkasekwinai et al. 2007, Saenz et al. 2008, Hammad et al. 2009). IL-25 acts through the adaptor 
protein CIKS (also known as Act1) (Claudio et al. 2009). Systemic administration of IL-25 protein 
(Fort et al. 2001), or its overexpression (Kim et al. 2002) results in eosinophilia, high IgE levels, 
and several asthma-like changes in respiratory tissues. Administration of neutralizing antibody 
against IL-25 reduces these effects (Ballantyne et al. 2007). Another important orchestrator of the 
cells responsible for allergies, the pro-cytokine IL-33 matures upon cleavage by caspase-1 produced 
by mucosal epithelial cells (Moussion et al. 2008). It induces the production of IL-5 and IL-13 via 
the IL-1R/TLR family member ST2 and intraperitoneal administration induces several 
immunological changes, including peripheral blood eosinophilia, and lymphocytosis (Schmitz et al. 
2005). Interestingly, mice with experimental allergic airway inflammation or patients with asthma 
show substantial levels of IL-33 in the lungs (Kearley et al. 2009, Préfontaine et al. 2009). Finally, 
epithelial cells can produce GM-CSF when exposed to allergens (Österlund et al. 2009, Österlund et 
al. 2011) and this expands DC locally to increase sensitisation and develop allergic airway 
inflammation (Stämpfli et al. 1998). Th2 sensitisation was shown to be induced either through 
airway exposure to HDM (Fattouh et al. 2005) or through the stimulation of BMDC grown in the 
presence of GM-CSF (Zhou et al. 1996, Lambrecht et al. 2000).  
1.2.2 Allergen processing and presentation by dendritic cells 
During sensitisation, allergen is processed after uptake by DC and then presented to T 
lymphocytes and possibly B cells. DC are classified under two broad categories: conventional 
(cDC) and plasmacytoid (pDC). Conventional DC have a strong capability to capture antigens 
which enables them to stimulate T cells. These major APC comprise a very heterogeneous group of 
cells expressing high levels of MHC class II and integrin CD11c on their cell surface, but also other 
adhesion molecules, such as LFA-1 (CD11a), LFA-3 (CD58), ICAM-1 (CD54), ICAM-2 (CD50), 
and ICAM-3 (CD102). Findings in mice demonstrated that antigen presentation by DC is capable of 
inducing allergic airway sensitisation, leading to an asthma-like state upon antigen re-exposure 
(Schröder et al. 2007). Conventional DC, in particular, the CD11b
+
CD8
–
 subset, continuously 
sample the environment and, constitutively migrate in a CC-chemokine receptor 7 (CCR7)- and 
CCR8-dependent manner to local lymph nodes (Vermaelen et al. 2004). CD8
+
, lymphoid resident, 
and migratory CD103
+
 cDC subsets are known for cross presenting exogenous antigens to CD8
+
 T 
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cells (Desch et al. 2011). Recently, CD103
+
 cDC have been shown to promote tolerance to airway 
allergen exposure (Khare et al. 2013). For Th2 cell-mediated immunity in allergy, priming is mainly 
performed by CD11b
+
 cDC (Plantinga et al. 2013). Here, DC present antigen in association with the 
major histocompatibility complex class II molecule on the cell surface to naïve T cells resulting in 
T-cell activation and differentiation (Banchereau et al. 1998). Evidence of this specifically in the 
respiratory system was presented by Lambrecht and co-workers where transferred moth cytochrome 
c (MCC)-specific T cells proliferated in the mediastinal lymph nodes soon after antigen presenting 
DC were intratracheally introduced (Lambrecht et al. 2000, Lambrecht 2005). The importance of 
DC in mediating Th2 responses to inhaled allergens was exemplified by conditional depletion of 
lung DC in mice which abolished the Th2 cell-mediated immunity to the allergen (van Rijt et al. 
2005, Hammad et al. 2010). This contrasts with another population of DC, CD11c
int
 plasmacytoid 
DC which express siglec-H, and bone-marrow stromal antigen-1 (BSTA-1) (de Heer et al. 2004, 
GeurtsvanKessel et al. 2008, Kool et al. 2009, Lambrecht et al. 2009). Evidence suggests that pDC 
not only induce Th1 responses, they can also prevent Th2 sensitisation and induce tolerance 
(Lambrecht et al. 2000, Eisenbarth et al. 2002, de Heer et al. 2004, Ochando et al. 2006). Recent 
studies investigated the tolerogenic capacities of three newly described subsets of pDC and 
confirmed the tolergonic effects of two of the subsets (CD8α+β- and CD8α+β+) (Lombardi et al. 
2012). However, the CD8α- β- subset lacks this capacity in experimentally induced allergic asthma 
and is more capable in priming CD4
+
Tcells in vitro (Lombardi et al. 2012). 
When an inflammatory response arises another subset of DC is formed from monocytes that 
migrate to the lung upregulate their MHC class II glycoproteins and CD11c (Robays et al. 2007). 
This subset is known as monocyte-derived DC (mo-DC) that are able to induce Th2 priming in the 
presence of high-doses of an allergen; otherwise mo-DC act as orchestrators of the allergic response 
in the lung by attracting effector Th2 cells through chemokine production (Medoff et al. 2009, 
Plantinga et al. 2013). 
1.2.3 Non-airway routes of allergic sensitisation 
1.2.3.1 Maternal antigen transfer 
In mice, studies have shown that offspring can develop allergic diseases following maternal 
exposure to allergens (Herz et al. 2001). In contradictory studies, maternal sensitisation reduced or 
inhibited allergy in offspring (Jarrett et al. 1979, Jarrett et al. 1983, Victor Jr et al. 2003). 
Alternatively, some consider development of atopy to reflect failure to redirect Th2-skewed fetal 
responses in early life (Delespesse et al. 1998, Adkins et al. 2002, Chen et al. 2006, Woodfolk 
2007). A study on a significant number of children born of mothers with asthma, showed that 
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maternofetal transfer of IgE underlies the presence of allergen-specific IgE in cord blood and does 
not reflect sensitisation in utero (Bønnelykke et al. 2008).  
1.3  Pathogenic immunity in allergic asthma 
Sensitised individuals may or may not develop allergic asthma, but they are more prone to 
do so than non-sensitised individuals (Sohi et al. 2008). Th2 cytokines such as IL-4, IL-5, IL-9, and 
IL-13 mediate many of the effects associated with asthma in airways and lungs including 
eosinophilia, increased mucus secretion, smooth muscle hyperplasia, and hypercontractility 
(reviewed by (Finkelman et al. 2010)). 
1.3.1 T cells and Cytokine production 
1.3.1.1 IL-4 
IL-4 is required for development of allergic inflammation as shown in a study where in 
response to allergen, IL-4-deficient mice had significantly decreased allergic inflammation 
compared to wild-type mice (Brusselle et al. 1994). IL-4 contributes to pathology by promoting a 
Th2 response (Finkelman et al. 1988, Coyle et al. 1995, Corry et al. 1996, Cohn et al. 1997, 
Henderson et al. 2000, Finkelman et al. 2010) by inducing Th2 cell differentiation and expansion, 
rather than as a direct effector (Kaplan et al. 1996). Conversely, IL-4 suppresses Th1 cell 
development (Street et al. 1990). Importantly, IL-4 is essential for inducing isotype switching of B 
cells that leads to IgE production (Finkelman et al. 1988). 
1.3.1.2 IL-13 
The importance of IL-13 in airway inflammation was evidenced in murine asthma models 
where its neutralization inhibits the characteristics of asthma after antigen exposure (Grunig et al. 
1998, Wills-Karp et al. 1998). This has also been observed in IL-13-deficient mice (Walter et al. 
2001). Administration of IL-13 is sufficient to induce infiltration of eosinophils, mucus 
hypersecretion and airway hyper responsiveness in mice (Grunig et al. 1998, Wills-Karp et al. 1998, 
Nakajima et al. 2007).  
IL-13 binds to a polymeric receptor, shared with IL-4, consisting of IL-4Rα and IL-13Rα1 
subunits (Hart et al. 1999, Wills-Karp et al. 2003). IL-13 induces hyper responsiveness of rabbit, 
rat, and human small airways in precision cut lung slices (Grunstein et al. 2002, Cooper et al. 2009, 
Cooper et al. 2010). Gene expression profiling using microarrays (Woodruff 2008) and other 
studies demonstrate the crucial role of IL-13 for allergen-induced AHR (Nath et al. 2007, Damera et 
al. 2011). IL-13 induces the production of eotaxin-1/CCL11 in human ASM in a STAT6-dependent 
manner (Peng et al. 2004) and in combination with IL-4 and TNF-α, IL-13 induces thymus and 
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activation-regulated chemokine (TARC/CCL17), which is involved in dendritic cell and Th2 cell 
recruitment to the airways (Faffe et al. 2003). IL-13 also increases the expression of the oxytocin 
receptor, which promotes force generation and airway narrowing (Xia et al. , Amrani et al. 2010).  
1.3.1.3 IL-5  
Interleukin-5 is a hematopoietic cytokine that has important effects on both eosinophils and 
basophils. A large number of cell types produce IL-5, including CD4
+
 Th2 lymphocytes (Ying et 
al., 1995), eosinophils (Dubucquol et al., 1994) and basophils (Phillips et al., 2003). IL-5 is required 
for the differentiation and maturation of eosinophils in the bone marrow (Shalit et al. 1995, 
Sitkauskiene et al. 2004), migration to tissue sites (Menzies-Gow et al. 2004), and prevention of 
eosinophil apoptosis (Ochiai et al. 1997). IL-5 also plays a role in the development, metabolism, 
and function of basophils (Gauvreau et al. 2009). Several lines of experimental evidence support the 
possible role of IL-5 in the pathogenesis of asthma. Firstly, IL-5 mRNA is increased in bronchial 
biopsies taken from asthmatics (Hamid et al. 1991). Secondly, IL-5 mRNA correlates with clinical 
severity (Humbert et al. 1997). Finally, inhaled bronchial provocation with allergen causes an 
increase in IL-5 mRNA (Robinson et al. 1999). These data suggest that IL-5 is present in patients 
with asthma and is inducible by acute allergen exposure, making it a possible target for 
intervention. Indeed, mepolizumab (anti-IL-5) trials recently showed some efficacy in a subset of 
patients with “eosinophilic” asthma (Bel et al. 2014, Ortega et al. 2014). 
1.3.1.4 IL-9 
IL-9 plays a role in asthma pathogenesis (Hauber et al. 2004) where it increases 
susceptibility to development of  airway hyper responsiveness (Nicolaides et al. 1997). Further 
studies have examined bronchial biopsy samples from asthmatics and found expression of IL-9 was 
increased compared to healthy controls (Shimbara et al. 2000). Transgenic overexpression of IL-9 
induces similar morphological changes to allergic asthma (Temann et al. 1998), But intriguingly, 
IL-9-deficiency in mice appears to have insignificant effects on eosinophils, T cell development, 
and IgE response (Townsend et al. 2000).  
1.3.2 B cells, IgE production and their role airway pathology in asthma 
Mature naïve B cells capture antigen directly or communicate with DC that present the 
antigen to B cells in lymphoid organs. For IgE production, class-switching to IgE is required and 
this is promoted by IL-4/IL-13 signalling through signal transducer and activator of transcription 
(STAT) 6, along with CD40 ligation signalling through nuclear factor κB (Pène et al. 1988, 
Dullaers et al. 2012). Accordingly, mice deficient in CD40 or IL-4 showed decreased levels of IgE 
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(Kuhn et al. 1991, Kawabe et al. 1994). Once produced by B cells, IgE can bind to tetrameric (αβγ2) 
high-affinity receptors (FcεRI) on the surface of mast cells and basophils, which then become 
“sensitised” (Henry et al. 1997). Allergen binding to the IgE–FcεRI complex can then induce a 
classic acute allergic reaction (Sin et al. 2011). Mast cells produce chemokines, such as CC-
chemokine ligand (CCL) 3 (macrophage inflammatory protein (MIP)-1α) (Prussin et al. 2006), 
which have the ability to stimulate histamine release from mast cells and basophils (Teran 
2000).The degranulation of basophils also produces histamine, eicosanoids, LTs, IL-4, and IL-13 
(Schroeder et al. 2001, Marone et al. 2005). The release of these mediators causes increased 
neutrophil and eosinophil chemokinesis and chemotaxis, increased vascular permeability, mucus 
secretion, and cholinergic-independent bronchospasm leading to anaphylaxis (Kaliner et al. 1982). 
Eosinophils in the airways release cytotoxic substances that damages mucosal surfaces (Zagai et al. 
2004). They are a rich source of fibrogenic factors, including IL-11, IL-17, IL-25, transforming 
growth factor-α (TGF-α), MMP-9, and particularly TGFβ1 (Jacobsen et al. 2007, Raap et al. 2008). 
FcεRI activation following IgE/anti-IgE cross-linking on mast cells induces IL-4, IL-5, IL-13, and 
CCL11/eotaxin-1 release in human airway smooth muscle (ASM) cells (Roth et al. 2010). The 
pathogenesis underlying allergen-induced goblet cell hyperplasia in mice is thought to involve a 
variety of mediators, including IL-4 (Dabbagh et al. 1999), IL-13 (Grunig et al. 1998, Shim et al. 
2001), IL-9 (Louahed et al. 2000), the EGF system (Takeyama et al. 1999), a disintegrin and 
metalloprotease family(Shao et al. 2003), and ion channels such as gob-5 (Nakanishi et al. 2001) 
(hCLCA1 in humans (Nakanishi et al. 2001). These mediators probably act by up-regulating the 
expression of mucin genes (Okayama et al. 2007) particularly mucin 5AC (MUC5AC) (Takeyama et 
al. 2001). FcεRI cross-linking by IgE/anti-IgE also induces a rapid and transient increase in 
intracellular Ca
2+
, a likely determinant of ASM contractility and subsequent AHR which might be 
influenced by matrix metalloprotease 1 (MMP-1) (Margulis et al. 2009). A blocking antibody for 
FcεRI-α chain abrogated the release of these mediators, suggesting that these effects were FcεRI-
mediated (Gounni et al. 2005, Gounni 2006). 
1.4  Current Therapies for asthma 
The treatment of allergic diseases is based principally on avoidance of allergen, 
pharmacological treatment and, in some instances, allergen-specific immunotherapy.  
1.4.1 Avoidance and Drugs  
One component of managing asthma is to avoid relevant allergens/irritants, e.g., keeping 
windows closed, using an air conditioner, and spending less time outdoors during peak pollen 
seasons. These strategies are hard to follow at all times and more than one strategy is needed to 
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accomplish asthma control, which makes this non-favoured by patients (Kim et al. 2011). As 
indicated, allergen avoidance for the prevention of sensitisation is controversial, but raises the 
broader issue of allergen dose in induction of tolerance. In this regard, high-dose exposure has been 
shown to be beneficial on some circumstances through induction of regulatory T cells (Platts-Mills 
et al. 2001, Jeal et al. 2006, Meiler et al. 2008). 
The mildest, intermittent form of asthma is often managed with a short acting β2-
adrenoreceptor agonist (SABA), such as salbutamol, in a relief therapy used on an as-needed basis. 
These agonists stimulate β-adrenoceptors in the airways leading to bronchodilatation resulting from 
the relaxation of airway smooth muscle (Cockcroft et al. 1987). Not all patients respond similarly in 
regard to the magnitude of the reduction, and in some cases, airway responsiveness remains 
abnormally increased. It is important to note that airway responsiveness usually returns to pre-
treatment levels when therapy is stopped (Chung et al. 2009). This approach is suitable for acute 
symptomatic attacks. Inhaled corticosteroids (ICS) on a scheduled long-term daily basis can be used 
as a controlling therapy and this forms backbone of treatment, with increased dosing in line with 
disease severity. As asthma increases in severity, the co-administration of long acting β2-
adrenoceptor agonist (LABA) (a controller) – salmeterol or formoterol – can be applied with 
steroids. However, as much as ICS is important for treatment, it does not eliminate the disease, and 
in some patients, asthma control can’t be achieved. Long-term side effects of corticosteroid 
inhalation can develop, such as osteoporosis and stunting of growth (Mullane 2011). 
Glucocorticoids have several functions, one of which is decreasing cytokine-mediated survival of 
eosinophils by stimulating apoptosis (Schleimer et al. 1994), and  reducing the number of mast cells 
within the airway (Djukanovic et al. 1992). They may also block the production of several pro-
inflammatory cytokines and chemokines (such as (IL)-1β, IL-4, IL-5, IL-8, granulocyte-
macrophage colony stimulating factor (GM-CSF)) (Chung et al. 1999) in the asthmatic lung and in 
airway smooth-muscle cells (Chung 2008). 
1.4.2 Specific immunotherapy (SIT) 
Allergen-specific immunotherapy (SIT) aims to reduce the sensitivity to allergens by several 
repeated administrations of the disease-eliciting allergen of interest. This takes place either 
subcutaneously (injection immunotherapy) or via the sublingual route (sublingual immunotherapy) 
and acts through various immunological mechanisms. SIT modifies T-cell responses, by inducing 
regulatory T cells, increasing the ratio of Th1 to Th2 cytokines and/or producing cytokines IL-10 
and TGF-β, which are known to have regulatory activities (Larché 2006). Some of the outcomes of 
IL-10 production are the reduction of mast cell density, growth and degranulation and thus, 
histamine concentration (Palaniyandi et al. 2004). TGF-β inhibits Th1 and Th2 cell differentiation 
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by inhibiting the expression of transcription factors T-Bet and GATA-3 (Gorelik et al. 2000, 
Gorelik et al. 2002). This can promote generation of Treg cells (Karagiannidis et al. 2004). Treg can 
then interact directly with mast cells through cell-cell contact involving OX40–OX40 ligand to 
inhibit the FcεRI-dependent mast cell degranulation, to increase mast cell cyclic AMP 
concentrations, and to reduce Ca
++
 influx (Gri et al. 2008). In this way, several aspects of 
immediate-type hypersensitivity reactions are inhibited by Treg in addition to their potential effects 
on pathogenic T cells.  
SIT may also block IgE-facilitated antigen presentation through the induction of allergen-
specific IgG (mostly IgG1 and IgG4) and, in a few reported cases, IgA levels (Gehlhar et al. 1999, 
van Neerven et al. 1999, Nouri-Aria et al. 2004, Jakobsen et al. 2005). Also, these antibodies could 
act as blocking antibodies by engaging low-affinity Fc receptors for Ig (e.g. FcγRII) expressed by B 
lymphocytes, basophils, and mast cells (Wachholz et al.). Although the increased specific IgG4 
levels have been shown to parallel clinical improvement (Flicker et al. 2003, Wachholz et al. 2004), 
it is still debatable whether the increase in IgG (and IgA) levels is a consequence of high allergen 
exposure during SIT or it truly plays a role in reducing symptoms.  
1.4.2.1 SIT disadvantages and limitations of current therapies 
The efficacy of SIT in allergic asthma has been established in the clinic (Abramson et al. 
2003). SIT used on HDM monosensitised children prevented further sensitisations (Des Roches et 
al. 1997). Although it has been performed in the clinic (applied by highly specialized allergologists) 
for the past 100 years, SIT encounters several obstacles as an effective immunotherapy. These are: 
limited effectiveness, side effects such as asthma attacks and life-threatening anaphylactic shock, 
low patient adherence, high costs, and long durations of treatment (3–5 years) (Akdis 2012). It is 
contraindicated in a subset of patients that have the severe or poorly controlled forms of asthma or 
those that have major cardiovascular diseases e.g., recent myocardial infarction and uncontrolled 
hypertension. Furthermore, special consideration is required for very young individuals, pregnant 
women, the elderly, and patients with immunodeficiency/autoimmune diseases.  
Natural allergen extracts typically comprise the active ingredients in immunotherapy. They are 
strongly allergenic when taken directly from the raw allergen sources. If not modified, several 
reasons may render allergen extracts often insufficient for SIT. One possibility is that optimal dose-
dependent results cannot be reached because of side-effects (Winther et al. 2006, Rezvani et al. 
2007). The most profound and unwanted effect is due to the cross-linking of mast cell and basophil-
bound IgE by the administered allergen. This induces the release of biologically active mediators 
such as histamine in very large amounts, which may cause life-threatening anaphylactic reactions. It 
occurs <30 min after allergen administration. Allergen extracts suffer from batch to batch 
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variability in allergen content. Thus an important consideration is that relevant allergens are not 
present, or even if present in the extract, exert poor immunogenicity (Focke et al. 2008). 
Furthermore, natural allergen extracts may induce new allergen-specific IgE responses or may 
activate already existing antibody secreting B cells to produce allergen-specific IgE antibodies 
(Movérare et al. 2002, Van Hage-Hamsten et al. 2002). These allergens may also activate T cells to 
proliferate and release pro-inflammatory cytokines when presented by IgE antibodies via Fcɛ 
receptors on APCs,  
As for late-phase side effects, mediators and cytokines released by mast cells and basophils may 
play a role by exhibiting chemotactic activity and inducing the migration of basophils, eosinophils 
and T cells to the site of allergen exposure (Macfarlane et al. 2000). Some late-phase side-effects 
during SIT may result from the activation of allergen-specific T cells by allergen-derived T-cell 
epitopes and this  is IgE-independent (Focke et al. 2010). This was demonstrated in patients who 
had received T-cell epitope-containing peptides without IgE reactivity (Haselden et al. 2000) and in 
patients who received immunotherapy with recombinant allergen derivatives of the major birch 
pollen allergen, Bet v 1 (Campana et al. 2008, Purohit et al. 2008). 
1.5  Immunological Tolerance 
1.5.1 Definition 
Immunological tolerance can be defined as a state that limits responsiveness to self or 
innocuous antigens. Allergic sensitisation and autoimmunity, for instance, result as a consequence 
of the breakdown of tolerance mechanisms.  
1.5.2 Central tolerance 
Central tolerance is the process by which potentially self-reactive B and T cells are deleted 
during bone marrow and thymic maturation respectively (Griesemer et al. 2010). For B cells, this 
process involves ‘clonal deletion’ to eliminate B cells with self-reactive B-cell receptor (BCRs) 
(Nemazee et al. 1989, Hippen et al. 2005). Additionally, receptor editing of autoreactive BCRs 
limits B-cell self specificity (Nemazee 1999). For T cells, two main checkpoints have been 
identified: positive and negative selection. Developing T cells with T cell receptors (TCR) that fail 
to effectively bind “self” major histocompatibility molecules (MHC) die by ‘neglect’ (Bevan 1977, 
Blackman et al. 1986, Berg et al. 1989, Lorenz et al. 1989, Zuniga-Pflucker et al. 1989). However, 
developing thymocytes with TCR that bind with ‘too high’ affinity undergo ‘negative selection’ and 
are deleted. Additionally, developing thymocytes are exposed to a broad range of self-peptides 
expressed by specialized thymic APCs and epithelial cells (tissue specific antigens, TSA), and are 
deleted if they recognise with high affinity such self-antigen(s) presented by self-MHC (Kappler et 
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al. 1987, Kisielow et al. 1988, Huseby et al. 2005). By selecting for T cells that express TCR able to 
bind self-MHC and selecting against those that recognize self-antigen, a mature T cell population is 
generated that can efficiently interact with APCs, binding self-MHC in conjunction with foreign 
peptides but which is not autoreactive (Mold et al. 2012). 
1.5.3 Peripheral tolerance 
Some autoreactive B and T cells escape the process of negative selection. For instance it is 
estimated that 25%-40% of antigen-specific T cells escape negative selection even when specific 
antigen is presented in the thymus (Bouneaud et al. 2000, Doan et al. 2009). As a result, additional 
peripheral tolerance mechanisms (anergy, deletion, and active suppression by regulatory T cells) 
exist (Hawiger et al. 2001, Probst et al. 2003, Nurieva et al. 2011) to prevent autodestructive 
responses. 
1.5.3.1 Anergy 
Anergy is a state of partial or total unresponsiveness in lymphocytes after TCR or BCR 
interactions with peptide-MHC complex (pMHC) or antigens (respectively) that take place in the 
absence of costimulation (Sloan-Lancaster et al. 1993, Lechler et al. 2001, Eroukhmanoff et al. 
2009). Anergy is maintained by cytotoxic T-lymphocyte antigen-4 (CTLA-4) which might 
outcompete CD28 for binding to B7 (Linsley et al. 1994, van der Merwe et al. 1997) and 
programmed death-1 (PD-1; an inhibitory receptor of the CD28 family which binds to PD-L1 and 
PD-L2 expressed on APCs) expression by activated T cells (Nishimura et al. 1999, Keir et al. 2006, 
Fife et al. 2009). CTLA-4 is a transmembrane protein expressed on T cells and inhibits T-cell 
activation by reducing IL-2 production , IL-2 receptor expression and arresting T cells at the G1 
phase of the cell cycle (Walunas et al. 1994, Greenwald et al. 2002). B cells binding antigen, enter a 
state of anergy due to the formation of a signalling block in the absence of a signal from helper T 
cells (CD40/CD40L). This is mediated by the formation of an inhibitory complex that disrupts the 
B cell receptor (BCR) signalling circuitry. Co-aggregation of the BCR with FcgRII-B (inhibitory 
receptor) promotes phosphorylation of the immunoreceptor tyrosine-based inhibitory motif (ITIM) 
of FcgRII-B by LYN (Src-related tyrosine kinase) and recruits an SH2-domain-containing inositol 
polyphosphate 5′ phosphatase 1 (SHIP-1) and its adaptor Downstream of Kinase protein (DOK1) 
(Yamanashi et al. 2000, Gauld et al. 2006, Cambier et al. 2007). The complex formed then inhibits 
cell proliferation, activation and survival. Phosphorylation of membrane adaptors such as CD22 by 
LYN (Dal Porto et al. 2004) also recruit an SH2-domain-containing protein tyrosine phosphatase 1, 
which downregulates BCR signalling by dephosphorylation of its substrates (Plas et al. 1998). 
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Chronic antigen signalling through the BCR also can have trans-effects in a SHIP1-dependent 
mechanism which inhibits signalling of remotely stimulated receptors (Brauweiler et al. 2007). 
1.5.3.2 Deletion 
Clonal deletion of auto-reactive T cells is the most inviting approach to induce peripheral 
tolerance since it is final and complete in eliminating T cells. The encounter of resting T cells 
through the TCR complex, in absence of co-stimulation, with the antigen expressed on immature 
APCs results in incomplete activation of the T cells leading to either anergy or deletion (Hawiger et 
al. 2001, Bonifaz et al. 2002, Steptoe et al. 2007). Although important parameters such as antigen 
dose and the frequency of stimulation through the TCR have an effect on the outcome (Smith et al. 
2014), the mechanisms dictating anergy or clonal deletion as the final outcome are not fully 
understood. One study shows that the exposure to a single high dose of antigen leads to anergy 
opposed to repetitive exposure to low doses of antigen or its sustained presentation which induce 
deletion (Redmond et al. 2005).  
Activation induced cell death (AICD) is one of the critical mechanisms of peripheral 
tolerance which lead to T cell death by apoptosis. The major pathway is via Fas/FasL interactions 
which mediates apoptosis through several caspase cascades ((Walsh et al. 2003) reviewed in (Siegel 
2006)). This pathway also plays a role in preventing lymphoid hyperproliferation which keeps 
immune responses in check (Hildeman et al. 2002). In addition to Fas, signalling by TNF-α has 
been shown to play a role in AICD (Zheng et al. 1995, Sytwu et al. 1996) by activating TNFR1 
which induces apoptosis through either the classical caspase-dependent or - intrinsic pathway 
(Holler et al. 2000). A novel death pathway has also been shown to induce apoptosis in CD8
+ 
activated T cells in the absence of CD4 T cell help (Janssen et al. 2005). This pathway is dependent 
on the TNF family member TRAIL (Janssen et al. 2005). Apart from these pathways, different T 
cell proteins such as granzymes (Sharma et al. 2006), IFN-γ (Refaeli et al. 2002), perforin 
(reviewed in(Voskoboinik et al. 2006)) and cathepsins (Liu et al. 2003) have been associated with 
induction of AICD. Another pathway of apoptosis requires the pro-apoptotic Bcl2 family member 
protein Bim which induces cell death through release of cytochrome C (CyC) from the 
mitochondria into the cytoplasm. CyC in turn combines to the apoptosis activating factor 1 leading 
to the induction of a caspase cascade and apoptosis (Davey et al. 2002, Hughes et al. 2008). 
1.5.3.3 Regulatory T cells 
Regulatory T cells (Tregs) are a distinct subtype of T cells. They act through IL-10, TGF-β, 
CTLA-4, and PD-1 to suppress immune responses (both Th2 and Th1) (Cottrez et al. 2000). Tregs 
can also induce apoptosis by direct cell–cell contact mechanism to inhibit effector T cells (reviewed 
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by (Sojka et al. 2008)). In addition, Tregs can suppress T-cell activation indirectly through effects on 
DC (Chen 2006). Two subsets of CD4
+
CD25
+
Foxp3
+
 Tregs have been described, natural (nTreg) 
which develop in the thymus or induced (iTreg) CD4
+
 CD25
+
 Foxp3
+
 Treg cells that can develop in 
the periphery under immunogenic conditions, chronic inflammation or as part of normal gut 
immune homeostasis (Curotto de Lafaille et al. 2009). Several other types of peripheral Treg cells 
have also been described, including Th3 (CD4
+
 TGF-β+Foxp3+) and Tr1 (CD4+ IL-10+ Foxp3−) 
(Saurer et al. 2009). The development of these Treg cells is influenced by dendritic cells both in vitro 
and in vivo (Hadeiba et al. 2008). In humans for instance, DC deficiency syndromes are often 
accompanied by reduced numbers of Tregs (reviewed in (Collin et al. 2011).  
In atopic patients conflicting data as to the relevance of Treg in control of allergies has been 
reported. In some studies, examination of atopic patients with active airway disease showed 
functionally-insufficient CD4
+
CD25
+
 T cells are present (Lin et al. 2008) while in others there was 
no differences in allergen-specific CD4
+
CD25
+
 T cell number and function between asthmatic and 
control subjects (Maggi et al. 2007). In animal studies it has been shown that depleting CD4
+
CD25
+
 
cells enhances allergic airways inflammation
 
and their systemic administration, intratracheal 
administration, or both is protective (Holt et al. 2010). Induced Treg-deficient mice have also shown 
spontaneous development of Th2-type mucosal inflammation entailing the essential function of Tregs 
in maintaining a proper immunological balance (Josefowicz et al. 2012). 
1.6  BM and HSC Transplantation 
Bone marrow transplantation (BMT) or hematopoietic stem cell (HSC) transplantation 
regardless of its complexity has become a therapeutic strategy to treat some solid tumours 
(Hamilton et al. 2015) and haematological diseases (reviewed in (Candotti 2014)). The procedure is 
usually performed where patients subjected to conditioning are infused with BM/HSC that was 
harvested from non-identical MHC donors (allogenic) or the patient themself (autologous) (Copelan 
2006). In the context of tumour therapy, reduction of tumour burden is controlled by high doses of 
radiation or chemotherapy and the patients then receive allogeneic HSCT after being subjected to 
complete ablative conditioning (Barrett et al. 2002). The transplant via a ‘graft-versus-tumor’ effect 
and the conditioning ensure clearance of residual disease and facilitate donor HSC engraftment 
respectively. Many genetic disorders such as thalassemia and sickle cell anemia can also be treated 
with BMT/HSCT (Hsieh et al. 2009, Mathews et al. 2014). However, allogeneic HSCT is 
associated with a high risk of graft-versus-host disease (GVHD) where only patients with severe or 
life-threatening illnesses accept such a risk (Przepiorka et al. 2001, Sakellari et al. 2013).  
Whole BM was the source for transplants at the early stages of the BMT therapeutic technique 
development. CD34
+
 cells became the source after. Generally for reliable engraftment 2x10
6
 
15 
 
CD34
+
cells/kg body weight is required (Schmitz et al. 1996, Winter et al. 1996). Nowadays, 
“mobilization” of HSC using granulocyte colony stimulating growth factor (G-CSF) alone or in 
combination with cyclophosphamide (Cy) is widely used (Fried et al. 1968, Siena et al. 1989). 
Although it is a successful technique in healthy donors or patients with cancer, the use of G-CSF 
and Cy introduced complexities in autoimmune diseases. These include irreversible neurological 
damage demonstrated in the animal model for multiple sclerosis (EAE) (Verda et al. 2006) and 
lethal exacerbation of disease such as in rheumatoid arthritis (de Vries et al. 1991). To overcome 
those complexities and difficulty to mobilise patients in some cases a substitute for Cy, plerixafor, 
has been introduced in 2008 with promising clinical trials (Fruehauf et al. 2009, Micallef et al. 
2009). 
1.7  HSCT and autoimmune diseases  
Hematopoietic stem cell (HSC) transplantation has also been used to treat autoimmune diseases. 
The rationale behind HSCT is the ability of HSCs to reconstitute the malfunctioning host immune 
system after immune- ablation thus “rebooting” its proper function.  
As allogeneic HSCT introduced extensive GVHD in several clinical trials for autoimmune disease 
treatment (Slavin et al. 2000), the use of autologous HSCT became the preferred choice for disease 
treatment (de Buys et al. 2005). Although autologous HSCT reduced disease impact and reset the 
immune system in autoimmune diseases, it did not eliminate auto-reactive memory T cells which 
could initiate disease relapse. This rationale was shown in an animal model of EAE, where despite 
the use of complete ablative conditioning followed by autologous HSC transplantation, auto-
reactive myelin-specific T cells were detected that responded ex vivo to myelin (Burt et al. 1998).  
The need to reduce the toxicity of complete conditioning and disease relapse, introduced the 
studies exploring the mixed cell or molecular chimerism concept. Mixed cellular chimerism can 
occur after transfer of MHC miss-matched donor BM to recipients, usually with suppression of  the 
immune system (Wekerle et al. 2001). One of the complications of mixed cell chimerism is 
allograft rejection which potentially limits the survival of the transplanted BM (Russell et al. 2001). 
Molecular chimerism is, however, induced when syngeneic bone marrow cells are genetically 
engineered to express allo or xeno antigens to induce specific tolerance (Bagley et al. 2002). 
Afterwards, the main interest for investigators has been to develop efficient non-myeloablative 
regimes and gene transfer techniques to achieve high levels of HSC engraftment for long-term 
tolerance induction.  
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1.8  Gene Therapy 
Gene therapy is aimed at treating acquired diseases or inherited medical disorders by replacing 
defective genes with healthy genes. The healthy gene may need to be permanently integrated into 
the host genome for efficient gene therapy. For transfer of genetic information, both non-viral and 
viral methods have been used. However, only viral methods, with the focus on retroviral and 
lentiviral vectors, will be discussed in this review. 
Gene therapy was first introduced in the late 1970s and was considered as a potential solution 
for genetic disorders (Friedmann et al. 1972, Friedmann 1976). Many genetic defects were, at that 
time, well understood, but due to knowledge gaps in the field of gene regulation and limited 
technology, gene therapy wasn’t officially active until the 1990s. Retroviral vectors gained 
popularity at that time due to their ability to permanently incorporate genetic modifications into the 
genome (Miller 1992, Miller et al. 1993). The first approved clinical applications were to correct 
severe combined immunodeficiency (SCID) by transducing peripheral blood CD34
+
 cells with a ɣ-
retrovirus encoding adenosine deaminase (Anderson et al. 1990, Levine et al. 1991, Blaese et al. 
1993). After that, gene therapy using retroviral vectors was used in several clinical trials for various 
diseases (Morizono et al. 2005, Gottlieb 2006, Morgan et al. 2006). One of the limitations of 
retroviral vector, however, is its inability to transduce non-dividing cells (Miller et al. 1990, Roe et 
al. 1993) such as quiescent HSCs which are a major target for gene therapy. In addition, a major 
concern about the safety of retroviruses emerged after some X-linked severe combined 
immunodeficiency (SCID-X) patients developed leukemia in a clinical gene therapy trial (Hacein-
Bey-Abina et al. 2003, Hacein-Bey-Abina et al. 2003, Check 2005). The cause was found to be 
insertional mutagenesis (Nienhuis et al. 2006). As substitutes for retroviral vectors, lentivectors 
have been developed with the promise of the required therapeutic efficacy and safety. 
1.8.1 Retroviral vectors a limited tool for gene transfer 
In the early 1980s, retroviruses were introduced as tools for gene delivery (Mann et al. 1983). 
Retroviruses are single-stranded RNA (ssRNA) viruses that integrate their genetic payload into host 
genome as double-stranded DNA intermediate which is then transcribed into viral RNA and the 
corresponding protein generated as long as the host cell is active. One of the forms of oncogenic 
retroviruses that have a simple genome and widely used are based on Moloney Murine Leukaemia 
Virus (MLV). Several polyproteins are required in for the packaging and replication of this viral 
genome which are identified as gag, pol and env. In addition, several sites and sequences are 
involved in packaging, RNA transport, integration, and reverse transcription. Regardless of their 
beneficial use in gene therapy mentioned above, retroviruses are associated with some limitations 
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concerning the number of viral particles that can be produced (Andreadis et al. 1997), the stability 
of the viral particle (Le Doux et al. 1999), and its ability to transduce dormant cells (Roe et al. 
1993). 
1.8.2 Lentiviral vectors as a better tool for gene transfer 
Lentiviral vectors which belong to a subclass of retroviruses were then developed to overcome 
the limitations encountered with retroviral vectors (Naldini et al. 1996). Lentiviral vectors have the 
same ability as γ-retroviral vectors (γ-RVs) to integrate genomic material of interest into the target 
genome resulting in sustained gene expression. An additional advantage of lentiviral vectors is their 
ability to transduce mitotically quiescent cells (Lewis et al. 1994) and to accommodate larger 
transgenes (Kumar et al. 2001). Lentiviral vectors are derived from several virus species such as 
simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) (Zufferey et al. 
1997). However, HIV-1 based vectors have advanced in safety and versatility and have been the 
most used in preclinical gene therapy studies (May et al. 2000, Woods et al. 2000). Lentiviral 
vectors are produced through transient co-transfection of three plasmids, the packaging plasmid, 
envelope-encoding plasmid, and transfer plasmid, into permissive cell-lines. The extent of deletion 
of lentiviral elements that permit self-replication during infection, from these plasmids determines 
the ‘generation’ type of the lentivirus produced. First-generation lentiviral vectors for example are 
produced from the packaging plasmids that contain the viral regulatory gene tat and rev in addition 
to other accessory genes that are necessary for the viruses’ virulency (Naldini et al. 1996). The 
presence of tat and rev render this generation of lentiviral vectors unsafe due to the risk of 
recombination events which allows the production of replication-competent viruses in hosts. The 
safety of using lentiviral vectors was improved substantially with the engineering of third-
generation vectors. The accessory genes responsible for the virus pathogenesis are deleted from the 
viral genome in third generation lentiviral vector system and are supplied, in addition to the 
packaging genes gag and pol, by separate plasmids to. Another modification in this system could be 
the replacement of tat by a strong constitutional promoter in the long terminal repeat (5’LTR), 
involved in integration, region of the transfer vector (Dull et al. 1998). The transfection plasmids in 
this system then encode for i) the vesicular stomatitis virus glycoprotein (VSV-G; which aids the 
entry of the virus particles into target cells) (Emi et al. 1991, Sanders 2002) on one plasmid, ii) the 
gag and pol genes on another and iii) rev on the third. Another type of lentivector was also 
engineered to further reduce the risk of the generation of replication-competent lentivirus (RCL) 
and to control the aberrant expression of unwanted cellular coding sequences near the vector 
integration site (Ginn et al. 2003). The self-inactivating (SIN) vector lacks the U3 region of the 
3’LTR which restricts the transcription of the virus genomic components in the host cells after LV 
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transduction (Miyoshi et al. 1998, Zufferey et al. 1998). However, the SIN vectors have their own 
limitations, including is their difficulty in inserting the genomic DNA into some cell types 
depending on the ability to convert the LV genome from the (ss)RNA form into dsDNA (Ravot et 
al. 2002). For example, limited reverse transcriptase activity due to the shortage in dNTP 
concentration limits transductions into human macrophages (Diamond et al. 2004). In addition, 
other problems such as mutations in the transgene or the LV genomic material can emerge due to 
nucleotide misincorporation by the reverse transcriptase (Preston et al. 1988, Roberts et al. 1988, 
Bakhanashvili et al. 1992).  
1.8.3 HSCs as a target for gene transfer 
Hematopoietic stem cells (HSC) having the ability to differentiate into multiple lineages giving 
rise to B and T lymphocytes and dendritic cells, for example, has made them an attractive target for  
genetic engineering to improve immune function. The idea of gene modification of HSC to induce 
tolerance came from the observation of induction of tolerance to donor MHC proteins due to donor-
host mixed chimerism development following allogenic HSC transplantation (Owen 1945, 
Billingham et al. 1953). However, allogenic HSC transplantation, as mentioned above, leads to 
GVHD and graft rejection. Autologous HSC then became the solution for the generation of 
molecular chimerism while reducing the risk of GVHD after transplant (Ildstad et al. 1984, Sundt et 
al. 1988, Wong et al. 1996). Investigators then found a way to induce tolerance by targeting 
transgene expression to a particular cell lineage through the use of miRNA targets or tissue specific 
promoters (Brown et al. 2007, Shi et al. 2008, Coleman et al. 2013). HSC gene modification so far 
has been a successful method for tolerance induction in various disease models. For example, 
expression of a foreign cytosolic reporter gene (eGFP) (Andersson et al. 2003, Tian et al. 2003) or 
expression of an allogenic MHCI and II genes (Bagley et al. 2002, Jindra et al. 2013) in bone 
marrow derived cells induced tolerance to skin grafts. Transplantation of genetically-engineered 
HSC under non-myeloablative conditions has been shown to control autoimmunity where the 
expression of the autoantigen MOG prevented MS disease development in an EAE mouse model 
(Nasa et al. 2012). Gene transfer to HSC has also shown success in tolerance induction and control 
of the disease in a non obese diabetes (NOD) mouse model (Steptoe et al. 2003), in mouse models 
of allergy (Baranyi et al. 2012, Gattringer et al. 2013), and in animal disease models of haemophilia 
(Chang et al. 2008, Du et al. 2013, Shi et al. 2014). As for gene transfer to HSC by lentiviral 
vectors, two clinical trials have been recently reported providing optimism for future adoption of 
this approach into new clinical studies for other diseases. One of the two clinical trials reported 
aimed to correct Wiskott-Aldrich syndrome (WAS) immunodeficiency, a defect in a gene encoding 
for a protein responsible for regulation of the cytoskeleton (WASP) (Aiuti et al. 2013), and the other 
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attempted to impair an inherited lysosomal storage disease, Metachromatic leukodystrophy (MLD) 
(Biffi et al. 2013).  
1.8.4 Targeted expression to DC to induce tolerance 
Dendritic cells are the key controllers of immune responses and T cell tolerance. This is 
mediated largely by regulating the signalling through the receptors responsible for either activation 
or inhibition (Banchereau et al. 1998). Induction of full T cell activation occurs when TCR binds to 
MHC/peptide complex presented by DC in the presence of CD28 -CD80/CD86 interactions which 
constitute the classical co-stimulatory interactions (Goronzy and Weyand 2008). The initiation of a 
full T-cell response takes place after the interaction between CD40L expressed by T cells and CD40 
expressed by APCs which leads to the upregulation of CD80/CD86 expression and subsequent T-
cell activation (Cella et al. 1996, Grewal et al. 1996). In the presence of pro-inflammatory cytokines 
the CD40/CD40L ligation leads to the expression of another co-stimulatory molecule (OX40L) on 
DC (Burgess et al. 2004, Ito et al. 2005). The interaction then between OX40L and OX40 on T cells 
initiates Th2 differentiation (Ito et al. 2005). In the absence of PAMPs or damage-associated 
molecular pattern molecules (DAMPs) generated by infection, trauma or necrosis, DC maintain a 
functionally immature state and continuously process and present self antigens (Reis e Sousa 2006). 
In this state they express little or no co-stimulatory molecules and antigen-specific interaction with 
T cells leads to tolerance. 
In the steady state, DC presenting antigens from dying cells (Liu et al. 2002) or low doses of 
intact soluble proteins targeted to DC (Hawiger, Inaba et al. 2001) can induce antigen-specific 
tolerance through deletion of responding T cells (Kurts et al. 1997, Mukhopadhaya et al. 2008, 
Mueller 2010) in addition to anergy. Several experiments show the dominance of DC in these 
processes either through the use of transgenic mice to target antigen to specific peripheral DC 
populations (Kurts et al. 1997, Bonifaz et al. 2002) or genetically engineering DC to express antigen 
under the CD11c promoter (Probst et al. 2005, Steptoe et al. 2007). These approaches all led to 
peripheral T cell tolerance when the antigen was presented to CD4
+
 and CD8
+
 T cells under non-
inflammatory conditions. Immature DC derived from bone-marrow induce alloantigen-specific T-
cell anergy in vitro and in vivo (Lu et al. 1995, Fu et al. 1996). Steptoe and colleagues (Steptoe et al. 
2003) exploited this approach to demonstrate that complete prevention of autoimmune diabetes in 
the spontaneously-diabetic NOD mouse can be achieved through the transfer of ‘gene-engineered’ 
HSC encoding proinsulin transgenically-targeted to MHC class II
+
 APC. 
The question follows “can lentiviral transduction and HSC transplantation be used to direct 
expression to DC to induce tolerance”? BM chimeras where antigen is targeted to DC have been 
generated after lentiviral vector transduction of HSC that leads to antigen-specific tolerance (Dresch 
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et al. 2008, de Andrade Pereira et al. 2013, de Andrade Pereira et al. 2015). However, this approach 
to tolerance induction, where antigens are targeted to DC, has not been tested as a therapy for 
allergic disease where established T-cell responses need to be ‘turned-off’.  
1.9  Hypothesis and Aims 
The chronic use of pharmacologic disease modifiers, to control symptoms of asthma, is 
associated with complications and current allergen-specific immunotherapies are incompletely 
efficacious. Genetically targeting antigens to APC is a robust method for the induction of tolerance 
that overcomes genetic tolerance defects and effectively induces tolerance to nominal (Steptoe et al. 
2007) and pathogenic antigens (French et al. 1997). Previous work in the host laboratory 
(unpublished) has established that Th2-skewed effector/memory T cells are inactivated upon 
transfer to mice in which DC express cognate antigen. Transfer and subsequent engraftment of 
HSPC carrying DNA encoding cognate antigen, can be used to transfer APC-targeted antigen 
expression. If derived from transgenic donors, then antigen expression in recipient mice reflects that 
of HSPC donors. The approach of gene-modified HSPC transfer for tolerance induction 
(tolerogenic HSPC therapy) was pioneered by Steptoe and co-workers who showed prevention of 
diabetes in NOD mice (Steptoe et al. 2003).Alternatively, bone marrow (BM) cells or HSPC can be 
gene-engineered using viral vectors containing appropriate promoter/antigen constructs and antigen 
targeted to any desired progeny of the transferred HSPC.  
 
Hypothesis: 
“Targeting antigen to antigen-presenting cells has the capacity to act as a powerful therapeutic for 
allergic T-cell responses and allergen-elicited airways disease”  
 
Aims: 
• Determine whether transgenic expression of an allergen in DC prevents sensitisation and 
allergen-induced airway inflammation. 
• Determine whether antigen-encoding BM transfer under non-myeloablative conditioning 
terminates Th2-mediated T-cell responses and allergen-induced airways inflammation using 
the OVA model. 
• Develop a grass pollen allergen (Lol p 1) - encoding lentiviral vector for genetic engineering 
of hematopoietic stem and progenitor cells.  
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CHAPTER 2: 
MATERIALS AND METHODS 
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2.1 Mice 
Mice were maintained in a specific pathogen-free environment at the Princess Alexandra Hospital 
Biological Resource Facility (Brisbane, Australia) and at the Translational Research Facility 
(Brisbane, Australia). All mice were euthanised by CO2 asphyxiation. Mice were sex matched 
within individual experiments. Animals were used between 6-15 weeks of age and all experiments 
approved by the University of Queensland Animal Ethics Committee.  
2.1.1 Inbred and congenic strains 
BALB/c mice: 
BALB/c mice carry the H-2
d
 MHC haplotye. All BALB/c mice were purchased from the Animal 
Resource Center (Perth, Australia) at 6-8 weeks of age. 
2.1.2 Transgenic strains 
11c.OVA mice: 
Transgenic mice expressing a membrane-bound truncated OVA from a construct encoding 
truncated OVA under the direction of the CD11c (Itgax) promoter. Only CD11c
hi
 conventional DC 
present OVA (Steptoe et al. 2007).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 OVA construct.  
Truncated form of OVA fused with the human transferrin receptor (hTFR) expressed in 
11c.OVA mice. 
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2.2 Cell strains 
E.coli (DH5α): 
E. coli DH5α were obtained from an inoculum from Blumethal lab, Translational Research Institute 
(TRI), Diamantina Institute, Brisbane, Australia (DH5α). 
HEK293T: 
The HEK293 cell line was derived from embryonic kidney cells (Graham et al. 1977). 293T is a 
highly transfectable derivative of the 293 cell line expressing simian vacuolating virus 40 (SV40) T-
antigen gene. SV40 T-antigen binds to SV40 region in packaging plasmids to allow their genome 
amplification and as a consequence increase expression of the desired gene product. This cell line 
was purchased from ATCC (The Global Bioresource Center). 
2.3 Reagents  
2.3.1 Peptides 
OVA323-339: 
OVA323--339 (ISQAVHAAHAEINEAGR) is the immunodominant H-2
b
-restricted determinant of 
OVA and together with I-A
b
 or I-A
d 
forms an MHC class II/peptide complex recognized by T cells.  
OVA323--339 (HPLC purified, 87%) was purchased from Auspep (Melbourne, Australia). OVA323-339 
was dissolved in pyrogen free H2O (Baxter, Deerfield, IL, USA) to a concentration of 10mg/ml, 
aliquoted, and stored at -30
o
C. 
2.3.2 Proteins 
Bovine serum albumin: 
Bovine serum albumin (BSA), Bovomax (Bovogen Biologicals, VIC, Autralia) was used at 4% 
BSA/PBS (0.4g BSA/10ml PBS) as the diluent/block in ELISA or filter sterilized and used at 2% 
BSA/PBS (0.2g BSA/10ml PBS) for the blocking step in the hematopoietic progenitor cell 
transduction protocol. 
Fibronectin: 
Fibronectin (Sigma-Aldrich, St. Louis, MA, USA) is an adhesion glycoprotein of the extracellular 
matrix (ECM) existing as a dimer of an A chain and the B chain containing the type III connecting 
segment (IIIcs) region. Fibronectin was stored at 4
o
C and kept sterile. It was used at 1 in 40 dilution 
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of stock in sterile MT-PBS for a final concentration of 25µg/ml for plate coating in the lentivirus 
transduction procedure. 
Lol p 1: 
Lol p 1 the major allergenic protein of RGP was purified by Ms Victoria Timbrell in Dr. Janet 
Davies’ laboratory (UQ School of Medicine, Translational Research Institute, Brisbane, Australia). 
Lol p 1 was purified from an aqueous extract of RGP by ammonium sulphate precipitation, 
hydrophobic interaction and size exclusion chromatography (Drew et al. 2011) and filter sterilized. 
The quality of purified Lol p 1 protein was confirmed by Coomassie staining of the purified fraction 
by SDS-PAGE and immunoblotting with specific monoclonal antibody (FMC-A1) (Smart et al. 
1983). The concentration of Lol p 1 protein provided was 0.499mg/ml. Lol p 1 was diluted in 
pyrogen-free saline (Baxter, Deerfield, IL, USA) to the working concentration on the day of use for 
intranasal administration and in vitro restimulation. 
Ovalbumin: 
Ovalbumin (Grade V; Sigma-Aldrich, St. Louis, MA, USA) is a glycoprotein component of chicken 
egg white. Ovalbumin was dissolved in pyrogen free saline (Baxter, Deerfield, IL, USA) to a 
concentration of 1mg/ml on the day of use for intraperitoneal injections or intranasal administration 
and in vitro restimulation. 
Ryegrass pollen extract (RGP): 
Non-defatted Ryegrass pollen (Greer Laboratories, Lenoir, NC, USA) dissolved in PBS was 
provided by Dr. Janet Davies (UQ School of Medicine, Translational Research Institute, Brisbane, 
Australia). RGP extract was subjected to diafiltration to remove low molecular weight components 
and filter sterilized. Protein concentration was estimated (BioRad Bradford assay) at 6.9mg/ml. 
RGP was diluted in pyrogen-free saline (Baxter, Deerfield, IL, USA) to a concentration of 1mg/ml 
on the day of use for intraperitoneal injections or intranasal administration and in vitro 
restimulation. 
2.3.3 Chemicals 
Ampicillin: 
Ampicillin Stock: (100mg/ml)-100mg Ampicillin (Roche, Switzerland) was dissolved in 1ml of 
sterile autoclaved Millipore water. Working concentration was 100μg/ml. 
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1.25M CaCl2: 
Calcium chloride (Astral Scientific, Australia) 1.25M was prepared by dissolving 18.38g CaCl2 in 
70ml of double-distilled H2O and adjusted to a final volume of 100ml with double-distilled H2O. 
Filter sterilized and aliquoted into 5ml sterile tubes and stored at -30°C. Once thawed, it was stored 
at 4°C for up to 2 weeks. For transfections, 1.25M CaCl2 was pre-warmed to room temperature. 
Chemically defined lipid formula:  
Chemically defined lipid formula (Gibco, USA) was used at 1/500 for addition to complete DMEM 
medium. 
0.01mM Cholesterol: 
Cholesterol (Sigma-Aldrich, St. Louis, MA, USA) was made up at 5mM in PBS, filter sterilized, 
and stored at -30°C in 1ml aliquots. Final concentration used for transfections was 0.01mM. 
Enhanced chemiluminescent substrate (ECL): 
Enhanced chemiluminescent substrate (Thermo Scientific, Waltham, Massachusetts, USA) used for 
detection of horseradish peroxidase (HRP) activity from antibodies and other Western blot probes. 
Substrate was provided by Blumethal lab (Diamantina Institute, Translational Research Institute, 
Brisbane, Australia). 
Ethidium Bromide: 
Ethidium bromide (EtBr; 10mg/ml) (Sigma-Aldrich, St. Louis, MA, USA) is an intercalating agent 
commonly used as a fluorescent tag in techniques such as agarose gel electrophoresis.  
0.5M H2SO4: 
Sulfuric Acid (Bacto, Australia) 0.5M was prepared by diluting 2.8ml 98% H2SO4 in 100ml MilliQ 
and was used as the stop solution in the final step in the ELISA procedure. 
4M NaCl solution: 
Sodium chloride (Bacto, Australia) 4M was prepared by dissolving 23.4g NaCl in 100ml MilliQ 
H2O. It was sterilized by autoclaving and stored at 4°C for up to 12 months. It was used for 
Lentivirus transductions. 
Polybrene:  
Hexadimethrine bromide (Sigma-Aldrich, St. Louis, MA, USA) is a cationic polymer used to 
increase the efficiency of infection of certain cells with a retrovirus in cell culture. Working stock 
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was 800µg/ml in complete medium (DMEM+10% FCS+5ml PSG). For HSPC transductions final 
concentration used was 6µg/ml. It was filter sterilized and stored at 4°C. 
50% PEG 6000 solution: 
Polyethylene glycol 6000 (Sigma-Aldrich, St. Louis, MA, USA) solution was prepared by 
dissolving 50g of PEG6000 in 100ml MilliQ H2O, autoclaved and mixed thoroughly. This solution 
was stored at 4°C and used for lentivirus precipitant concentration.  
Propidium iodide: 
Propidium iodide solution (Sigma-Aldrich, St. Louis, MA, USA), was used for dead cell exclusion 
in flow cytometry. It was diluted in PBS to a working concentration of 100µg/ml and stored at 4
0
C 
(foil-wrap). Final concentration used for flow analysis was 1-10µg/ml. 
Sodium Butyrate:  
Sodium butyrate (Sigma-Aldrich, St. Louis, MA, USA) was made up at 1M in PBS, filter sterilized, 
and stored at -30°C. 
Trypsin/EDTA: 
Trypsin/EDTA was supplied by Invitrogen (Invitrogen, USA). 
2.3.4 Buffers  
ACK red cell lysis buffer: 
ACK red cell lysis buffer was made in house and was composed of NH4Cl (8.29g/L), KHCO3 
(1g/L) add Na2EDTA (0.0372g/L) dissolved in MilliQ water. pH was adjusted to 7.2-7.4, filter 
sterilized and stored at 4°C. ACK buffer was used to eliminate red blood cells (RBCs) from mouse 
lymphocyte preparations. It was used routinely to remove bulk RBCs from spleens, bone marrow 
preparations and peripheral blood. 
2xBBS (BES buffered saline): 
BBS consists of 16.36g of NaCl, 10.65g of BES (N,N-bis-(2-Hydroxyethyl)-2-aminoethanesulfonic 
Acid - BES, CalBiochem, CA, USA) and 0.21g of Na2HPO4 dissolved in 900ml of double-distilled 
water. This mix was titrated carefully with 1M NaOH to the range of pH values (pH6.95, pH7.00 
and pH7.05), filter sterilized, and then tested efficiency for DNA transfection of 293T. The most 
effective of the 3 was stored at -20°C for further use. Once thawed, it was kept at 4°C for up to 2 
weeks.  
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Coating buffer:  
Sodium bicarbonate NaHCO3 (Sigma-Aldrich, St. Louis, MA, USA) buffer 50mM, pH 9.4 was 
prepared by dissolving 0.21g of sodium bicarbonate to 50ml of milliQ water and pH was adjusted. 
This buffer was used to coat the plates with the capture antibody in the ELISA technique. 
ELISA wash buffer: 
ELISA wash buffer was prepared from 0.05% Tween-20 (Sigma-Aldrich, St. Louis, MA, USA) in 
PBS (0.5ml Tween-20 / 1000ml PBS). It was used to wash the plates between steps in the ELISA 
technique. 
FACS buffer: 
FACS wash was made in house to 10x concentration (1% BSA 20mM EDTA in MT-PBS) and 
diluted in MT-PBS. 10x FACS wash was stored at -20°C and 1x FACS wash was stored at 4°C. 
FACS blocking buffer: 
FACS block was made in house from the supernatant of 2.4G2 hybridoma cells producing anti-
CD16/32 to allow blocking of mouse Fc-receptors Fc-gamma II (CD32) and Fc-gamma III (CD16). 
1% BSA was added to 2.4G2 tissue culture supernatant and filter-sterilized aliquots were stored at -
20°C.  
MT-PBS: 
Mouse tonicity phosphate buffered saline (MT-PBS) 10x stock was composed of Na2HPO4.2H20 
(28.5g/L), NaH2PO4.1H20 (5.52g/L) and NaCl (87g/L) dissolved in MilliQ water and diluted for use 
in all experiments. MT-PBS was sterilized by autoclaving prior to use. 
MT-PBS / 2.5% FCS or FBS: 
MT-PBS / 2.5% FCS (F2.5) was used routinely for organ collection and cell washes. MT-PBS was 
made up with 2.5% fetal calf serum (FCS) for cells used in animal transfer experiments, or 2.5% 
bovine serum for cells used exclusively in vitro. 
F10/EDTA: 
F10/EDTA was composed of 10xMT-PBS, 10%FCS, and 10mM disodium salt dihydrate EDTA 
(Astral, Australia) and pH adjusted to 7.4. F10/EDTA was filter sterilized and stored at 4°C. It was 
used for bone marrow cell harvest and AUTOMACS HSPC enrichment. 
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5x Reducing Sample buffer 
RSB buffer was, provided by Dr. Janet Davies (UQ School of Medicine, Translational Research 
Institute, Brisbane, Australia), prepared from 3.55ml deionized water, 1.25ml 0.5M Tris-HCl, pH 
6.8, 2.5ml glycerol, 2ml 10% (w/v) SDS, 0.2ml 0.5% (w/v) Bromophenol Blue, and 0.5ml β-
mercaptoethanol . Store at -20
o
C and used to dilute the lysate samples in 20% of this buffer to be 
heated at 95°C for 4 minutes and loaded on gel. 
RIPA buffer: 
RIPA buffer (RadioImmunoPrecipitation Assay) was made from 50mM Tris HCl pH 7.4, 150mM 
NaCl, 1% NP-40, 0.5% sodium Deoxycholate, 0.1% SDS, and the Ultra protease inhibitor cocktail 
(Roche, Basel, Switzerland). This buffer was used to extract the lysates for immunoblotting.  
10x SDS-PAGE Running buffer 
Running buffer (pH) 8.3 was provided by Dr. Janet Davies (UQ School of Medicine, Translational 
Research Institute, Brisbane, Australia), made from Tris base, 144.0g glycine, 10% SDS dissolved 
and brought to a final total volume up to 1,000ml with deionized water. It was diluted, 100ml of 
10x stock with 900ml deionized water, for each electrophoresis run. 
1xTAE buffer: 
TAE buffer (50x) (pH) 8.0 was made from 100ml (autoclaved Millipore water), Tris Base (MW: 
121.1) -24.20g, and EDTA (MW: 372.2) -1.86g. For working stock 1xTAE (500ml), 10ml of TAE 
buffer (50x) was added to 490ml of autoclaved Millipore water. 
10x Towbin Transfer buffer: 
Towbin transfer buffer was composed of 25mM Tris, 192mM Glycine, 20% Methanol, dissolved in 
1L water. For working stock (1x), 100ml of 10x Towbin Transfer buffer was added to 200ml of 
methanol and 700ml of water and stored at 4°C. 
TRIS buffer: 
Tris (hydroxymethyl) aminomethane (Astral, Australia) 50mM Tris-HCl, (pH) 7.4 was used to 
resuspend and store lentivirus at -80°C. 
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2.3.5 Adjuvants 
ALUM: 
Aluminium hydroxide (alum, Alu-Gel-S; Serva, Germany) was the adjuvant of choice for OVA, 
OVA323-339, and control (sham) immunizations. Alum was kept sterile and stored at room 
temperature. 
2.3.6 Tissue culture and bacterial culture media 
Complete Roswell Park Memorial Institute 1640 (RPMI-1640) Medium: 
Complete RPMI-1640 consists of sterile liquid RPMI-1640 (Gibco-Invitrogen, Carlsbad, CA, USA) 
supplemented with 1mM sodium pyruvate (Gibco-Invitrogen, Carlsbad, CA, USA), 5 x 10
-5
M 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, MA, USA), 1 x 10
-4
M non-essential amino acids 
(Gibco-Invitrogen, Carlsbad, CA, USA), 100 units/ml penicillin, 100 units/ml streptomycin and 
2mM L-glutamine (Gibco-Invitrogen, Carlsbad, CA, USA). 
Complete Dulbecco’s Modified Eagle Medium (DMEM): 
Complete DMEM was sterile liquid DMEM (Gibco-Invitrogen, Carlsbad, CA, USA) supplemented 
with 100 units/ml penicillin, 100 units/ml streptomycin and 2mM L-glutamine (Gibco-Invitrogen, 
Carlsbad, CA, USA) and 10% FCS (Hyclone, Logan, UT, USA).  
Iscove's Modified Dulbecco's Medium (IMDM): 
Complete IMDM was sterile liquid IMDM (Gibco-Invitrogen, Carlsbad,CA, USA) supplemented 
with 1mM sodium pyruvate (Gibco-Invitrogen, Carlsbad, CA, USA), 5 x 10
-5
M 2-mercaptoethanol 
(Sigma-Aldrich, St. Louis, MA, USA), 1 x 10
-4
M non-essential amino acids (Gibco-Invitrogen, 
Carlsbad, CA, USA), 100 units/ml penicillin, 100 units/ml streptomycin and 2mM L-glutamine 
(Gibco-Invitrogen, Carlsbad, CA, USA).  
Luria Bertoni (LB) broth and agar plates: 
LB broth was prepared from Tryptone 10.0g (Astral, Australia), Yeast Extract 5.0g (Astral, 
Australia), and NaCl 10.0g (Bacto, Australia), in 1000ml MilliQ water. From the 1000ml prepared 
500ml was used to prepare agar plates by adding agar (1.5%) 7.5g (Astral, Australia). Both media 
were autoclaved and kept sterile. LB broth was stored at 4°C. Ampicilin was added to a 
concentration of 100µg/ml to LB-agar when the medium had cooled to 50°C. LB-amp agar was 
plated at 20ml volume in petri dishes and stored at 4°C for later use in bacterial plating. 
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2.3.7 Electrophoresis gels 
Agarose gel: 
0.7% agarose gel: In 150ml 1x TBE buffer, 1.05g of agarose was added, heated in a microwave for 
3 minutes, cooled to approximately 44°C to 50°C, 2µl ethidium bromide (10mg/ml) added and 
poured into a gel platform with the comb in position. 
1% agarose gel: In a 150ml 1x TBE buffer 1.5g of agarose was added, heated in a microwave oven 
for 3 minutes, cooled to approximately 44°C to 50°C, 2µl ethidium bromide (10mg/ml) added and 
poured into a gel platform with the comb in position. Loading, running, and visualization methods 
are described in section 2.4.4. 
Sodium dodecyl sulphate- polyacrylamide gel electrophoresis (PAGE): 
12% SDS-PAGE reducing gel and 5% stacking gel were prepared with the following materials: 
40% acrylamide, separating gel buffer (for separating gel; 1.5M Tris pH 8.8), stacking gel buffer 
(0.5M Tris pH 6.8), 20% SDS, distilled water, 10% Ammonium persulphate, and TEMED. The 
Laemli method was used for SDS-PAGE (Laemmli 1970). 
2.3.8 Cytokines 
rmSCF: 
Recombinant mouse stem cell factor (rmSCF) (Peprotech, NJ, USA) was used in lentiviral HSPC 
transduction procedures. Working stock diluted in PBS/5% FCS at 10µg/ml and stored at -80
o
C. 
Final concentration used in transductions = 50ng/ml. Final concentration for HSPC cultures = 
20ng/ml. 
rmIL-3:  
Recombinant mouse IL-3 (Peprotech, NJ, USA) is used in combination with other cytokines to 
promote growth of early myeloid progenitors of all lineages. Working stock diluted in PBS/5% FCS 
at 10µg/ml and stored at -80
o
C. Final concentration used in transductions = 10ng/ml. 
rmIL-6: 
Recombinant mouse IL-6 (Peprotech, NJ, USA) is a pleiotropic cytokine for growth and 
differentiation of hematopoietic progenitors. Working stock diluted in PBS/5% FCS at 10µg/ml and 
stored at -80
o
C. Final concentration used in transductions = 10ng/ml.  
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rhIL-11: 
Recombinant human IL-11 (Peprotech, NJ, USA) is characterized as a hematopoietic cytokine with 
thrombopoietic activity. Working stock diluted in PBS/1% FCS at 10µg/ml and stored at -80
o
C. 
Final concentration used in transductions = 100ng/ml.  
GM-CSF:  
Mouse granulocyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech, NJ, USA) used 
for growth of granulocytic and monocytic progenitors. Working stock diluted in PBS/5% FCS at 
10µg/ml and stored at -80
o
C. Final concentration for HSPC cultures = 4ng/ml. 
TNF-α: 
Mouse tumor necrosis factor alpha (TNF-α) (Peprotech, NJ, USA) favors the development of 
monocytic cells. Working stock diluted in PBS/5% FCS at 10µg/ml and stored at -80
o
C. Final 
concentration for HSPC cultures = 25ng/ml. 
2.3.9 Plasmids 
puC57.TfR-Lolp1: 
Vector was provided as lyophilized plasmid (GenScript, Piscataway, NJ, USA). 4μg was dissolved 
in 20μl of sterile water and stored at -30°C until transformation. 
puC57.TfR-fulllengthOVA: 
Vector was provided as lyophilized plasmid (GenScript Piscataway, NJ, USA) of 4μg was dissolved 
in 20μl of sterile water and stored at -30°C until transformation. 
pRRLsin.CMV.GFP: 
Lentivirus transfer plasmid containing CMV-GFP for lentiviral vector production. Supplied by Ian 
Alexander taken from glycerol stock bacteria from Amanda Boyce 02/04 
(pRRLsin18PPTCMVGFPpre) 
pRRLsin.CMV.IRES.GFP: 
This plasmid was cloned by Tanya Waldie. It was derived from pRRLsin.PPT.CMV.GFP.PRE and 
pLV411. 
pRRLsin.11c960.SIINFEKL.IRES.GFP.EF1a.td-Tomato: 
This vector was generated by subcloning of EF1α-tdTomato from pUC57.EF1α-tdTomato 
(GenScript Piscataway, NJ, USA) into pRRLsin.11c960.SIINFEKL.IRES.GFP. 
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Lentivirus packaging plasmids: 
pMD.G 
pMD.G is a 2
nd
 or 3
rd
 generation envelope plasmid containing VSV.G for lentivirus production. 
This plasmid was provided by Ian Alexander. Source pMD.G (Dull et al. 1998) 
pRSV.Rev 
pRSV.Rev is a 3
rd
 generation packaging plasmid containing Rev under RSV for lentivirus 
production. This plasmid was provided by Ian Alexander. Source pRSV.Rev (Dull et al. 1998) 
pMDLg/pRRE 
pMDLg/pRRE is a 3
rd
 generation packaging plasmid containing gag, pol, RRE for lentivirus 
production. This plasmid was provided by Ian Alexander. Source pMDLg/pRRE (Dull et al. 1998) 
2.3.10 Flow cytometry and western blot antibodies 
All antibodies used are listed in Table 2.1. and Table 2.3 
Table 2.1: List of flow cytometry antibodies. 
Antigen Conj. Isotype Dil
n
 (FACS) Clone Supplier/Cat # 
CD45R  
(B220) 
FITC ratIgG2a k 
ratIgG2a k 
1/800 
1/400 
RA3-6B2 
RA3-6B2 
In House  
Biolegend 
Cat#103206 
CD45R  
(B220) 
biotin rat IgG2a k 1/200 RA3-6B2  Pharmingen 
Cat#553085 
CD3  FITC Armenian hamster IgG 1/100 145-2C11 Biolegend 
Cat#100306 
CD4 PE rat IgG2b k 1/400 or > GK1.5 Biolegend 
Cat#100408 
CD4 biotin rat IgG2b k 1/1600 GK1.5 In house 
CD8(Ly-2) 
PerCP.Cy5.5 rat IgG2ak 1/200 53-6.7 Biolegend 
Cat#100734 
CD8(Ly-2) 
biotin rat IgG2b 1/800 YTS-169 In house 
CD317 
(PDCA-1) 
(BST2) 
APC rat IgG2b κ 1/100 927 BioLegend  
Cat#127016 
CD45.2 
PE.Cy7 mIgG2a k 1/100 104 BioLegend 
Cat#109830 
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CD45.2 
APC mIgG2a k 1/100 104 BioLegend 
Cat#109814 
CD117  
(c-kit) 
FITC rat IgG2b 1/400 ACK-2 In House 
Ly-6G/C  
(Gr-1) 
FITC rat IgG2b k 1/800  RB6-8C5 In House 
Ly-6G/C  
(Gr-1) 
biotin rat IgG2b k 1/800 RB6-8C5 In House 
Siglec-F PE rIgG2ak 1/100 E50-2440 Pharmingen 
Cat#552126 
TER-119 
(Ly-76) 
biotin rat IgG2b k 1/400 TER-119 In House 
CD11b PerCP.Cy5.5 rat IgG2b k 1/400 M1/70 Biolegend 
Cat#101228 
CD11b 
 
biotin rat IgG2b 1/400 M1/70 Biolegend 
Cat#101204 
CD11c FITC hamster IgG 1/200 N418 Biolegend 
Cat#117306 
CD11c APC hamster IgG 1/100 N418 Biolegend 
Cat#117310 
CD11c APC. 
Cy7 
hamster IgG 1/100 N418 Biolegend 
Cat#117824 
I-A
d
 Alexa Fluor 
647 
mIgG3 k 1/400 39-10-8 Biolegend 
Cat#115010 
Mouse Isotype 
biotin mouse IgG2a k 2ug/ml MOPC-173 
Biolegend 
Cat#400204 
 
unconj. 
Rabbit Pre-immune  
serum 
1/5000  Sigma Cat#R9133 
Donkey anti- 
 Rabbit 
 IgG 
biotin rabbit IgG 1/5000 polyclonal 
EMD Millipore 
Cat# AP182B 
Chicken  
OVALBUMIN 
unconj Rb polyclonal 1/5000  Sigma Cat# C6534 
Lol p 1 
(FMC-A1) 
biotin Mouse monoclonal A1 2ug/ml  Provided by Dr 
Janet Davies 
*Staining panels:  
T cells: CD3-Fz / CD4-PE /CD8-PerCP Cy5.5/ CD45.2-APC or B2-20-Fz / CD4-PE /CD8-PerCP-
Cy5.5 /CD317pDCA1-APC/ CD45.2-PE Cy7 
 
Myeloid: CD11c-Fz / SIGLEC-F- PE/ CD11b-PerCP.Cy5.5 / CD45.2-APC or Gr-1-Fz / Siglec-F-
PE/ CD11b-PerCP/CD11c-APC / CD45.2-PE-Cy7 
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Table 2.2: List of secondaries. 
 
Table 2.3: List of western blot antibodies 
 
2.4 Cell culture and animal procedures 
2.4.1 Lymph nodes and spleens 
Mediastinal lymph nodes were aseptically excised and placed in a 15ml Falcon tube (BD 
Biosciences, San Jose, CA, USA) filled with cold F2.5. Likewise, spleens were aseptically extracted 
and placed in a 15ml Falcon tube with 5ml of cold F2.5. 
To obtain single cell suspensions, lymph nodes and spleens were placed into separate 70µm nylon 
mesh cell strainers (BD Biosciences, San Jose, CA, USA) positioned on 50ml Falcon tubes (BD 
Biosciences, San Jose, CA, USA) in a laminar flow hood. The rubber end of a plunger from 5ml 
syringes (BD Biosciences, San Jose, CA, USA) was used to manually disrupt cells, with regular 
flushes of F2.5. Cells were then collected by centrifugation (at 367g, for 5 minutes, 4°C). Spleen 
cells were subjected to RBC lysis (ACK buffer) while lymph node cells underwent a further 
Antigen Conj. Isotype Dil
n
 (FACS) Clone Supplier/Cat # 
Streptavidin APC  1/200  Caltag Cat# SA1005 
Streptavidin Brilliant 
Violet 421 
 1/400  Biolegend 
Cat#405226 
Antigen Conj. Isotype Dil
n
 (FACS) Clone Supplier/Cat # 
Chicken  
OVALBUMIN 
unconj Rb polyclonal 1/10000  Sigma Cat# C6534 
Lol p 1 
( FMC-A1) 
biotin Mouse monoclonal A1 1/5000  Provided by Janet 
Davies 
Beta actin biotin Rabbit polyclonal 1/3000  Cell signalling 
Cat#4967 
anti-mIgG HRP 
conjugated 
Mouse monoclonal 1/3000  Promega 
Cat#W4021 
Anti-Rabbit IgG HRP 
conjugated 
polyclonal 1/3000 
1/5000 
1/10000 
 Promega 
Cat#W401B 
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washing step. Both lymph node and spleen cells were then re-suspended in F2.5 or culture medium 
as required for trypan blue cell enumeration using a haemocytometer, with the volume subsequently 
adjusted as needed.   
2.4.2 Bone marrow transplantation 
Using aseptic technique, femurs and tibiae were harvested from donor mice by severing the femur 
at the hip and the tibia above the ankle. Bulk tissue was removed from bones before being placed 
into a 50ml Falcon tube containing cold MT-PBS.  
In a laminar flow hood, bone marrow was flushed from individual bones. Forceps and scissors were 
used to pry the epiphyseal plate from the proximal end of the tibia and a 22-25g needle (BD 
Biosciences, San Jose, CA, USA) inserted into the marrow cavity. Approximately 2-3ml of F2.5 
was sufficient to flush bone marrow from an individual bone. Likewise the distal end of the femur 
was cut and the marrow flushed. Bone marrow was resuspended by passing cell clumps through the 
needle several times. Cells were then transferred to a sterile 50ml Falcon tube and collected by 
centrifugation (at 350g, 5 minutes, 4°C). Erythrocytes were then removed by ACK lysis. Cells were 
counted and re-suspended to the appropriate concentration for transplantation. 
In some experiments, recipient mice were couriered to the Mater Medical Research Institute 
(Brisbane, Queensland) and gamma-irradiated (
137
Cs source) with a single dose of 300cGy. 
Following irradiation, mice were returned to the Princess Alexandra Hospital Biological Resources 
Facility (Brisbane, Australia) and injected with bone marrow. Otherwise, gamma-irradiation was 
conducted at the Translational Research Institute (Brisbane, Queensland). Cells were transported on 
ice and delivered by intravenous (i.v.) injection into the lateral tail vein. 1x10
7
 bone marrow were 
injected in 200µl MT-PBS unless stated otherwise. 
2.4.3 Sensitisations 
Sensitisations were performed using i.p. injection. For i.p. sensitisation, 200ul of suspended 
allergens at 50µg of OVA (albumin from chicken egg white; Sigma), 10 or 50µg of OVA323-339 
(Auspep Batch #Y20329), or 30µg of RGP in 1mg of alum (aluminium hydroxide, Alu-Gel-S; 
Serva) were injected.  
2.4.5 Intranasal challenges 
Mice were lightly anaesthetised with inhalational anaesthetic (Methoxyflurane or isoflurane). Mice 
were held gently up at approximately a 70-80
o
 angle with nose canted slightly forward at about 10
o
 
from the vertical. OVA, RGP or Lol p 1 solution was applied to nares with a P200 pipette in small 
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(~5-10μl) portions at approximately 1-2 seconds intervals. The solution was applied drop-wise until 
the complete dose (50µg or 20µg in 50µl pyrogen-free saline) has been administered. The mouse 
was retained in the ‘upright position for 10-20 seconds after the last application to ensure full 
inhalation of the solution. 
2.4.6 Bronchoalveolar lavage 
Mice were euthanised by CO2 narcosis and trachea was exposed. A small incision was made and a 
blunt 18G needle was inserted into the trachea. 1ml mouse tonicity-PBS (MT-PBS) was slowly 
injected and aspirated four times and fluid was collected. This was repeated with another 2x 1ml 
portions of MT-PBS. Samples were placed on ice. In some experiments the first 1ml harvested was 
centrifuged and the supernatant used for cytokine analysis by ELISA and the cell pellet pooled with 
the remaining 2ml of BALF.  
2.4.7 Serum collection 
Mice were culled and immediately blood was collected by cardiac puncture using a 25G needle 
with 1ml syringe. Blood was allowed to clot at room temperature. Serum was then collected after 
centrifugation (microcentrifuge 5424, Eppendorf, Hamburg, Germany) at 14,000g for 5 minutes. 
Serum was stored at -30
 o
C for further analysis by ELISA. 
2.5 Lentiviral vector design and production 
2.5.1 TfR-Lol p 1 and TfR-OVA construct design and plasmid preparation 
Two allergen sequences were chosen to design lentiviral transfer plasmids, the plant allergen Lol p 
1 (accession#P14946) sequence described by Griffith et al. (Griffith et al. 1991) (Appendix Fig.I.1-
I.2) and OVA (accession#P01012). cDNA encoding aa 1-118 of the human transferrin receptor 
(accession#P02786), which contains the transmembrane domain that effectively targets proteins to 
the cell membrane (Zerial et al. 1986), was added in-frame 5’ to the full-length cDNA encoding Lol 
p 1 or OVA. The DNA sequences were codon optimized for mouse using the EnCor Biotechnology 
online Codon Optimisation Calculator (http://www.encorbio.com/protocols/Codon.htm) and sent to 
GenScript (GenScript, USA) to be synthesized as a mini-gene. The lypholized plasmid 
(pUC57.TfR-Lolp1 (4µg); pUC57.TfR-OVA (4µg)) synthesized by Genscript was dissolved in 
20µl sterile distilled water (Baxter, Deerfield, IL, USA) and 1µl of DNA, was mixed with 50µl of 
E.coli (DH5α) and incubated on ice for 10 minutes. The transformation was performed by heat 
shock for 45-50 seconds at 42°C in a water bath and the transformation mix immediately cooled on 
ice for 2 minutes. The bacteria were then transferred to 900µl of LB media and incubated in a rotary 
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shaker (KS 4000 ic control, IKA, Wilmington, NC, USA) at 37°C for 1 hour at speed of 220 rmp. 
After incubation, the LB mixture was centrifuged at 10,062g for 5 minutes and the supernatant 
discarded. The pellet was resuspended in 200µl of LB broth. Resuspended bacteria were then plated 
on LB agar plate containing Ampicillin (100µg/ml) and incubated overnight at 37°C. One colony of 
the transformed E.coli (DH5α) was picked and inoculated into 10ml of LB broth containing 
ampicillin and cultured for 8 hours at 37°C in a rotary shaker. A small volume of the LB mixture 
was stored in 100% glycerol at -80°C and the rest was used for plasmid isolation extraction using 
Qiaprep spin miniprep Kit (250) (Qiagen, Venlo, Limburg, Netherlands). The concentration of 
plasmid DNA was then measured using a Nanodrop Lite spectrophotometer (ThermoScientific, 
Waltham, MA, USA) at 260nm and 280nm wavelengths (A260/A280 ~1.82). The plasmid DNA 
was then stored at -80°C for future use in cloning. 
2.5.2 Restriction digests, DNA extraction, ligation, transformation 
In separate tubes, the plasmid DNA (pRRLsin.11c960.SIINFEKL.IRES.GFP.Ef1a.td-Tomato or 
pRRLsin.CMV.IRES.GFP) and (pUC57.TfR-Lolp1 or pUC57.TfR-OVA) were digested with the 
appropriate restriction enzyme(s) MluI (5´- ACGCGT-3´) (NEB, Ipswich, MA, USA) and XbaI (5´-
TCTAGA-3´) (NEB, Ipswich, MA, USA). In a microfuge tube, the following mixture was set up 
for each digest reaction: DNA (2-3.5μg), 10x restriction enzyme buffer3 (2μl), Restriction 
enzyme(s) (1μl), nuclease-free dH2O to a final volume of 20μl. A control reaction was set up 
containing all the reagents listed above except the restriction enzyme(s). The digest was performed 
in microfuge tubes at 37°C for 5 hours. When digestion was completed, 5x Gel loading dye (5μl) 
(Bioline, London, UK) was added to each reaction. Digested samples (25μl) and Hyperladder1 (5μl) 
(Bioline, London, UK) were each loaded onto 0.7% agarose gel and electrophoresed (Bio-Rad 
powerpac300V, Hercules, CA, USA) at 60V for 1½ hours. An image of the gel was taken using 
GelDoc (QuantumST5, Vilber Lourmat, France) and analysed Quantum software (Quantum 
ST4Xpress v16.04, Vilber Lourmat, France). The agarose gel was then placed on a plastic bag over 
the bench-top UV transilluminator (Major Science, Saratoga, CA, USA). The bands of interest were 
visualized and excised using sterile lancet blades (1122bp TfR-Lolp1; 1566bp TfR-OVA; 12kb 
pRRLsin.11c960.IRES.GFP.Ef1a.Tdtomato). DNA extraction from the excised gel was then 
performed as detailed in the protocol for the Gel/PCR DNA fragments extraction kit (IBI, Toronto, 
ON, Canada). A ligation reaction for the DNA was then setup as follows: plasmid vector DNA 
(pRRLsin.11c960.SIINFEKL.IRES.GFP.Ef1a.td-Tomato or pRRLsin.CMV.IRES.GFP) (200ng), 
insert DNA (at 3:1 molar excess over vector calculated using Ligation calculator (insilico)), 10x 
Ligation buffer (2μl) (NEB, London, UK), T4 DNA Ligase (1μl) (NEB, London, UK), nuclease-
free dH2O to a final volume of 20μl. A control reaction was set up containing all the reagents listed 
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except the insert DNA(s). The mixture was incubated for 5 hours at room temperature. A volume of 
5μl of the ligation mixture was used to transform E. coli DH5α as described in section 2.4.3. The 
colonies formed were stored at 4 °C for confirmation of the ligation clone later. 
2.5.3 Ligation confirmation and sequencing 
Colonies were picked from the transformant plate, grown in LB broth containing ampicillin at 37°C 
for 8 hours in a rotary shaker and plasmid DNA was prepared using Qiaprep spin miniprep Kits. 
Miniprep DNA was digested with restriction enzymes (as described in section 2.4.4). The digested 
samples were electrophoresed in 1% agarose gel and the fragment sizes confirmed with the aid of 1 
kb ladder. 
Miniprep DNA confirmed by restriction digest was prepared for sequencing. The reaction mixture 
for PCR was: 5x Big Dye Terminator (BDT) reaction buffer (1.5μl), BDT v3.1 (1μl) (Life 
Technologies, CA, USA), plasmid DNA (200-500ng), Primers for each separate reaction (3.2μl), 
nuclease-free dH2O to a final volume of 10μl. The reaction was performed in a thermocycler (PTC-
100, Marshall Scientific, Brentwood, NH, USA) using the cycling conditions: denaturation 95°C for 
30 seconds, annealing 55°C for 30 seconds, extension 72°C for 30 seconds and number of cycles 
35. The samples were cleaned (ethanol/EDTA) as instructed in the Applied Biosystems (AB, 
3730/3730xl) Sequencing Chemistry Guide and sent to the Australian Genome Research Facility 
(AGRF) for sequencing. Sequencing chromatograms were viewed and analyzed using Chromas 
(version 1.45, Conor McCarthy, Griffith University, Australia) and aligned using CLC DNA 
Workbench 6.0.2 (Qiagen, Germany). The transformed E.coli (DH5α) with the correct plasmid 
DNA sequences were then expanded and plasmid DNA isolated using a maxiprep kit (Endo-free 
plasmid maxikit, Qiagen, Germany) or a megaprep kit (Endo-free plasmid megakit, Qiagen, 
Germany) for later use in transfections and lentivirus production. Plasmid DNA was concentration 
was determined using a Nanodrop Lite spectrophotometer (ThermoScientific, Waltham, MA, USA) 
at 260nm and 280nm wavelengths. 
Sequencing Primers (GeneWorks, MA, USA) for: 
pRRLsin.CMV.TfR-Lolp1.IRES.GFP 
Universal external forward primer: (5’-3’) GACAGAGACAGATCCATTCG 
Lol p 1 internal forward primer 1: (5’-3’) TGA TTG GCT ACT TGG GCT ATT GT 
Lol p 1 internal forward primer 2: (5’-3’) TGA CCA TCA CCG ACG ACA AC 
Universal external reverse primer: (5’-3’) GCATCCTTCAGCCCCTTG 
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pRRLsin.CMV.TfR-Lolp1.IRES.GFP 
Universal external forward primer: (5’-3’) GACAGAGACAGATCCATTC 
OVA internal forward primer 1: (5’-3’) ATT GGC TAC TTG GGC TAT TGT 
OVA internal forward primer 2: (5’-3’) AGA GAC ATC CTC AAC CAA ATC A 
OVA internal forward primer 3: (5’-3’) TGA GCA AGA AAG CAA ACC 
Universal external reverse primer: (5’-3’) GCATCCTTCAGCCCCTTG 
pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1a.td-Tomato 
Universal external forward primer: (5’-3’) GCCTCCTGACCACCTTTCTT 
Lol p 1 internal forward primer 2: (5’-3’) TGATTGGCTACTTGGGCTATTGT 
Lol p 1 internal forward primer 3: (5’-3’) TGACCATCACCGACGACAAC 
Universal external reverse primer: (5’-3’) AGG AAT GCT CGT CAA GAA GAC 
pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1a.td-Tomato 
Universal external forward primer: (5’-3’) GCCTCCTGACCACCTTTCTT 
OVA internal forward primer 2: (5’-3’) ATTGGCTACTTGGGCTATTGT 
OVA internal forward primer 3: (5’-3’) AGAGACATCCTCAACCAAATCA 
OVA internal forward primer 5: (5’-3’) TGAGCAAGAAAGCAAACC 
Universal external reverse primer: (5’-3’) AGG AAT GCT CGT CAA GAA GAC 
All primers were designed using NCBI primer tool (Bethesda, MD, USA). The primers were then 
checked for hairpin formation, and self-dimerization using NetPrimer program (Premier Biosoft, 
Palo Alto, CA, USA). Primers were aligned against their respective plasmid using CLC workbench 
6.0.2 (Qiagen, Germany). 
2.5.4 Transient transfections 
The vectors pRRLsin.CMV.TfR-Lolp1.IRES.GFP, pRRLsin.CMV.TfR-OVA.IRES.GFP, and 
pRRLsin.CMV.IRES.GFP were used for transient expression of TfR-Lolp1, TfR-OVA, and GFP 
respectively in HEK293T cells. HEK293T cells were seeded at a density of 1 × 10
3
 cells in T25 
flasks (Greiner, Austria) in complete DMEM. The following day, medium was exchanged with 
DMEM medium containing chemically-defined lipid formula, and 0.01mM cholesterol. HEK293T 
cells were then transfected with pRRLsin.CMV.TfR-Lolp1.IRES.GFP (3.3μg), pRRLsin.CMV.TfR-
OVA.IRES.GFP (3.3μg), or pRRLsin.CMV.IRES.GFP (3.3μg) using a CaCl2 transfection method. 
As negative controls, transfections were also performed without addition of DNA to the 
CaCl2/2xBBS mixture. One day later, the cells were harvested and stained for Lol p 1 and OVA 
surface expression and analysed by flow cytometry. 
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2.5.5 Lentivirus production and titration 
HEK 293T cells were seeded at a density of 1 × 10
6
 cells in T75 flask (Greiner, Austria) and unless 
stated otherwise were transfected with vector DNA (6.6µg) (pRRLsin.CMV.GFP, pRRLsin-
11c960.SIINFEKL.IRES.GFP.EF1a.td-Tomato, pRRLsin.11c960.TfR.Lolp1.IRES.GFP.EF1a.td-
Tomato, or pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1a.td-Tomato), pMDL gag/pol RRE (3.3µg), 
pRSV.Rev (3.3µg), and pMD-G (3.3µg) plasmids in endotoxin-free H20, CaCl2, and 2xBBS pre-
warmed to room temperature. Twelve hours after transfection, fresh medium was added containing 
chemically-defined lipid formula, 0.01mM cholesterol, and 10mM sodium butyrate. Viral vector-
containing supernatant was collected the next day and stored at 4
o
C and fresh medium containing 
chemically-defined lipid formula, and 0.01mM cholesterol was added to the cells. Twenty-four 
hours later, viral vector-containing supernatant was collected and pooled with the supernatant 
collected from the previous day. The supernatant was centrifuged at 500g for 7 minutes at 4
o
C to 
remove 293Ts and then filter clarified using a 250ml benchtop filter (0.22µm) (Thermo Scientific, 
Waltham, Massachusetts, USA). The virus was then precipitated by polyethylene glycol 6000 
(PEG6000) precipitation adapted from Kutner, RH., et al. (Kutner et al. 2009), centrifuged at 
7,000g for 10 minutes at 4°C using Beckman fixed-angle JLA16.250 rotor and resuspended in 1ml 
of 50mM Tris-HCl, pH7.4. The virus was then aliquoted and stored at -80
o
C for later use. Vector 
titer was determined by transducing 293T with 1/100 - 1/1,000,000 dilutions of the virus and two 
days later expression for marker gene (GFP or td-Tomato) was determined by flow cytometry.  
 
Calculation of Viral Titer 
 
1. Calculate titer in a well where between 1% and 10% of cells are positive for marker gene 
expression. 
 
2. Refer to table below, and work out the volume of virus used. 
Dilution  Volume virus used (µL) 
10
-2
  (1/100) 20 
10
-3
  (1/1000)  2 
10
-4 
  (1/10,000) 0.2 
10
-5
  (1/100,000) 0.02 
10
-6
  (1/1,000,000) 0.002 
 
3. Formula for titer is; 
[viral titer was expressed as number of viral particles (or transducing units: TU)  per mL] 
 
Titer /ml (TU/ml) =                      
          
   
      
 
               
              
          
Example calculation: 5% of cells GFP
+ve
 in 10
-3
 dilution plate using 2x105 cells 
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Titer /ml (TU/ml) =              
 
   
      
 
 
         = 5 x 106 /ml 
 
2.5.6 AUTOMACS enrichment of c-kit
+
 hematopoietic stem and progenitor cells 
Hematopoietic stem and progenitor cells (HSPC) were isolated from bulk bone marrow by 
enrichment for c-kit
+
 cells using AUTOMACS (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Following RBC lysis, BM cells were washed and transferred to a polypropylene FACS tube (BD 
Biosciences, San Jose, CA, USA) through a 70µm cell strainer (BD Biosciences, San Jose, CA, 
USA). Cells were centrifuged at 350g for 5 minutes at 4
0
C were then re-suspended in F10/EDTA at 
a concentration of 10
8
 cells/ml and stained with anti-c-kit-FITC. After staining, cells were washed, 
centrifuged and re-suspended in F10/EDTA (90L/107cells) and anti-FITC MACS beads at 
10L/107cells (Miltenyi Biotec, Germany ) were then added for an incubation time of 15 minutes at 
4
0
C. Cells were constantly kept on ice between steps. c-kit-FITC stained cells were then separated 
on AUTOMACS using program POSSELD. Following AUTOMACS separation, cells were 
counted and re-suspended in IMDM for lentivirus transduction. c-kit positive cells were typically > 
70% of recovered cells. Aliquots of cells were kept from, before (unstained BM and c-Kit-FITC 
stained BM) and after AUTOMACS separation and stained with anti-lineage mix (CD4, CD8, 
CD45R (B220), CD11b, Gr-1 (Ly-6G), TER-119 (Ly-76) monoclonal antibodies using standard 
FACS staining protocols to determine purity by cytometric analysis. Sterile propidium iodide (PI) 
(Sigma-Aldrich, St. Louis, MA, USA) was added to cells immediately prior to cytometric analysis 
to determine cell viability.  
2.5.7 Lentiviral transduction of c-kit
+
 HSPC and in vitro DC differentiation 
Flat bottom 96 well plates were coated with fibronectin (50µl/well at 25µg/ml; final fibronectin 
concentration = 3.9µg/cm
2
) including well(s) for untransduced controls and incubated at R.T. for 2 
hours. Fibronectin was then flicked off the plate and the wells were blocked with 200μl of 2% BSA 
in PBS for 30 minutes. pRRLsin.CMV.GFP lentivirus was diluted to 10
6
 transduction units/ml. 
pRRLsin11c960.TfR-Lolp1.IRES.GFP. EF1α.td-Tomato and pRRLsin11c960.TfR-
OVA.IRES.GFP. EF1α.td-Tomato were used undiluted. The blocking solution was flicked off the 
96-well plate and 50μl/well of virus (or complete IMDM (I20) for untransduced controls) was 
added as required. The plate was then loaded into lidded plate holders and centrifuged (Sigma 
4K15) for 2 hours, 2000g at 10-14
0
C. c-kit-enriched HSPC were diluted to 10
6
/ml in I20/cytokine 
(rmSCF 20ng/ml, rm IL-3 10ng/ml, rm IL-6 10ng/ml, rm IL-11 100ng/ml)/polybrene mix. Then 
50μl/well of the HSPC mix was added to the wells containing the virus without removing the virus 
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solution. The plate was incubated at 37
o
C for 18 hours and cells from each transduction condition 
were harvested, rinsed with F2.5, and stained with anti-lineage mix (CD4, CD8, CD45R (B220), 
CD11b, Gr-1 (Ly-6G), TER-119 (Ly-76)) monoclonal antibodies using standard FACS staining 
protocols. Propidium iodide (PI) (Sigma-Aldrich, St. Louis, MA, USA) was added to cells 
immediately prior to analysis to exclude dead cells. GFP and td-Tomato expression for determining 
transduction rates was then analysed on a MoFlo Astrios (Beckman Coutler, Fort Collins, USA). 
For the remaining wells, the plate was centrifuged at 200g for 3 minutes. The medium was 
exchanged with 200µl of IMDM/cytokine (rmSCF 20ng/ml; GM-CSF 4ng/ml; TNF-α 25ng/ml) 
mix. One day later the plate was centrifuged at 200g for 3 minutes, 100µl of media removed from 
each well and substituted with fresh IMDM/cytokine (rmSCF; GM-CSF; TNF-α) mix. At day six 
post-transduction, the cells were then harvested and stained with: CD11c APC-cy7/IA
d
- alexa 647, 
anti-Lolp1, anti-OVA, Streptavidin brilliant violet 421, Isotype (mIgG2A-bio), Rabbit serum; 
Donkey anti-rabbit using standard FACS staining protocols. Propidium iodide (PI) (Sigma-Aldrich, 
St. Louis, MA, USA) was added to cells immediately prior to analysis to exclude dead cells. DC 
differentiated cells were analysed for GFP, td-Tomato, Lol p 1, and OVA expression using a MoFlo 
Astrios (Beckman Coutler, Fort Collins, USA). 
2.6 Western blot 
2.6.1 Sample preparation 
HEK293T untransfected or transiently transfected with either pRRLsin.CMV.TfR-Lol.IRES.GFP or 
pRRLsin.CMV.TfR-OVA.IRES.GFP, as described (section 2.5.4), were trypsinized (Invitrogen, 
USA) to harvest cells at two days post-transfection, then washed with PBS. The cells were 
centrifuged at 350g for 5 minutes at 4°C and resuspended in 1ml PBS for counting. Cells were then 
transferred to 1.5ml PCR tubes and centrifuged at 845g for 5 minutes at 4°C. Supernatant was 
discarded and cells resuspended in 200µl of RIPA buffer (200µl for 1x10
6
 cells/ml). The cells were 
incubated on ice for 30-45 minutes with light vortexing every 10 minutes. After the incubation, 
tubes containing the lysed cells were centrifuged (microcentrifuge 5424R, Eppendorf, Hamburg, 
Germany) at 14,000 g for 15 minutes at 4°C. Lysates were then transferred to fresh PCR tubes for 
further analysis and the pellet was discarded.  
2.6.2 Electrophoresis and blotting 
Lysates from untransfected or transfected HEK293T cells (50µl) were each mixed on ice with 5x 
reducing sample buffer (RSB) (20µl) and distilled water (30µl) and then heated in a heating block at 
95°C for 4 minutes. For the positive controls, 3.6µl of RGP (2.8mg/ml) and 10µl of OVA (1mg/ml) 
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were each mixed with 5x reducing sample buffer (RSB) (20µl) and the respective volume of 
distilled water added for a final volume of 100µl of each mixture. The Seeblue pre-stained 
molecular weight standard (5 µl) (Life techonologies, CA, USA) and each of the samples (10 µl) 
were loaded for SDS-PAGE gel electrophoresis (at 130V for 70 minutes). 5x TGS buffer was used 
as the running buffer. Gel transfer and electrophoresis was according to manufacturer’s instructions 
(Mini-Protean 3 cell manual, Bio-Rad). The method for electrophoretic transfer to nitrocellulose 
membrane was adopted from Towbin, et. al (Towbin et al. 1979). The Mini Trans-blot apparatus for 
the transfer was positioned in a cold room and set to run at 30V for 3 hours. The membranes were 
blocked for ½ to 1 hour in blocking buffer (5% Skim Milk Powder (SMP) /0.05%Tween 20 in PBS; 
pH~ 7.4) at room temperature and washed 3 times with PBS/0.05%Tween 20. Membranes were 
incubated overnight at 4°C with the following optimal dilutions of primary antibodies in blocking 
buffer: 1/5000 for monoclonal anti-mouse Lol p 1 (FMC-A1; (Smart et al. 1983)), 1/10000 for 
rabbit polyclonal anti-OVA (Sigma-Aldrich, St. Louis, MA, USA), and 1/3000 for rabbit polyclonal 
anti-β actin (Cell Signalling, MA, USA). The next day, after thorough washing in PBS containing 
0.05% Tween 20, membranes were incubated for 2 hours in a 1/3000 dilution of the second 
antibody, horseradish peroxidase (HRP)-conjugated anti-Mouse IgG (Promega, Madison, WI, USA) 
and, 1/3000, 1/5000, and 1/10000 horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG–
HRP (Promega, Madison, WI, USA) in blocking buffer. Control blots, developed with secondary 
antibody alone (i.e no primary antibody) were routinely included to allow detection of non-specific 
bands reacting directly with the second antibody. No non-specific binding of the secondary 
antibodies were detected. Blots were washed with washing buffer and then PBS alone to remove 
Tween 20 and developed by the enzyme chemiluminescence method according to the 
manufacturer's instructions (Thermo Scientific, Waltham, Massachusetts, USA) using the gel 
documentation system (Fusion, Vilber Lourmat, France). Replica white light images of the blots 
were used to align the location of bands with the molecular weight markers. Images were inverted 
using Bio-ID (version 15.04,Vilber Lourmat, France), cut from photoshop and assembled in 
Microsoft Word. 
2.7 Flow cytometry 
2.7.1 Surface staining 
All staining procedures were performed on ice. Samples were centrifuged at 367g for 5 minutes at 
4
o
C and supernatant was discarded. Cells were resuspended in 1ml F2.5 then each sample was 
transferred to FACS (fluorescence activated cell sorting) tubes in equal proportions. Samples were 
then centrifuged at 805g for 2 minutes at 4
o
C to collect cells. Supernatant was tipped off to leave 
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~100μl which was vortexed to resuspend cells. All samples were treated with 10μl FACS-block 
(anti-CD16/32 [2.4G2]) for 5 minutes. Next, 10μl of required antibodies (at working 
concentrations) (Table 2.1) were added to each sample and tubes were incubated in the dark for 30 
minutes. Following staining, cells were washed with cold FACS-wash (0.1% BSA/2mM EDTA) 
and cells collected. Supernatant was ‘tipped off’ to leave ~100μl and briefly vortexed to resuspend 
cells. Samples were then analysed by flow cytometry (BD Canto, TRI Flow Cytometry Facility or 
MoFLo Astrios, TRI Flow Cytometry Facility) with or without addition of flow count beads 
(20μl/tube) (Beckman Coulter, Miami Lakes, FL, USA). FACS Diva (BD Biosciences, San Jose, 
CA, USA) or FlowJo (FlowJo, Ashland, OR, USA) software was used to analyse data. FlowJo 
software (FlowJo, Ashland, OR, USA) was used to plot representative gating. 
2.8 In vivo and in vitro assays 
2.8.1 In vitro lymphocyte restimulation 
Single cell suspensions were adjusted to 2.5x10
6
 cells/ml, plated in 24 well plates (up to 2ml per 
well), with four stimulation conditions per sample where possible: unstimulated, OVA (10μg/ml), 
OVA323-339 (10μg/ml) and anti-CD3 (Biolegend, Clone 145-2C11, 1μg/ml). Cells were incubated at 
37
o
C, 5% CO2 for three days. Supernatant was then harvested and stored at -20
o
C until analysis. 
2.8.2 Cytokine enzyme-linked immunosorbent assay (ELISA)  
For recombinant cytokines and antibodies used, see Table 2.4. Maxisorp ELISA plates 
(eBioscience, CA, USA) were coated with 50μl/well capture antibody (50mM sodium bicarbonate, 
pH 9.4) overnight at 4
o
C. Plates were washed (0.05% Tween-20/MT-PBS, five times) and blocked 
with diluent (100μl/well (4% BSA/MT-PBS)) for 2 hours, room temperature (R.T). Blanks, 
cytokine standards and samples were then added (50μl/well) in duplicate and incubated for 1 hour 
R.T. After washing, detection antibody was next applied (50μl/well) for a further 1 hour, R.T. 
Plates were washed and avidin-HRP enzyme (Sigma-Aldrich, St. Louis, MA, USA) was added 
(50μl/well) for 30 minutes, R.T. Following a subsequent wash, 50μl/well TMB substrate (Reagent 
A and Reagent B, 1:1) (Biolegend, CA, USA) was added and plates were incubated in dark until 
developed. The reaction was stopped with 0.5M sulphuric acid (50μl/well). Absorbance was 
analysed at 450nm and 540nm and cytokine concentrations calculated based on standard curves for 
each plate. The detection limit was defined as the lowest concentration at which absorbance began 
to increase from baseline. 
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Table 2.4- ELISA Antibodies and Standards. 
 
2.8.3 Airway hyper responsiveness measurement 
Airway resistance (Rl) and dynamic compliance (Cdyn) were determined as a change in airway 
function after aerosolized methacholine (MCh) challenge. The technique was performed by 
collaborators in Newcastle. Mice were anaesthetized (ketamine and xylazine [80–100 and 10 
mg/kg, respectively]; Troy Laboratories, Smithfield, Australia) and the tracheas cannulated. Each 
cannula was connected to an inline aerosol administrator and ventilator, which were attached to a 
preamplifier and computer (Buxco, Wilmington, NC) to analyse pressure and flow waveforms and 
to determine airway resistance and dynamic compliance (Takeda et al. 1997, Kanehiro et al. 2001). 
Mice were nebulized with saline followed by increasing doses of methacholine (Sigma-Aldrich, St. 
Louis, MA, USA) as described (Horvat et al. 2007). 
2.8.4 Lung histology 
After lavage, lungs were removed and fixed in 10% buffered formalin. Paraffin blocks with the 
lungs facing upwards were prepared and serial lung sections (3 sections cut at 500µm intervals) 
Cytokine 
Capture 
Antibody 
Supplier / Cat # 
(Working conc.) 
Detection 
Antibody 
Supplier / Cat # 
(Working conc.) 
Standard 
IFN- γ R4-6A2 
Biolegend #505706    
(2μg/ml) 
XMG1.2 
Biolegend 
#505804 
(0.1μg/ml) 
rmIFN-g  
US 
Biological,C
at# I1000.  
(-80
o
C)  
IL-4 11B11 
Biolegend LEAF #504108 
(0.5mg) or #504115 (1mg)    
(2μg/ml) 
BVD6-24G2 
Biolegend 
#504202    
(0.5μg/ml) 
rm IL-4    
Peprotech,   
Cat# 214-4.   
(-80
o
C) 
 
IL-5 TRFK5 
Biolegend #504302    
(2μg/ml) 
 
 
TRFK4 
Biolegend 
#504402    
(2μg/ml) 
rm IL-5   
BioLegend,   
Cat# 
563303.  
(-80
o
C) 
IL-13 13A 
eBioscience #14-7133 
(2μg/ml) 
1316H 
eBioscience #13-
7135 
(0.1μg/ml) 
rm-IL13 
eBioscience 
Cat# 148131 
(-80
o
C) 
Immunoglobulin 
Capture 
Antibody 
Supplier / Cat # 
(Working conc.) 
Detection 
Antibody 
Supplier / Cat # 
(Working conc.) 
Standard 
IgE RME-1 
Biolegend #406902 
(1μg/ml) 
UH297 
Biolegend 
#408804 
(0.2μg/ml) 
IgEκ 
(BALB/c) 
Biolegend, 
Cat#401701 
(-80
o
C) 
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were prepared. Sections were stained with haematoxylin and eosin or with periodic acid-Schiff 
(PAS) reagent. Stained slides were scanned at 20x magnification with an Olympus VS120 
(Olympus corporation, Shibuya-KU, Tokyo, Japan) and the images were prepared using the 
OlyVIA2.6 software (Olympus Soft Imaging Solutions GmbH, US). 
2.8.5 Histological analysis of respiratory tissues 
Quantitation of mucus-filled goblet cells: 
Images were sampled from scanned slides, using the OlyVIA2.6 software (Olympus Soft Imaging 
Solutions GmbH, US). For each mouse, images of every airway from 3 individual lobes were taken. 
Images were encoded for blinding and fifteen images of individual airways for each mouse were 
used. Counting of mucus-filled cells (PAS
+
 cells)/100μm and quantitation of the length of 
epithelium analysed was performed using NIS Elements Basic Research Software (BR 3.2 64 bit, 
Nikon, USA). Data was collated in Microsoft Excel and unblinded. Means for each lobe and each 
mouse were then calculated.  
Quantitation of cellular infiltrate: 
A semiquantitative histopathologic scoring system was modified from the method of Gavett, et al. 
(Gavett et al. 1999) and was based on the following criteria: 0) no infiltrate in parenchyma or 
surrounding airways , 1) sparse: 0-20% airways and vessels with infiltrate (<50% of 
circumference), 2) moderate: 0-20% airways and vessels with infiltrate (>50% of circumference), 3) 
extensive: 20-70% of large airways (bronchus and large bronchioles) surrounded by cellular 
infiltrate, 4) massive: 70-100% of large airways (bronchus and large bronchioles) surrounded by 
cellular infiltrate and small airways surrounded by infiltrate in addition to areas of infiltrate away 
from airways/vessels. Each of the 3 individual lobes for each mouse blinded, individually scored for 
overall inflammatory infiltrate unblinded and the data collated. The average of the 3 individual lobe 
scores was calculated as the score for each individual mouse.  
2.9 Statistical analysis 
GraphPad Prism 6 was used to generate all graphs and statistical analyses. Statistical significance 
was tested by student’s t-test for comparison of means between 2 groups, or one-way ANOVA with 
Tukey’s multiple comparison post-test for multiple comparisons of means. Significance was 
assigned for the following p-values: < 0.05 (*), < 0.01 (**), < 0.001 (***), < 0.0001 (****). 
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CHAPTER 3: 
TRANSGENIC EXPRESSION OF AN ALLERGEN IN 
DC PREVENTS SENSITISATION AND ALLERGEN-
INDUCED AIRWAY INFLAMMATION 
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3.1 Introduction 
The breakdown of tolerance mechanisms leads to allergies (reviewed in (Lloyd et al. 2010)). 
Classically, allergic diseases are considered to result from Th2-skewed immunity to ubiquitous 
environmental allergens, associated with the production of IL-4, IL-5, and IL-13, (Romagnani 
1994). There is no ‘endogenous’ tolerance to environmental allergens and a repertoire of 
recombined TCR specific for allergens will exist. The only immunological control mechanism for 
allergens is therefore development of regulatory controls that most likely occur by environmental 
exposure. If this fails no control of allergen responses exists to protect against allergic disease 
development exists. One way to control unnecessary immune responses would be to induce a ‘form’ 
of ‘endogenous’ tolerance. 
Administration of soluble antigens (Dietrich et al. 1964, Mitchison 1964) or immunogenic 
peptides (Ria et al. 1990) can generate immune tolerance. Mice fed with OVA (Nakao et al. 1998, 
Russo et al. 2001) or intranasally exposed to OVA (Tsitoura et al. 2000) before being sensitised 
intraperitoneally were unable to develop a Th2 response, airway eosinophilia, airway hyper 
responsiveness, or IgE production (Holt et al. 1981, van Halteren et al. 1997). Mucosal tolerance 
can also be induced using peptides of clinically-relevant allergens (Bet v 1, rPhl p 1, and rPhl p 5) 
(Hufnagl et al. 2005). DC transferred from tolerant mice after intranasal OVA challenges rendered 
recipient naïve mice tolerant to OVA/alum sensitisation (Akbari et al. 2001). This indicates DC can 
be strong inducers of tolerance  
Previously it has been shown that expressing non-MHC neo-self antigens such as ovalbumin 
(Kurts et al. 1996, Kurts et al. 1997), and influenza virus hemagglutinin (HA) (Roman et al. 1990, 
Lo et al. 1992) under the control of a rat insulin promoter induces tolerance in transgenic mice. 
While this relies on ‘cross-presentation of antigen’ for tolerance induction, another way to induce T 
cell tolerance might be through targeting antigen to DC by genetically-engineering steady state DC 
to express cognate antigen under a specific promoter. Genetically engineering APCs to express and 
present the autoantigen acetylcholine receptor (AChR) via the MHC Class II pathway and 
simultaneously delivering FasL led to the elimination of autoreactive T cells (Wu et al. 2000). 
Memory and effector CD8
+
 T cells are deleted or rendered unresponsive in mice expressing cognate 
antigen in DC (Kenna et al. 2008). It is possible this approach could be used to induce tolerance to 
allergens. Indeed, several transgenic mouse models have been developed based on the concept of 
molecular chimerism. These models were used to study the mechanisms that lead to the 
development of allergic diseases or to demonstrate approaches for tolerance induction (reviewed in 
(Hausding et al. 2008, Baranyi et al. 2009)). Persistent molecular chimerism of membrane-bound 
Phl p 5 induces permanent immunological tolerance (Baranyi et al. 2012, Gattringer et al. 2013). 
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However, in these models expression of allergen has been ‘ubiquitous’. The goal of the work 
described in this Chapter is to utilize an ovalbumin-based model in which OVA is targeted to DC, 
to investigate the potential of DC targeting of allergen for tolerance induction.  
The hypothesis to be investigated in this chapter is “OVA expression in DC prevents allergic 
sensitisation and subsequent airway inflammation”. It is well defined that antigen presentation by 
steady-state DC induces tolerance (Probst et al. 2005, Steptoe et al. 2007). The main goal for 
tolerance induction in this chapter is to “prevent allergen specific T-cell responses and, as a 
consequence, allergen-induced airway inflammation. Two key questions will be addressed. Firstly, 
to determine whether expressing OVA in DC protects against establishment of Th2 T-cell 
responses. As a component of this, mice will be sensitised using whole OVA or the peptide 
OVA323-339 to investigate i) whether the immune response mounted is specific to OVA323-339 and ii) 
whether tolerance is achieved to the full length OVA. Secondly, to investigate whether preventing 
priming subsequently prevents allergen-induced airway inflammatory response. 
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3.2 Results 
3.2.1 OVA expression in DC prevents allergen-specific priming 
As the antigen targeting construct used to generate the 11c.OVA transgenic mouse encodes 
a truncated form of OVA (OVA119-386) fused with the transmembrane portion of the human 
transferrin receptor (hTFR) (Fig. 2.1), 11c.OVA mice may show ‘tolerance’ only to the expressed 
fusion protein. If this were the case, then 11c.OVA mice may be responsive to the portion of OVA 
(OVA1-118) that is not contained within the expressed fusion protein. This represents a challenge 
because 11c.OVA mice could mount an immune response to determinants within OVA1-118 if 
sensitised with full-length native OVA protein. To compare responsiveness to full-length OVA or a 
peptide determinant (OVA323-339) contained within OVA119-386, 11c.OVA mice or non-transgenic 
littermate controls were sensitised (OVA/alum) or sham-sensitised (saline/alum). Seven days later, 
spleen cells were collected and stimulated in vitro with OVA, OVA323-339, and anti-CD3 or left 
unstimulated and culture supernatants collected 3 days later (Fig. 3.1A). Culture supernatants of 
spleen cells restimulated with OVA323-339 from the majority of OVA/alum-sensitised non-transgenic 
littermate control mice contained higher levels of the Th2-associated cytokines, IL-5 and IL-13 than 
those from sham-sensitised equivalent controls (Fig. 3.1B note: no significant difference between 
IL-5 11c.OVA and non-transgenic response due to variability which could be resolved by 
increasing the mice numbers). In contrast, there was no indication of increased production of either 
cytokine in splenocyte cultures from OVA/alum-sensitised 11c.OVA mice (Fig. 3.1B). Spleen cells 
from OVA/alum-sensitised non-transgenic littermate control mice, when restimulated with OVA 
protein, produced substantial levels of the Th2-associated cytokines IL-5 and IL-13 (Fig. 3.1C) and, 
overall, cytokine production was significantly greater than in sham-sensitised controls (Fig. 3.1C). 
In OVA/alum-sensitised 11c.OVA mice, restimulation with OVA also induced significant IL-5 and 
IL-13 production and this was virtually equivalent to that of similarly-treated non-transgenic mice 
(Fig. 3.1C). Overall, in non-transgenic controls, the levels of cytokine production elicited by OVA 
restimulation were considerably higher than those elicited by OVA323-339 (Fig. 3.1B vs Fig. 3.1C 
note the different Y-axis scales). IL-4 production was also measured, but the concentrations 
detected (detection limit: 10pg/ml) were low, < 20pg/ml in sensitised non-transgenic OVA-
stimulated cultures and <15pg/ml in OVA323-339 peptide-restimulated cultures from sensitised non-
transgenic mice and are not shown. These data indicate firstly that 11c.OVA mice are capable of 
responding to full-length OVA, but not a peptide determinant within the transgene-expressed 
portion implying induction of tolerance only to determinants within the expressed transgene. 
Tolerance induction to OVA323-339, a major immunogenic T-cell epitope within the expressed 
transgene, will be directly tested by sensitising with OVA323-339 and then comparing responsiveness 
to full-length OVA or OVA323-339 in vitro in further experiments (e.g. Fig.3.10) in this chapter. 
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Secondly, in vitro restimulation with OVA323-339 appears to induce less cytokine production from 
full-length OVA-sensitised mice then in vitro restimulation with OVA. In conclusion, expression of 
full length OVA is likely to be required in order to induce tolerance to the full-length protein. 
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A) 
B) 
C) 
OVA323-339 in vitro stimulation 
OVA in vitro stimulation 
Figure 3.1 T-cell tolerance specifically to a determinant within the expressed OVA transgene.  
(A) Non-transgenic or transgenic (11c.OVA) mice were sham-sensitised (saline/alum) or sensitised 
(OVA/alum). At day 7 post-sensitisation, spleens were collected and restimulated in vitro with (B) 
OVA323-339 peptide or (C) OVA. Three days later supernatant was collected and IL-5 and IL-13 
concentration determined by ELISA. (Data are pooled from 4 separate experiments. Each point 
represents an individual mouse). Statistical test: ANOVA followed by Tukey’s post-test. (*p<0.05). 
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3.2.2 OVA323-339  induces a weak airway inflammatory response  
Given that 11c.OVA mice, when sensitised with full-length OVA, appear capable of 
mounting a Th2 response to determinants within the portion of OVA (OVA 1-118) that is not 
expressed as transgene, but not to OVA323-339 present within the expressed transgene (Fig. 3.1B), it 
was plausible to expect i.n. challenge of OVA/alum sensitised 11c.OVA mice with full-length OVA 
might elicit localised airways inflammation. Alternatively, it would be expected that challenge with 
OVA323-339 would not. To restrict immune responses to OVA119-386, to avoid Th2 responses that 
might be associated with full-length OVA, and to test whether expression of the 11c.OVA transgene 
prevented an airways inflammatory response to challenge with a determinant contained in the 
expressed transgene, mice were sensitised (OVA/alum) or sham-sensitised (saline/alum) and 11 
days later intranasally challenged with OVA323-339 for four consecutive days (days 11-14). One day 
later, bronchoalveolar lavage fluid (BALF) was collected for analysis by flow cytometry 
(Fig.3.2A). In this particular experiment, CD4
+
 T-cell and eosinophil content did not differ in the 
BALF of sensitised and sham-sensitised transgenic or non-transgenic mice (Fig. 3.2C).This was 
unexpected as previously in the lab, i.n challenge of sensitised non-transgenic mice with OVA323-339 
had resulted in evident numbers of CD4
+
 T cells and eosinophils in BALF (unpublished data). It 
was possible that the lack of observable BALF T-cell infiltration induced by OVA323-339 might have 
be due to batch-to-batch variations in peptide used between experiments. Therefore several different 
batches of peptide were purchased and tested. When these were compared, no difference was found 
between batches of OVA323-339 for either CD4
+
 T-cell or eosinophil content in BALF (Fig. 3.3B-E). 
This could indicate that restimulation of a full-length OVA-sensitised immune response is poor by 
in vivo exposure to peptide. This would be consistent with the weak in vitro recall response 
observed with OVA323-339 relative to full-length OVA. Alternatively, OVA323-339 might be poorly 
taken up and presented after i.n. administration.  
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Figure 3.2 Absence of strong airway inflammatory response when using OVA323-339 i.n 
challenge.  
(A)Non-transgenic or transgenic (11c.OVA) mice were sham-sensitised (saline/alum) or 
sensitised (OVA/alum). At days 11,12,13,14 post-sensitisation mice were challenged intranasally 
with OVA323-339 peptide. At day 15, bronchoalveolar lavage fluid was collected and CD4
+
 T cells 
and eosinophils enumerated by flow cytometry. Representative gating strategy and FACS plots 
for (B) CD4
+
 T cells and (C) eosinophils are shown. Total number of (D) CD4
+
 T cells and (E) 
eosinophils and percentage of (F) CD4
+
 T cells and (G) eosinophils in BALF were determined. 
Each data point represents an individual mouse (n=2-6/group) from 2 separate experiments. 
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Figure 3.3 Different batches of OVA323-339 give similar results after intranasal challenges.  
(A)BALB/c were sensitised (OVA/alum). At days 11,12,13,14 post-sensitisation mice were 
challenged intranasally with different batches of OVA323-339 or left unchallenged. At day 15 
bronchoalveolar lavage fluid was collected and CD4
+
 T cells and eosinophil infiltration 
enumerated by flow cytometry. Representative gating strategy and FACS plots for CD4
+
 T cells 
and eosinophils are as shown in Fig. 3.2. Total number of (B) CD4
+
 T cells and (C) eosinophils 
and percentage of (D) CD4
+
 T cells and (E) eosinophils in BALF were determined. Each data 
point represents an individual mouse (n=2/group) from a single experiment. 
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3.2.3 OVA is superior to OVA323-339 for induction of airway inflammation in 
OVA/alum-sensitised mice 
Using OVA323-339 for i.n. challenges was unsuccessful in inducing airways inflammation. It 
is possible that OVA, as a heavily glycosylated molecule is much more effectively taken up by 
airway DC, possibly by C-type lectin-mediated uptake, for subsequent presentation than peptide. 
To determine if this was the case I then directly compared the effect of OVA to OVA323-339 
intranasal challenges in inducing a robust airway inflammatory response. Mice were sensitised 
(OVA/alum) or sham-sensitised (saline/alum) and 11 days later intranasally challenged with 
OVA323-339 or OVA for four consecutive days (days 11-14). At day 15 bronchoalveolar lavage 
fluid was collected, CD4
+
 T cells and eosinophil accumulation was determined by flow 
cytometry (Fig. 3.4A). Intranasal challenges with OVA323-339 failed to induce a strong airway 
inflammatory response determined by the number and percentage of CD4
+
 T cells and 
eosinophils in BALF of OVA/alum-sensitised mice (Fig. 3.4D,E). However, intranasal 
challenges with OVA induced a highly prolific T-cell (Fig. 3.4D) and eosinophilic infiltrate (Fig. 
3.4E) in BALF that was approximately 200-fold that with i.n challenge with OVA323-339. 
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Figure 3.4 OVA vs. OVA323-339 in intranasal challenges. 
(A) BALB/c mice were sensitised with OVA/alum. At days 11,12,13,14 post-sensitisation mice 
were challenged intranasally with OVA323-339, OVA, or left unchallenged. At day 15 BALF was 
collected and CD4
+
 T cells and eosinophils enumerated by flow cytometry. Representative 
gating strategy and FACS plots for CD4
+
 T cells and eosinophils is as shown in Fig. 3.2. Total 
number of (B) CD4
+
 T cells and (C) eosinophils and percentage of (D) CD4
+
 T cells and (E) 
eosinophils in BALF were determined. Each data point represents an individual mouse 
(n=2/group) from a single experiment.   
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3.2.4 Sensitisation and challenging system optimization 
Intranasal challenge with OVA leads to a significant BALF infiltration in contrast to 
OVA323-339 peptide challenge (Fig. 3.4). However, as 11c.OVA mice, when sensitised with full-
length OVA, appear to mount a Th2 response to determinants within the portion of OVA 
(OVA1-118) not expressed as transgene (Fig. 3.1C) I explored whether the effect of this could be 
minimised. To avoid sensitising and challenging with full-length OVA where a substantial 
response to OVA1-118 could complicate interpretation, and to focus sensitisation to a determinant 
within the portion of OVA expressed in 11c.OVA mice, I used OVA323-339/alum in a 
sensitisation and boost setting with different challenge regimes in non-Tg BALB/c mice (Fig. 
3.5). As expected, OVA323-339/alum-sensitised mice that received two 4-day cycles of intranasal 
challenges, with one of the 4-day cycle challenges with OVA, showed an increased number and 
percentage of CD
+
 T cells (Fig. 3.6A,C) and eosinophils (Fig. 3.6B,D) present in the BALF. 
Based on the outcomes of experiments shown in Fig.3.6 different intranasal challenge 
regimes were then tested in 11c.OVA mice to assess the airway inflammatory response in 
transgenic mice (Fig. 3.7A). This time, two 4-day cycles of OVA challenges were included, 
instead of one 4-day cycle of OVA i.n challenge, to determine whether a robust airway 
inflammatory response could be induced. The two 4-day cycle of OVA i.n. challenges resulted 
in an increase in CD4
+
 T cells (Fig 3.7B) and eosinophils (Fig 3.7C,E) in the BALF in the 
OVA323-339/alum-sensitised non- transgenic mice, while the response was inhibited in 11c.OVA 
mice. It can be concluded that the expression of allergen in DC limits respiratory immune 
responses to antigen challenge. For cytokine analysis, in vitro recall assays restimulated with 
OVA and OVA323-339 showed higher IL-13 levels in the spleen (Fig. 3.8B) and mediastinal 
lymph nodes (Fig. 3.8A) in the group that had two 4-day cycles of OVA i.n. challenges in 
comparison to the other groups. Therefore an optimised regime of two OVA323-339 /alum 
sensitisations and two 4-day cycles of OVA i.n challenges was used in subsequent experiments. 
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Figure 3.5 Different sensitisation and challenge regimes tested in BALB/c mice.  
BALB/c mice were sensitised with OVA323-339 /alum and challenged with OVA323-339 or OVA i.n. 
daily (25-28 days post-sensitisation and 33-36 days post-sensitisation). One day after the last i.n. 
challenge mice were euthanized. Bronchoalveolar lavage fluid was collected and CD4
+
 T cells and 
eosinophils enumerated by flow cytometry. 
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Figure 3.6 Comparison of different challenge regimes after OVA323-339 sensitisation. 
BALB/c mice were sensitised with OVA323-339 (OVAp) /alum and challenged with OVA323-339 
(OVAp) or OVA i.n. daily (25-28 days post-sensitisation and 33-36 days post-sensitisation). One 
day after the last i.n. challenge mice were euthanized. Bronchoalveolar lavage fluid was 
collected and CD4
+
 T cells and eosinophils enumerated by flow cytometry. Representative 
gating strategy and FACS plots for CD4
+
 T cells and eosinophils is as shown in Fig. 3.2. Total 
number of (A) CD4
+
 T cells and (B) eosinophils and percentage of (C) CD4
+
 T cells and (D) 
eosinophils in BALF were determined. Each data point represents an individual mouse 
(n=3/group) from a single experiment. Statistical test: ANOVA followed by Tukey’s post-test. 
(*p<0.05). 
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Figure 3.7 Analysis of cellular accumulation in BALF after different intranasal challenge 
regimes in 11c.OVA mice.  
(A)Non-transgenic or transgenic (11c.OVA) mice were sensitised with OVA323-339 (OVAp) 
/alum and challenged with OVA323-339 (OVAp) and or OVA i.n. daily (25-28 days post- 
sensitisation & 33-36 days post-sensitisation). One day after the last i.n. challenge mice were 
euthanized. Bronchoalveolar lavage fluid was collected and CD4
+
 T cells and eosinophils 
enumerated by flow cytometry. Representative gating strategy and FACS plots for CD4
+
 T cells 
and eosinophils is as shown in Fig. 3.2.Total number of (B) CD4
+
 T cells and (C) eosinophils 
and percentage of (D) CD4
+
 T cells and (E) eosinophils in BALF were determined. Each data 
point represents an individual mouse (n=2/group) from a single experiment. 
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Figure 3.8 Cytokine production of the different challenge regimes in 11c.OVA mice.  
Non-transgenic or transgenic (11c.OVA) mice were sensitised with OVA323-339(OVAp) /alum 
and challenged with OVA323-339(OVAp) or OVA i.n. daily (25-28 days post- sensitisation & 33-
36 days post-sensitisation). One day after the last i.n. challenge mice were euthanized. Spleens 
and MLNs were collected and restimulated in vitro with OVA323-339 peptide or OVA. Three days 
later the supernatant was collected IL-13 concentration in the (A) MLNs and (B) spleens was 
determined by ELISA. Each point represents an individual mouse (n=2/group) from a single 
experiment.  
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3.2.5 OVA expression in DC prevents OVA323-339 priming 
It was previously shown in the host lab, using ELISpot assays, that expression of OVA in 
DC prevented development of IL-4 producing CD4
+
 T cells in response to OVA sensitisation 
(unpublished). Having optimized a sensitisation and challenge regime in the OVA model I then 
addressed the question of whether OVA expression in DC prevented OVA323-339 priming by 
testing Th2 cytokine induction. Mice were sensitised (OVA323-339/alum) or sham-sensitised 
(saline/alum) and spleen cells collected 21 days later and restimulated in vitro with OVA, or 
OVA323-339. Culture supernatants were collected 3 days later for analysis by ELISA (Fig. 3.9A). 
Spleen cells from OVA323-339/alum-sensitised non-transgenic littermate control mice 
restimulated with OVA323-339 produced more of the Th2-associated cytokines, IL-4, IL-5 and IL-
13 in comparison to sham-sensitised controls. In contrast, there was no difference in cytokine 
production in splenocyte cultures from 11c.OVA mice, regardless of whether they were 
sensitised or not (Fig. 3.9B-D). The low levels of IL-4 observed in splenocyte cultures in 
comparison to IL-5 and IL-13 levels is likely due to its consumption by various cell types 
present in the culture (Bullens et al. 1998). Spleen cells from OVA323-339/alum-sensitised non-
transgenic littermate control mice restimulated with OVA produced very low levels of the Th2-
associated cytokines IL-4, IL-5 and IL-13 (Fig. 3.9B-D). This was also the case for 11c.OVA-
sensitised and sham-sensitised mice. There was no significant increase in IFN-γ production, in 
OVA323-339 or OVA restimulated splenocyte cultures from any of the mice (Fig. 3.9E). Since 
IFN-γ production was not affected by any of the conditions it was not measured in further 
experiments. Consistent with the previous observations in this chapter, these data indicate that 
expression of OVA by DC in 11c.OVA mice prevented sensitisation to the 323-339 determinant 
in the expressed portion of OVA. Moreover, the data shows that most of the response in 
sensitised non-transgenic mice is specific to OVA323-339. 
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E) 
Figure 3.9 In vitro induction of a Th2 response in cultures from OVA323-339 sensitised non-
transgenic mice after OVA323-339 stimulation.  
(A)Non-transgenic or transgenic (11c.OVA) mice were sham-sensitised (saline/alum) or 
sensitised (OVA323-339 (OVAp) /alum) days 0&14. At day 21 spleens were collected and 
restimulated in vitro with OVA323-339 or OVA. Three days later the supernatant was collected and 
(B) IL-5, (C) IL-13,(D) IL-4 and (E) IFNγ concentration was determined by ELISA. (Data are 
pooled from 3 experiments. Each point represents an individual mouse (n=9/group)). Statistical 
test: ANOVA followed by Tukey’s post-test. (*p<0.05 and ****p<0.0001) 
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3.2.6 OVA expression in DC prevents OVA323-339 priming and OVA-elicited airways 
inflammation 
Allergen-specific Th2 cells trigger the activation of the pathophysiological symptoms in 
allergic diseases through the secretion of Th2 cytokines. Expression of allergen in DC prevented 
allergen-specific sensitisation. I next tested whether stopping sensitisation prevents allergen 
induction of allergic airways inflammation. Mice were sensitised (OVA323-339/alum) or sham-
sensitised (saline/alum) twice and then exposed to intransal OVA challenges (days 25-28 & 33-
36). One day after the last intransal challenge, mediastinal lymph nodes, spleens, BALF, and 
lungs were harvested for analysis (Fig. 3.10A). 
Due to the limited usefulness of measuring IL-4 found in previous experiments, cytokine 
measurements were restricted to IL-5 and IL-13 only. When the cytokine production by spleen 
cells (indicating systemic sensitisation) was measured, Th2-associated cytokine production was 
elevated in sensitised and challenged non-transgenic mice relative to sham-sensitised mice. In 
contrast, the cytokine production in response to OVA323-339 and OVA in spleen cultures from 
sensitised 11c.OVA mice was completely absent and equivalent to that in non-sensitised, 
challenged controls (Fig. 3.10B,C). In lung-draining mediastinal LN, a strong OVA323-339-
specific Th2 recall response was observed in non-transgenic mice after sensitisation and 
intranasal challenge. Cytokine production was much greater than in comparable cultures from 
spleens (Fig. 3.10. N.B. Y-axis scale relative to Fig. 3.11) and this is attributable to localised 
exposure to allergen in MLNs. However, in 11c.OVA mice cytokine production in response to 
OVA323-339 was absent and overall did not differ significantly from sham-sensitised and 
challenged controls (Fig. 3.11B,C). Nevertheless, when MLNs were restimulated with OVA, IL-
5 and IL-13 production was minimal in cultures from all non-transgenic and transgenic OVA-
challenged groups, except that some mice in the sensitised non-transgenic OVA-challenged 
controls showed higher levels of cytokine production (Fig. 3.11B,C). 
In addition to systemic Th2 responses, Th2 responses in respiratory tract-related 
lymphoid tissues that would otherwise normally be elicited by i.p sensitisations and expanded by 
respiratory tract allergen exposure were prevented by expression of allergen in DC. To determine 
whether this ablation of allergen-specific Th2 responses systemically and locally in respiratory 
tract-associated lymphoid tissues prevented respiratory tract inflammation, BALF was collected 
from allergen-challenged and unchallenged mice. Significantly higher numbers of CD4
+
 T-cells 
were recovered in BALF after OVA-challenge of sensitised non-transgenic mice relative to 
sham-sensitised non-transgenic controls (Fig. 3.12C). However, the percentage of CD4
+
 cells did 
not differ between challenged non-transgenic groups which were elevated compared to naïve 
(unchallenged) controls (Fig. 3.12E). Expression of allergen in DC, however, prevented the 
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allergen-induced increase in CD4
+
 T-cell accumulation in the majority of 11c.OVA mice (Fig. 
3.12C). On the other hand, allergen-induced accumulation of eosinophils in BALF, a classic 
marker of Th2-associated respiratory tract inflammation, was consistently abrogated by allergen 
expression in DC (Fig. 3.12D, F). Sensitised non-transgenic mice, as expected, showed a 
significantly greater total number and proportion of eosinophils in BALF relative to sham 
sensitised non-transgenic controls and sensitised 11c.OVA mice (Fig. 3.12D, F). To note, there 
was no change in the neutrophilic response across the groups (data not shown). 
Histological analysis of lung sections showed substantial inflammatory cell infiltration 
near major and minor airways in sensitised non-transgenic mice (Fig. 3.13A). 11c.OVA mice 
typically demonstrated less inflammatory infiltration than all other challenged groups (Fig. 3.13 
A). The presence of inflammatory infiltrates in sham-sensitised, but OVA-challenged mice not 
present in unchallenged mice indicated that OVA-challenge itself elicited some degree of 
inflammatory cell infiltration. When quantitated, inflammatory infiltrate scores were highest in 
sensitised non-transgenic mice and the infiltrate score was significantly lower for sensitised 
11c.OVA mice (Fig. 3.14A) and was equivalent to challenged, but sham sensitised mice 
indicating a return to the ‘baseline’ for in OVA-challenged mice. 
Periodic Acid Schiff’s (PAS) staining showed goblet cell hyperplasia was prominent in 
airways of sensitised and challenged non-transgenic mice (Fig. 3.13B). 11c.OVA mice typically 
demonstrated less goblet cell hyperplasia than all the other challenged groups (Fig. 3.13B). The 
extent of goblet well hyperplasia in sham-sensitised but OVA-challenged mice relative to 
unchallenged mice indicated the OVA challenges themselves introduced some increase in mucus 
accumulation in goblet cells possibly through a sensitisation effect. When quantitated, the 
frequency of mucus-filled cells was highest in sensitised non-transgenic mice and was 
significantly lower for sensitised 11c.OVA mice (Fig. 3.14B). 
In conclusion, where there is an increased production of IL-5 and IL-13, a significant 
eosinophilic infiltration is induced and goblet cell hyperplasia observed when sensitised non-
transgenic mice were challenged intranasally with OVA. However, 11c.OVA mice were 
protected from developing an airway inflammatory response associated with intranasal 
challenges with OVA although some sensitisation to the unexpressed portion of OVA (OVA1-118) 
may have occurred. Together, these data show that antigen targeted to DC prevented systemic 
and respiratory allergen-specific T-cell responses and protected against allergen-induced airways 
inflammation and potentially sensitisation by respiratory-allergen challenge. 
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C) 
Figure 3.10 In vitro stimulation of splenocytes with OVA323-339 or OVA induces Th2 
cytokine production.  
(A)Non-transgenic or transgenic (11c.OVA) mice were sensitised with OVA323-339 
(OVAp)/alum at days 0 &14. Mice were then intransally challenged with OVA at days 25-28 & 
33-36. One day after the last i.n. challenge mice were euthanized. Spleens were collected and 
restimulated in vitro with OVA323-339 peptide or OVA. Three days later the supernatant was 
collected and (B) IL-5 and (C) IL-13 concentration was determined by ELISA. (Data are pooled 
from 4 separate experiments. Each point represents an individual mouse n=6-12). Statistical test: 
ANOVA followed by Tukey’s post-test. (**p<0.01 and ****p<0.0001) 
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Figure 3.11 In vitro stimulation of MLNs with OVA323-339 or OVA induces an amplified Th2 
response.  
(A)Non-transgenic or transgenic (11c.OVA) mice were sensitised with OVA323-339 (OVAp)/alum 
at days 0 &14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. One day 
after the last i.n. challenge mice were euthanized. MLNs were collected and restimulated in vitro 
with OVA323-339 peptide or OVA. Three days later the supernatant was collected and (B) IL-5 
and (C) IL-13 concentration was determined by ELISA. (Data are pooled from 4 separate 
experiments. Each point represents an individual mouse n=5-10; n=1-8). Statistical test: 
ANOVA followed by Tukey’s post-test. (*p<0.05 and **p<0.01) 
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Figure 3.12 OVA intranasal challenges leads to profound eosinophil infiltrate in BALF of 
sensitised non-transgenic mice.  
Non-transgenic or transgenic (11c.OVA) mice were sensitised with OVA323-339 (OVAp)/alum at 
days 0 &14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. One day 
after the last i.n. challenge mice were euthanized. Bronchoalveolar lavage fluid was collected 
and CD4
+
 cells and eosinophils enumerated by flow cytometry. Representative gating strategy 
and FACS plots for (A) CD4
+
 cells and (B) eosinophils are shown. Total number of (C) CD4
+
 
cells and (D) eosinophils and percentage of (E) CD4
+
 cells and (F) eosinophils in BALF were 
determined. (Data are pooled from 4 separate experiments. Each point represents an individual 
mouse n=6-12). Statistical test: ANOVA followed by Tukey’s post-test. (*p<0.05, **p<0.01 and 
**** p<0.0001). Note: refer to appendix figure I.8 for total BAL counts. 
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OVA i.n challenged 
Figure 3.13 Transgenic mice protected from the effect of OVA intranasal challenges.  
Non-transgenic or transgenic (11c.OVA) mice were sensitised with OVA323-339 (OVAp)/alum at 
days 0 &14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. One day 
after the last i.n. challenge mice were euthanized. Lungs were collected, fixed, embedded and 
sectioned at 500 μm intervals and stained with (A) hematoxylin & eosin (H&E) or (B) periodic 
acid-Schiff (PAS). Bar=1mm (low power) and 50 μm (high power). (One lobe from an 
individual mouse is shown).  
tr
an
sg
en
ic
 
n
o
n
-t
ra
n
sg
en
ic
 
B) PAS 
tr
an
sg
en
ic
 
n
o
n
-t
ra
n
sg
en
ic
 
H&E A) 
OVAp/alum sham no sens no sens  
1 mm 
50 μm 
OVA i.n challenged 
OVAp/alum sham no sens no sens  
1 mm 
50 μm 
71 
 
  
0
5
1 0
1 5
P
A
S
+
 c
e
ll
s
/1
0
0

m
n o n -tra n s g e n ic tra n s g e n ic
s h a m O V A p /
a lum
n o
s e n s
s h a m O V A p /
a lum
n o
s e n s
O V A  i.n  c h a lle n g e d O V A  i.n  c h a lle n g e d
n o
s e n s
n o
s e n s
n .s .* * * *
* * * * *
0
1
2
3
4
in
fi
lt
r
a
te
 s
c
o
r
e
n o n -tra n s g e n ic tra n s g e n ic
s h a m O V A p /
a lum
n o
s e n s
s h a m O V A p /
a lum
n o
s e n s
O V A  i.n  c h a lle n g e d O V A  i.n  c h a lle n g e d
n o
s e n s
n o
s e n s
n .s .* * * *
* * * *A) 
B) 
Figure 3.14 Quantitative analysis of the stained lung sections showing 11c.OVA mice 
protected from OVA challenges.  
Non-transgenic or transgenic (11c.OVA) mice were sensitised with OVA323-339 (OVAp)/alum at 
days 0 &14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. One day 
after the last i.n. challenge mice were euthanized, lungs were collected, fixed, embedded and 
sectioned at 500 μm intervals and stained with hematoxylin & eosin (H&E) or periodic acid-
Schiff (PAS). (A) Inflammatory infiltrate score and (B) PAS
+
 cells/100 μm of basement 
membrane was quantitated. (Data are pooled from 4 separate experiments. Each point represents 
an individual mouse n=6-12). Statistical test: ANOVA followed by Tukey’s post-test. (**** 
p<0.0001) 
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3.3 Discussion 
Ovalbumin (OVA) is an important food allergen in humans (Bleumink et al. 1969, 
Langeland 1982), and also serves as a widely used and useful allergen in rodent models examining 
respiratory immune responses (Kumar et al. 2008). Although other approaches are sometimes used, 
models of allergic airways disease (AAD) employing OVA typically involve induction of strong 
Th2-skewed responses by i.p. injection of OVA adsorbed to the adjuvant aluminium hydroxide 
Al(OH)3 (Brewer et al. 1999, Lloyd et al. 2001). After sensitisation, repetitive intranasal challenges 
with specific allergen are typically then used to induce airway inflammatory responses (Lloyd, 
Gonzalo et al. 2001)(Kumar et al. 2002). Here I adapted this system to firstly test whether 11c.OVA 
mice are protected from sensitisation, and secondly, to determine whether this prevented subsequent 
allergen-induced airway inflammation. In this chapter, I showed expression of OVA in DC prevents 
allergic priming and, consequently, respiratory immune responses to respiratory OVA challenge. 
This is evidenced by a reduction in IL-4, IL-5 and IL-13 production, a reduction in accumulation of 
inflammatory cells in BALF, and a reduction in inflammatory cell infiltration in lung tissues and 
airway epithelial mucus production in 11c.OVA mice.  
Important functions are attributed to CD4
+
 T helper cells one of which is the production of 
IL-4, IL-5 and IL-13 (Robinson et al. 1992). IL-4, the major modulator for Th2 cell differentiation, 
plays a critical role during the early phase of the immune response where it stimulates B cell 
activation and Ig switching to IgE (Coffman et al. 1986, Del Prete et al. 1988). IL-5 plays a major 
role at later stages where it stimulates the maturation and differentiation of eosinophils (Yamaguchi 
et al. 1988). It was shown that in an allergic inflammation setting, mRNA of these two cytokines 
was up-regulated in T cells, demonstrating the conclusion of their importance in the pathogenesis of 
allergies (Robinson et al. 1992, Ying et al. 1995). Another important cytokine is IL-13 whose 
mRNA is elevated after allergen challenge of sensitised atopic mice (Huang et al. 1995). CD4
+
 T 
cells also affect the development of AHR and lung inflammation through these Th2 cytokines 
(Walker et al. 1991). Production of large amounts of the Th2 cytokines IL-5 and IL-13 in spleen 
and MLN cultures from sensitised non-transgenic controls in the present OVA model indicated 
induction of Th2 immune responses. In 11c.OVA mice on the other hand, their absence indicated 
impaired function or absence of OVA-specific CD4
+
 T cells in those mice, attributed here to 
induction of tolerance.  
Preventing allergic priming in 11c.OVA mice protected against development of airway 
inflammation. In naïve mice the total BALF cell count is about 20,000 cells/ml and the major 
constituent is macrophages. OVA/alum sensitisations increase the number of cells to around 
1.5x10
6
/ml where the measurements peak 24 and 48 hrs after the last nebulisation (Jungsuwadee et 
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al. 2002). The dominant cellular response in these mice is eosinophilic (70-80%) which is resolved 
completely after 11 days (reviewed by (Epstein 2004)). Consistent with this observation, the results 
here show a significant increase in the percentage of eosinophils recovered from the BALF of 
sensitised non-transgenic mice 24 hrs after the last intranasal challenge with OVA indicating an 
antigen-specific response in non-transgenic mice, but this was blocked in transgenic mice. Evidence 
links airway remodelling to the presence of eosinophils. One example is the association of increased 
bronchial mucosal eosinophils to the thickening of the subepithelial basement membrane in severe 
asthmatics (Wenzel et al. 1999). In mice, the importance of eosinophils was also demonstrated 
where the absence of these cells attenuated Th2 immune responses after allergen reencounter in 
both acute and chronic models of asthma (Lee et al. 2004, Fulkerson et al. 2006). Eosinophils are a 
source of VEGF (Hoshino et al. 2001), TGF-α (Wong et al. 1990), TGF- β (Wong et al. 1991) that 
induce fibrotic changes. Support for the relation between eosinophils and cytokines was shown in a 
study done by Schmid-Grendelmeier et al. in which the stimulation with GM-CSF or IL-5 led 
human eosinophils to produce functional IL-13 (Schmid-Grendelmeier et al. 2002). In vivo studies 
show that reconstitution of eosinophils in IL-5/eotaxin double knockout (KO) mice restores Th2 
cell production of IL-13 (Mattes et al. 2002). As eosinophilia is dependent on IL-5 (Nakajima et al. 
1992, Mould et al. 1997, Rothenberg 1998), the observations of eosinophil infiltration is validated 
by the systemic and local immune responses, where IL-5 levels are elevated in sensitised non-
transgenic, but not 11c.OVA mice. 
Histological lung sections from OVA/alum-sensitised OVA-challenged mice show 
substantial cellular infiltration accumulated near large airways (Jungsuwadee et al. 2002). The 
major cell types identified are eosinophils in addition to lymphocytes and other infrequent cells 
such as plasma cells, macrophages, multinucleated giant cells and neutrophils (Jungsuwadee et al. 
2002). Hematoxylin and eosin stained lung sections from the sensitised non-transgenic mice 
analysed here showed profound cellular infiltrate but this was absent from11c.OVA mice. 
Similarly, goblet cell hyperplasia was absent in 11c.OVA mice. In normal mice, low production of 
mucus in indicated by the few mucus-stained goblet cells in the airways; on the contrary, abundant 
production of mucus is detected in mice with acute airway disease (Jungsuwadee et al. 2002). A 
consistent feature in asthmatics is goblet cell hyperplasia and excessive mucus in airways. IL-4, IL-
13 and neural elements exert strong hyperplastic effects on goblet cells (Marom et al. 1982) and IL-
13 increases expression of MUC5AC (Kondo et al. 2002) and Gob-5 (Lee et al. 2002). IL-13 
treatment leads to mucus overproduction (Zuhdi Alimam et al. 2000). Genetic deficiency of IL-13 
prevents goblet cell metaplasia and epithelial hypertrophy but these are restored by administration 
of IL-13 (Kumar et al. 2002). IL-5 may contribute to mucus production as transgenic over-
expression in the lungs of mice has also been associated with mucus production where CD4
+
 T cells 
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are the major effectors (Justice et al. 2002) possibly through their production of IL-13 (Mattes et al. 
2002). Therefore, given the pivotal role of IL-13 in goblet cell hyperplasia and mucus 
overproduction, and IL-5 in eosinophilia, preventing Th2 development production would likely 
alleviate these features of allergic airways disease. Indeed, in 11c.OVA mice where Th2 
sensitisation is blocked mice are protected from eosinophilia and goblet cell hyperplasia.  
The mechanisms that lead to transgene-specific tolerance in models such as the 11c.OVA 
mouse where an antigen or allergen is transgenically expressed are not entirely defined. In an early 
study it was shown that expression of α chain of the I-E MHC class II antigen under the CD11c 
promoter contributed to negative selection in the thymus (Brocker et al. 1997). Similarly, later 
studies (Doan et al. 2009) confirmed this , but also showed that negative selection mediated by DC 
expressing an antigen might be inefficient in  eliminating all antigen-specific T cells by itself. As a 
consequence, induction of peripheral tolerance mechanisms by resting DC is crucial to eliminate 
antigen-specific T cells. An explanation can be provided from pilot studies done by Steptoe and co-
workers, where Th2-skewed OT-II T cells transferred to 11c.OVA underwent several rounds of 
division within 3 days. Following the initial expansion, the OT-II population contracted and within 
three weeks of transfer the number of residual OT-II T cells was low. OVA/CFA challenge 21 days 
after transfer resulted in substantial expansion of OT-II T cells in spleen and LN of non-transgenic 
recipients but not in mice expressing OVA in DC. This indicated residual OT-II T cells were 
rendered unresponsive (unpublished data). In this setting, transferred OT-II cells recognise and are 
activated by the OVA expressed within DC and undergo population expansion in the first 3 days, 
but contraction of the population is consistent with deletion as reported previously for some 
tolerance models (Hawiger et al. 2001, Probst et al. 2003, Mayerova et al. 2004). For example, 
deletion was the major mechanism in transgenic mice expressing large amounts of OVA in 
pancreatic β cells (Kurts et al. 1998). However, as residual OT-II cells were present, and these were 
not responsive to immunogenic OVA challenge, anergy is also a likely contributor. This is similar 
to the studies done by Steptoe et. al that showed transient proliferation and expansion of CD4
+
 and 
CD8
+
 T cells followed by deletion  and induction of unresponsiveness in response to Ag presented 
by resting DC (Steptoe et al. 2007). Kenna et al. extended this observation to memory and effector 
CD8
+
 T cells in vivo where induction of deletion and unresponsiveness were also shown (Kenna et 
al. 2008). Studies by Brocker et al., (Brocker et al. 1997) and Steptoe et al., (Steptoe et al. 2007) 
investigated the expression specificity of transgenes expressed under the control of the CD11c 
promoter.  In thymus, flow cytometry and immunohistochemistry showed CD11c-controlled 
transgene expression was restricted to DC in the medulla and cortico-medullary junction (Brocker 
et al. 1997).  Using functional analyses where antigen presentation was tested, OVA expressed 
under the CD11c promoter was shown to be processed and presented only by CD11c
hi
 conventional 
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DC but not, for instance, CD11c
int
  cells sorted from spleens of CD11c.OVA mice (Steptoe et al. 
2007). Although the hypothesis for this chapter is that OVA-expression in DC prevents allergic 
sensitisation, however it is well known in mice that CD11c expression is not restricted to DC, but is 
also expressed on other APC such as interstitial and alveolar macrophages (Katsura et al. 2015). 
Resident alveolar macrophages have been shown to suppress allergic inflammation although Ag 
sensitisation in some instances is sufficient to “brake” their immunosuppressive activities (Zaslona 
et al. 2014). 
As discussed in the previous paragraph, it has been shown that expression of OVA in DC in 
the 11c.OVA mouse model induces tolerance to immunodominant CD4
+
 and CD8
+
 T-cell 
determinants (OVA323-339 and OVA257-264 respectively) within the expressed transgene (Steptoe et 
al. 2007, Doan et al. 2009). Here I extended these studies and examined whether tolerance to 
determinants within the expressed transgene extended to full length OVA. The ability to respond to 
full-length OVA strongly suggests 11c.OVA mice are responsive to the portion of OVA (OVA1-118) 
that is absent from the expressed transgene. One way to categorically determine this would be to 
transgenically express full-length OVA and test the response to sensitisation and restimulation with 
full-length OVA. Another way would be to sensitise with peptides from OVA1-118 and test the 
response upon restimulation with full-length OVA or the sensitising peptide. 
Recall assays of spleens indicated that sensitisation with OVA323-339/alum, on the contrary to 
OVA/alum sensitisations, revealed only a peptide-specific response with little recall response to 
whole OVA. However, recall assays of spleens and MLNs indicated that sensitisation with OVA323-
339/alum followed by OVA intranasal challenges revealed a peptide-specific response in addition to 
a response to whole OVA. These observations could be due to the generation of different subsets of 
primed T cells. It has been reported that sensitising with full-length OVA results in an increase in 
the percentage of both TCR Vbeta 8.1 and Vbeta 8.2-expressing T cells (Renz et al. 1993). 
However, peptide sensitisation selectively stimulates expansion of only TCR Vbeta 8.1 T cells 
(Renz et al. 1993). Alternatively, there is emerging evidence that peptides and whole protein 
antigens may be processed and presented in different conformations in MHC class II leading to the 
expansion of non-crossreactive (Type A and Type B) T-cell subsets (Lovitch et al. 2005, Mohan et 
al. 2010). Some studies also show that different subsets of T cells are activated in different organs 
due to the variation in antigen processing, and the generation of different determinants (Collado et 
al. 2013). Comparing the systemic (i.e spleen) and respiratory response in this data reveals that the 
local respiratory immune response is increased in comparison to the systemic response in the 
sensitised non-transgenic mice due to the intranasal challenges introduced to these mice. This 
suggests then that OVA323-339-specific Th2 CD4
+
 T cells primed following i.p sensitisation were 
recruited directly into respiratory tissues after i.n challenges leading to the increased recall response 
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observed. One must not disregard the possibility of the added effect of intranasal challenges to the 
i.p. sensitisations. In the OVA model used here, OVA intransal challenges could have resulted in 
sensitisation through the airways, generating specific T cells to different peptides in the OVA 
protein (Jeffery et al. 2009). Migration of those T cells to the spleens could have led to the Th2 
responses to OVA restimulation which were not observed in intranasally unchallenged controls. 
Additionally, a non-specific inflammatory of in OVA administration may be present, possibly due 
to bacterial endotoxin or other contaminants in the OVA used for i.n. challenges.  This could also 
influence the extent of sensitisation that may have occurred from the i.n. OVA administration. 
Investigating different sensitisation and challenge regimes indicated that one 4-day cycle of 
i.n challenges with the peptide OVA323-339 was poor at inducing an airway inflammatory response 
regardless of whether mice were sensitised with OVA/alum or OVA323-339/alum. In contrast, i.n. 
challenge with full-length OVA led to an airway inflammatory response 200 fold greater than i.n. 
OVA323-339 in OVA/alum sensitised mice. OVA323-339, which has been shown to bind to human and 
rabbit MHC class II (Ia) (Buus et al. 1986, Elsayed et al. 1986), as well as mouse MHC class II (I-
Ab and I-Ad) (Robertson et al. 2000) is an immunogenic CD4
+
 T cell determinant. In addition, it is 
possibly the immunodominant determinant (Shimonkevitz et al. 1983) reportedly responsible for 
25-30% of CD4
+
 T-cell OVA responsiveness in BALB/c mice (Buus et al. 1986, Sun et al. 2010). 
My data suggest OVA323-339 was also responsible for approximately 25-30% of the in vitro CD4
+
 T-
cell recall response to OVA-sensitised mice in the present study indicating substantial 
responsiveness to other determinants. A study that repeatedly introduced OVA323-339 intranasally, 
induced a positive response to full-length OVA in 69% of the mice and a positive response to 
OVA323-339 in 77% of the mice (Renz et al. 1993). However, studies by Wilder et al. and Tourney et 
al have shown that weak immune responses are elicited when sensitising mice with fewer Ag 
exposures or lower Ag dose using aerosolized OVA323-339 (Wilder et al. 1999, Tournoy et al. 2000). 
It is unlikely that Ag dose and number of exposure alone accounts for the difference in 
inflammation induced by i.n. OVA323-339 and OVA in sensitised mice. It is possible that OVA, as a 
heavily glycosylated molecule is much more effectively taken up by airway DC, possibly by C-type 
lectin-mediated uptake, for subsequent presentation. The effectiveness of OVA for i.n. challenge, 
however, allowed the development of a tractable model of airways inflammation for testing the 
effects of allergen expression in DC. It is important to consider that Holt et al. and others stress the 
importance of priming prior to introducing antigen mucosally in order to induce airway 
inflammation. That is antigen inhalation on its own can lead to mucosal tolerance and suppression 
of antigen-specific IgE (Fox et al. 1981, Holt et al. 1981, Holt et al. 1987). Some alternative studies 
showed that aerosolised antigen exposure or antigen application via the intranasal route induces Th2 
and antigen-specific IgE responses (Renz et al. 1992, Nelde et al. 2001). The Th2 responses to OVA 
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restimulation observed in the sham-sensitised but OVA intranasally challenged mice which were 
not observed in intranasally unchallenged controls in the current study imply sensitisation via the 
intranasal route. This also revealed that the intranasal challenge with the possibly LPS contaminated 
OVA induced influx of immune cells non-specifically. However, the dose of antigen and the 
efficiency of its uptake could play a role in dictating the final outcome of immunity or tolerance 
(Frolund et al. 1992, Viney et al. 1998, Chung et al. 2005).  
Taken together, findings in this chapter correlate with studies showing pathophysiological 
symptoms of experimental allergic airway disease are a result of events initiating with a profound 
Th2, followed by an eosinophil influx and goblet cell abnormalities induced by localised airway 
allergen-exposure. Strikingly, this process is interrupted in 11c.OVA mice where allergen is 
expressed in DC. This provides strong proof-of-principle for this as the basis for a potential 
therapeutic strategy. 
3.4 Future directions 
The lack of response to i.n OVA323-339 could be investigated in future experiments by 
performing a dose response. The need for a permanent therapeutic strategy to fight asthma is rising, 
so in order to progress the concept of DC-induced tolerance towards a clinical application, it is 
important to determine the mechanisms underlying tolerance induction by genetically-targeted 
antigen to DC. In considering therapy, the development of a means to enable DC-induced tolerance 
in non-genetically modified, WT mice would be a major step forward. This will be addressed in 
Chapter 4. 
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CHAPTER 4: 
TRANSFER OF ANTIGEN-ENCODING BONE 
MARROW REVERSES ESTABLISHED TH2 
IMMUNITY AND REDUCES ALLERGEN-ELICITED 
AIRWAY INFLAMMATION 
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4.1  Introduction 
In Chapter 3 the effect of transgenic expression of OVA in DC was investigated and I found 
expression protected mice from developing allergen-specific T-cell responses, thus protecting them 
from airways inflammation elicited by allergen exposure. In this chapter, I will address the 
important next question of whether a therapeutic approach can be developed by using transfer of 
OVA encoding BM. 
In 1945, Ray Owen espoused the initial idea of using hematopoietic chimerism to achieve 
tolerance (Owen 1945). In the years that followed, treatment with allogeneic HSC transplantation 
became clinically applied for fatal immunodeficiencies and hematologic cancer (reviewed in 
(Appelbaum 2007). This has been recently extended clinically to treat severe autoimmune diseases 
(reviewed in (Burt et al. 2002). Animal models with spontaneous autoimmune diseases have shown 
complete resistance to disease when transplanted with allogeneic BMT (Ikehara et al. 1985, Himeno 
et al. 1988, El-Badri et al. 2000). However, many risks are associated with allogeneic BMT one of 
which is use of complete myeloablative conditions (Singer et al. 1981, Sykes et al. 1988) and 
another the risk of GVHD (Ratanatharathorn et al. 2001). This renders the approach clinically 
unfavourable. To avoid these problems, syngeneic or autologous HSCT has been tested and shown 
to be effective in animal models of experimental allergic encephalomyelitis (EAE) (Karussis et al. 
1993) and  arthritis (van Bekkum et al. 1989, Knaan-Shanzer et al. 1991).  
In the early 90s, the importance of dendritic cells and other APCs in controlling tolerance 
became known, and thus, were recognized as a potential tool to be investigated for therapeutic uses 
(Steptoe et al. 1996). As this concept progressed, it was shown that antigen-specific tolerance 
defects in autoimmune prone mice could be restored by expressing the antigen in APC (Alderuccio 
et al. 1993, French et al. 1997, Jaeckel et al. 2003). Steptoe and colleagues then demonstrated that 
transfer of gene-modified HSC encoding proinsulin expression driven under an MHC class II 
promoter, prevented diabetes development in spontaneously-diabetic NOD mice (Steptoe et al. 
2003). This established the principle that transfer of HSC encoding an antigen targeted to APC 
could be used to induce antigen-specific tolerance. In an allergy setting, Baranyi and colleagues 
showed that molecular chimerism generated through transfer of BM engineered with retroviral 
vectors, in a preventive setting, effectively established tolerance to an encoded allergen and 
prevented development of experimental type I allergy (Baranyi et al. 2008). However, in allergies, 
including allergic asthma subtypes, it is established Th2 T-cell responses that underlie and 
perpetuate the disease. Immunotherapies, therefore, are required that terminate the pathogenic 
effector and memory T cell responses that mediate disease.  
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Targeting antigen to DC and the use of autologous (gene-engineered) BM transfers are two 
concepts that can be merged to provide functional immunotherapies to utilize clinically. Thus 
transfer of autologous antigen-encoding BM diminishes the need for complete myeloablation by 
reducing the toxicity of immune-ablation. The host laboratory has shown high levels of HSPC 
engraftment is achieved under low-dose (300cGy) irradiation while preserving immune function 
(Coleman et al. 2013). Therefore, this dose of irradiation will be used in this chapter. Significantly, 
once engrafted, antigen-encoding BM provides a permanent self-renewing source of antigen-
expressing tolerogenic DC which could reduce or prevent disease-relapse. 
Here I test the hypothesis “transfer of OVA-encoding BM terminates Th2 T-cell responses and 
allergen-elicited airway inflammation”. The ultimate goal in of the approach tested is to ‘turn off’ 
existing pathogenic antigen-specific effector and memory T cell responses that underpin allergic 
asthma. BM from 11c.OVA transgenic mice (OVA+ve) where OVA is expressed by DC, and used 
in the previous chapter, will be the source of OVA-encoding BM. Two key questions will be 
addressed. Firstly, to determine whether transfer of OVA-encoding BM reverses Th2 T-cell 
responses in OVA323-339-sensitised mice. As a component of this, I will investigate whether reversal 
of Th2 T-cell responses is antigen-specific and whether this prevents development of allergen-
induced airways inflammation. Secondly, to determine whether transfer of OVA-encoding BM 
alleviates ongoing allergen-induced airways inflammation in OVA323-339-sensitised mice. As a 
component of this, I will investigate whether elimination of allergen-specific Th2 T-cell responses, 
once allergen–induced airways inflammation is established, alleviates inflammation and airway 
hyper responsiveness.  
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4.2 Results 
4.2.1 Transfer of OVA encoding BM reverses Th2 responses and prevents airway 
inflammation 
Conditions for effective transfer and engraftment of BM or hematopoietic progenitor cells 
(HPC) but which preserve immunity have been established by the host lab in C57BL/6 mice 
(Coleman et al. 2013). Based on this, similar conditions were tested in BALB/c mice. Under the 
immune-preserving conditions reported previously (Coleman et al. 2013), substantial engraftment 
of wild type CD45.1-congenic BM or HPC is achieved (Fig. 4.1). In the following experiments 
engraftment was not tracked due to the inability to separate donor (11c.OVA) BM from recipient 
(BALB/c) BM since 11c.OVA mice were backcrossed to BALB/c mice. 
First I tested whether transferring OVA-encoding BM was able to inhibit or ablate 
established Th2 T-cell responses. BALB/c mice were sham-sensitised (unsen; saline/alum) or 
sensitised (sen; OVA323-339/alum) twice. Fourteen days later, mice were irradiated (300cGy) and 
non-transgenic control (OVA-ve) or OVA-encoding 11c.OVA (OVA+ve) BM was injected i.v. 
Mice were rested for 4 weeks and then exposed to intransal OVA challenges (days 56-59 & 64-67). 
One day after the last intransal challenge, mediastinal lymph nodes, spleens, BALF, and lungs were 
harvested for analysis (Fig. 4.2A).  
In vitro cultures were established from MLNs which drain the site of respiratory allergen 
exposure. When restimulated with OVA323-339, little IL-5 and IL-13 was produced from cultures 
established from unsensitised mice regardless of whether they were intranasally-challenged or not 
(Fig. 4.2B,D). Substantial IL-5 and IL-13 was, however, produced in cultures established from mice 
that were sensitised and rechallenged but received no BMT, and this was similar in recipients of 
control, OVA-ve BM (Fig. 4.2B,D). In contrast, in cultures from recipients of OVA+ve BM, 
cytokine production was significantly less and almost at the level of that from unsensitised mice 
(Fig. 4.2B,D). When restimulated with OVA, IL-5 production showed a largely similar pattern to 
that seen in OVA323-339-stimulated cultures except, that in cultures from unsensitised, challenged 
controls, some IL-5 production was evident (Fig. 4.2C). However, for IL-13 cytokine production 
was evident in all OVA-challenged groups regardless of treatment, except, some mice in the 
OVA+ve BMT grouped showed lower levels of IL-13 production. (Fig. 4.2E). 
Next, cultures established from spleen which is distal to the site of allergen exposure, and 
may reflect the systemic response, were analysed. Again, restimulation with OVA323-339 led to little 
IL-5 and IL-13 production from cultures prepared from unsensitised mice regardless of whether 
intranasally-challenged or not (Fig. 4.3B,D). IL-5 and IL-13 were produced in cultures from mice 
that were sensitised and OVA-challenged without BMT, (Fig. 4.3B,D) but production was much 
less than in comparable cultures from MLNs (Fig. 4.2. N.B. Y-axis scale relative to Fig. 4.3). Less 
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cytokine production from spleen cultures compared to MLNs cultures exemplifies the effect of the 
intranasal exposure of the allergen on the allergen-specific Th2 response. In the irradiated controls, 
cytokine production was somewhat reduced from the already low levels, by the BMT procedure, 
regardless of whether BM encoded OVA or not (Fig. 4.3B,D). This was most obvious for IL-5 (Fig. 
4.3B). When restimulated with OVA, low levels of IL-5 were detected in all challenged groups 
regardless of treatment (Fig. 4.3C). For IL-13, cytokine production was evident in all challenged 
groups, but was significantly reduced in the sensitised, challenged OVA+ve BMT group relative to 
sensitised, challenged but no BMT group (Fig. 4.3E). For the OVA restimulated cultures it was 
notable that the OVA+ve BMT group typically produced the lowest levels of cytokines although 
this was not necessarily statistically significant (Fig. 4.3C,E). Together, comparison of cytokine 
production from MLNs and spleen cultures indicate intranasal OVA challenge strongly amplifies 
the cytokine response in LN draining respiratory tract, but has much less effect systemically. To 
note, non-Th2 cytokines were not tested in those experiments. However, OVA+ve BM transfer 
turned off the Th2 response rendering intranasal OVA challenges ineffective on the cytokine 
response in respiratory tract draining LN and systemically in spleens.  
In the experimental setting being tested here, OVA-specific Th2 T-cell responses are 
established prior to BMT. Intranasal challenge with OVA after BMT might then allow a measure of 
the effectiveness of BMT in reversing established Th2 immunity as any residual OVA-specific T-
cell responsiveness present would likely lead to development of airways inflammation after 
intranasal OVA challenge. To test this, BALF was collected from intranasally OVA-challenged and 
unchallenged mice. The number of CD4
+
 cells in BALF was similar between all intranasally-
challenged groups and this was elevated compared to unchallenged controls (Fig. 4.4C). This was 
also reflected in the proportion of CD4
+
 cells present in BALF (Fig. 4.4E). This revealed that OVA-
challenge by itself was inducing influx of immune cells regardless of the sensitisation status of the 
mice. The number and proportion of eosinophils in BALF was elevated in sensitised, challenged no 
BMT controls compared to unsensitised, challenged no BMT controls as expected (Fig. 4.4D,F). 
This also shows that eosinophils were the dominant infiltrating cell type in these sensitised, 
challenged no BMT controls. However, the proportion of eosinophils was significantly reduced in 
recipients of OVA+ve BM compared to sensitised, challenged but no BMT controls and sensitised 
mice that received OVA-ve BM (Fig. 4.4D,F).  
To study the effect of intranasal challenges on other infiltrating cells, alveolar macrophages 
(CD11c
+
SIGLEC-F
+
) and neutrophils (Gr-1
+
SIGLEC-F
-
) were also analysed. The total number and 
proportion of alveolar macrophages in BALF was similar across all intranasally challenged groups 
and the unchallenged control group (Fig. 4.5C,E). This demonstrates that challenges exert little 
effect on alveolar macrophage influx. While the total number of neutrophils in BALF did not show 
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any significant differences across intranasally challenged groups and unchallenged controls (Fig. 
4.5D),the proportion of neutrophils was significantly higher in unsensitised but challenged controls 
compared to unchallenged controls (Fig. 4.5F). Moreover, the proportion of neutrophils in BALF of 
recipients of OVA+ve BM was significantly higher than the sensitised, challenged no BMT group 
and those that received OVA-ve BM (Fig. 4.5F). This is possibly due to some LPS contamination 
of the OVA used for in challenges.  
Histological analysis of lung sections showed substantial inflammatory cell infiltration near 
major and minor airways in sensitised, no BMT controls and in recipients of OVA-ve BM (Fig. 
4.6A). Recipients of OVA+ve BM typically demonstrated less inflammatory infiltration than all 
other challenged groups (Fig. 4.6A). The presence of inflammatory infiltrates in unsensitised, but 
OVA-challenged mice not present in unchallenged mice indicated that OVA-challenge itself 
elicited some degree of inflammatory cell infiltration. When quantitated, inflammatory infiltrate 
scores were highest in sensitised, challenged, no BMT controls and recipients of OVA-ve BM and 
the infiltrate score was significantly lower for the OVA+ve BMT group (Fig. 4.7A) and was 
equivalent to challenged, but unsensitised mice indicating a return to the ‘baseline’ for in OVA-
challenged mice. 
Periodic Acid Schiff’s (PAS) staining showed goblet cell hyperplasia was prominent in 
airways of sensitised, challenged, no BMT controls and also in recipients of OVA-ve BM (Fig. 
4.6B). Recipients of OVA+ve BM typically demonstrated less mucus staining than all the other 
challenged groups (Fig. 4.6B). The extent of mucus production in unsensitised but OVA-challenged 
mice relative to unchallenged mice indicated the OVA-challenges themselves introduced some 
increase in mucus accumulation possibly through a sensitisation effect. When quantitated, the 
frequency of mucus-filled cells was highest in sensitised, challenged, no BMT controls and 
recipients of OVA-ve BM and was significantly lower for the OVA+ve BMT group (Fig. 4.7B). 
In conclusion, the reduction in IL-5 and IL-13 cytokine production in recipients of OVA+ve 
BM indicated a termination of allergen-specific Th2 T-cell responses. This protected mice from 
developing eosinophilia, lymphocytic infiltration and goblet cell hyperplasia when challenged 
intranasally with OVA. In general, the eosinophil content of BALF, inflammatory infiltration, and 
mucus hypersecretion was lower in OVA+ve BM recipients than in other test groups including 
unsensitised, but challenged mice although this was not always statistically significant (when 
comparing OVA+ve BM recipients to other groups).  Although there was a general trend this was 
not statistically significant for all groups principally due the differences in the degree of variability 
within experimental groups.  It is possible that more replicates of these particular experiments may 
have led to more robust statistically-identifiable patterns. This suggests that the intranasal 
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challenges with OVA may have been sensitising mice and that OVA+ve BMT prevented or 
inhibited this. 
Together, these data show that transfer of BM encoding antigen targeted to DC, under 
immune-preserving, non-myeloablative conditions, ‘turned-off’ pre-existing and ongoing allergen-
specific T-cell responses and protected against allergen-induced airways inflammation and 
potentially sensitisation by respiratory-allergen challenge.  
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Figure 4.1 High levels of engraftment are achieved with immune-preserving conditioning.  
BALB/c mice were irradiated (300cGy) and BM (2 x10
7
, open squares) or lin
-ve 
c-kit
+ve
 HPC 
(10
5
, open triangles) from CD45.1
+
 congenically-marked BALB/c mice injected i.v. At the 
indicated times blood was collected from transplanted mice and unirradiated untransplanted 
controls (open circles) and (A) engraftment determined by flow cytometry. Data shown are mean 
± SD (n= 4/gp) pooled from 2 separate experiments. 
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Figure 4.2 Cytokine production by MLN cell cultures of OVA+ve BM recipients as an 
indication of the local response to OVA323-339 stimulation.  
(A) BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 
/alum) at days 0 & 14. At day 28 mice were irradiated (300cGy) and non-transgenic control 
(OVA-) or 11c.OVA BM (OVA+) injected i.v. 4 weeks later, at days 56-59 and 64-67, the mice 
were intransally challenged with OVA. One day after the last i.n. challenge mice were 
euthanized, MLNs were collected and restimulated in vitro with OVA323-339 peptide or OVA. 
Three days later the supernatant was collected and (B-C) IL-5 and (D-E) IL-13 concentration 
was determined by ELISA. (Data are pooled from 2 separate experiments. Each point represents 
an individual mouse n=6). Statistical test: ANOVA followed by Tukey’s post-test. (*p<0.05, 
**p<0.01, ***p<0.001, and **** p<0.0001) 
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Figure 4.3 Cytokine production by spleen cells of OVA-ve and OVA+ve BM recipients. 
(A) BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 
/alum) at days 0 & 14. At day 28 some mice were irradiated (300cGy) and non-transgenic 
control (OVA- BMT) or 11c.OVA BM (OVA+BMT) injected i.v. 4 weeks later, at days 56-59 
and 64-67, the mice were intransally challenged with OVA. One day after the last i.n. challenge 
mice were euthanized, spleens were collected and restimulated in vitro with OVA323-339 peptide 
or OVA. Three days later the supernatant was collected and (B-C) IL-5 and (D-E) IL-13 
concentration was determined by ELISA. (Data are pooled from 2 separate experiments. Each 
point represents an individual mouse n=6). Statistical test: ANOVA followed by Tukey’s post-
test. (*p<0.05, ***p<0.001, and ****p<0.0001) 
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Figure 4.4 Cellular infiltrates in BALF after OVA intranasal challenge are reduced in 
OVA+ve BM recipients.  
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 /alum) at 
days 0 & 14. At day 28 mice were irradiated (300cGy) and non-transgenic control (OVA-) or 
11c.OVA BM (OVA+) injected i.v. 4 weeks later, at days 56-59 and 64-67, the mice were 
intransally challenged with OVA. One day after the last i.n. challenge mice were euthanized. 
BALF was collected and CD4+ cells and eosinophils enumerated by flow cytometry. 
Representative gating strategy and FACS plots for (A) CD4+ cells and (B) eosinophils are 
shown. Total number of (C) CD4+ cells and (D) eosinophils and percentage of (E) CD4+ cells 
and (F) eosinophils in BALF were determined. (Data are pooled from 2 separate experiments. 
Each point represents an individual mouse n=6). Statistical test: ANOVA followed by Tukey’s 
post-test. (*p<0.05, **p<0.01, and **** p<0.0001) 
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Figure 4.5 Minimal effect of OVA intranasal challenge on alveolar macrophages and 
neutrophils in BALF.  
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 /alum) at 
days 0 & 14. At day 28 mice were irradiated (300cGy) and non-transgenic control (OVA-) or 
11c.OVA BM (OVA+) injected i.v. 4 weeks later, at days 56-59 and 64-67, the mice were 
intransally challenged with OVA. One day after the last i.n. challenge mice were euthanized. 
BALF was collected and alveolar macrophages and neutrophils enumerated by flow cytometry. 
Representative gating strategy and FACS plots for (A) alveolar macrophages and (B) neutrophils 
are shown. Total number of (C) alveolar macrophages and (D) neutrophils and percentage of (E) 
alveolar macrophages and (F) neutrophils in BALF were determined. (Data are pooled from 2 
separate experiments. Each point represents an individual mouse n=6). Statistical test: ANOVA 
followed by Tukey’s post-test. (*p<0.05, **p<0.01) 
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Figure 4.6 Protective effect of 11c.OVA BM transfer on airway and lung inflammation in 
OVA challenged mice.  
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 /alum) at 
days 0 & 14. At day 28 mice were irradiated (300cGy) and non-transgenic control (OVA-) or 
11c.OVA BM (OVA+) injected i.v. 4 weeks later, at days 56-59 and 64-67, the mice were 
intransally challenged with OVA. One day after the last i.n. challenge mice were euthanized 
lungs were collected, fixed, embedded and sectioned at 500 μm intervals and stained with (A) 
hematoxylin & eosin (H&E) or (B) periodic acid-Schiff (PAS). Bar=1mm (low power) and 50 
μm (high power). (One lobe from an individual mouse is shown).  
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Figure 4.7 Quantitative analysis of lung histology reflects the protective effect of 11c.OVA 
BM.  
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 /alum) at 
days 0 & 14. At day 28 mice were irradiated (300cGy) and non-transgenic control (OVA-) or 
11c.OVA BM (OVA+) injected i.v. 4 weeks later, at days 56-59 and 64-67, the mice were 
intransally challenged with OVA. One day after the last i.n. challenge mice were euthanized, 
lungs were collected, fixed, embedded and sectioned at 500 μm intervals and stained with 
hematoxylin & eosin (H&E) or periodic acid-Schiff (PAS). (A) Inflammatory infiltrate score and 
(B) PAS+ cells/100 μm of basement membrane was quantitated. (Data are pooled from 2 
separate experiments. Each point represents an individual mouse n=6). Statistical test: ANOVA 
followed by Tukey’s post-test. (*p<0.05, **p<0.01, and **** p<0.0001) 
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4.2.2 Tolerance induced by transfer of OVA-encoding BM is antigen-specific  
Having shown that transfer of OVA-encoding bone marrow reverses OVA-specific Th2 T 
cell responses and prevents induction of local airway inflammatory response to OVA challenge, I 
then investigated the antigen-specificity of the effect. 
To test for antigen-specificity, I determined whether established ryegrass pollen (RGP)-
specific Th2 T-cell responses remained intact after OVA+ve BM transfer. BALB/c mice were sham 
sensitised (unsen; saline/alum) or sensitised (sen; OVA323-339+RGP/alum) twice. Fourteen days 
later, mice were irradiated (300cGy) and non-transgenic control (OVA-) or OVA-encoding 
11c.OVA BM (OVA+) was injected i.v. Mice were rested for 4 weeks and then exposed to intransal 
OVA or RGP challenges (days 56-59 & 64-67). One day after the last intransal challenge, 
mediastinal lymph nodes and BALF were harvested. Supernatants form In vitro cultures of MLNs 
restimulated with OVA323-339 or RGP were analysed by ELISA, and cellular infiltrate in BALF by 
flow cytometry (Fig. 4.8A).  
When cultures were established from MLNs, which drain the site of respiratory allergen 
exposure, and restimulated in vitro with OVA323-339, very little IL-5 and IL-13 was produced from 
any OVA-challenged groups, regardless of treatment, with no significant differences between the 
groups (Fig. 4.8B,D). In cultures re-stimulated in vitro with RGP, substantial IL-5 and IL-13 was 
produced in cultures from mice that were OVA323-339 /RGP-sensitised and RGP-challenged, 
regardless of whether they got no BMT, OVA+ve BMT or OVA-ve BMT, particularly when 
compared to unsensitised, but RGP-challenged, control group (Fig. 4.8B,D). When restimulated 
with OVA323-339, substantial cytokine production was evident in OVA323-339/RGP-sensitised and 
RGP-challenged groups, regardless of treatment (Fig. 4.8C,E). Interestingly, spontaneous 
production of IL-5 and IL-13 was observed in the unstimulated cultures of all OVA323-339 /RGP-
sensitised and RGP challenged groups (Fig. 4.9A,B). This could explain the cytokine production in 
OVA323-339 stimulated cultures form OVA323-339 /RGP-sensitised and RGP-challenged groups. When 
restimulated with RGP, some cytokine production was evident in OVA323-339 /RGP-sensitised and 
OVA-challenged groups (Fig. 4.8B,D). However, the difference in response between OVA-
challenged groups or RGP-challenged groups in RGP restimulated cultures manifests the expansion 
of the response in the draining lymph nodes of RGP-challenged groups, which is due to the 
intranasal challenges with RGP. 
In this experimental setting, as in the previous experiments, OVA-specific and RGP-specific 
Th2 T cell-responses were established prior to BMT. Intranasal challenge with OVA or RGP after 
BMT here would similarly allow a measure of any residual established Th2 immunity as any 
responsiveness present would lead to development of airways inflammation after OVA or RGP 
93 
 
challenge. Therefore, I analysed BALF collected from allergen-challenged and unchallenged mice. 
The number and proportion of CD4
+
 cells in BALF was similar from all OVA intranasally 
challenged groups and unchallenged controls (Fig. 4.10A,C). The number of CD4
+
 cells in BALF 
from all OVA323-339 /RGP-sensitised and RGP intranasally-challenged groups was relatively similar 
and mostly elevated compared to RGP-challenged but unsensitised controls (Fig. 4.10A). However, 
the proportion of CD4
+
 cells in BALF for those groups was mostly lower than RGP challenged but 
unsensitised controls (Fig. 4.10C). While eosinophil infiltration after OVA in challenge was 
somewhat less than other experiments where OVA323-339/RGP-sensitised mice have been 
intranasally challenged with OVA, eosinophil-proportion was reduced in OVA-challenged 
recipients of OVA+ve BM compared to OVA323-339 /RGP-sensitised, OVA-challenged mice that 
received OVA-ve BM (Fig. 4.10B,D). However, eosinophils were present in high numbers and 
proportions in all OVA323-339 /RGP-sensitised, RGP-challenged groups compared to unsensitised but 
RGP challenged control group (Fig. 4.10B,D).  
In conclusion, the substantial production of IL-5 and IL-13 in RGP restimulated cultures 
from OVA323-339 /RGP-sensitised and RGP intranasally-challenged groups indicated an expansion of 
RGP-specific Th2 T-cell responses by RGP intranasal challenges. The RGP challenges also elicited 
cellular infiltration of BALF in all OVA323-339 /RGP-sensitised and RGP intranasally-challenged 
groups. This shows that RGP responses were preserved regardless of whether OVA-encoding BM 
transfer was performed or not. Therefore, tolerance was induced in an antigen-specific manner. 
Taken together and consistent with previous observations (Fig. 4.2, 4.4) antigen-expressing 
BMT under immune preserving conditions reverses Th2 responses and prevents airway 
inflammation; however maintains immune responses to irrelevant allergens. 
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Figure 4.8 Preservation of Th2 responses to RGP after OVA+ve BM transfer.  
(A) BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen; OVA323-339+RGP 
/alum) at days 0 & 14. At day 28 mice were irradiated (300cGy) and non-transgenic control 
(OVA-) or 11c.OVA BM (OVA+) injected i.v. 4 weeks later, at days 56-59 and 64-67 the mice 
were intransally challenged with OVA or RGP. One day after the last i.n. challenge mice were 
euthanized. MLNs were collected and restimulated in vitro with OVA323-339 peptide or RGP. 
Three days later the supernatant was collected and (B-C) IL-5 and (D-E) IL-13 concentration 
was determined by ELISA. (Data are pooled from 2 separate experiments. Each point represents 
an individual mouse n=4). Statistical test: ANOVA followed by Tukey’s post-test. (**p<0.01 
and ****p<0.0001) 
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Figure 4.9 Spontaneous production of IL-5 and IL-13 in unstimulated cultures of MLNs 
from RGP-challenged mice. 
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen; OVA323-339+RGP 
/alum) at days 0 & 14. At day 28 mice were irradiated (300cGy) and non-transgenic control 
(OVA-) or 11c.OVA BM (OVA+) injected i.v. 4 weeks later, at days 56-59 and 64-67 the mice 
were intransally challenged with OVA or RGP. One day after the last i.n. challenge mice were 
euthanized, MLNs were collected and left un-restimulated in vitro. Three days later the 
supernatant was collected and (A) IL-5 and (B) IL-13 concentration was determined by ELISA 
(note: ELISA performed at a later stage than in fig 4.8). (Data are pooled from 2 separate 
experiments. Each point represents an individual mouse n=4).  
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Figure 4.10 Development of airway inflammatory response in RGP-challenged mice after 
transfer of OVA+ve BM.  
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen; OVA323-339+RGP 
/alum) at days 0 & 14. At day 28 mice were irradiated (300cGy) and non-transgenic control 
(OVA-) or 11c.OVA BM (OVA+) injected i.v. 4 weeks later, at days 56-59 and 64-67 the mice 
were intransally challenged with OVA or RGP. One day after the last i.n. challenge mice were 
euthanized. BALF was collected and CD4+ T cells and eosinophils enumerated by flow 
cytometry. Representative gating strategy and FACS plots for CD4+ T cells and eosinophils is as 
shown in Fig.4.4. Total number of (A) CD4+ T cells and (B) eosinophils and percentage of (C) 
CD4+ T cells and (D) eosinophils in BALF were determined. (Data are pooled from 2 separate 
experiments. Each point represents an individual mouse n=4). Statistical test: ANOVA followed 
by Tukey’s post-test. (*p<0.05, **p<0.01, ***p<0.001, and****p<0.0001) 
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4.2.3 Transfer of OVA-encoding BM prevents exacerbation of established Th2 responses 
and reduces airways inflammation  
In the first experiments presented in this chapter, transfer and engraftment of OVA-encoding 
BM reversed established Th2 T-cell responses, and protected mice from developing OVA-elicited 
airway inflammation. The next question investigated was “what is the effect of OVA-encoding BM 
transfer on the T-cell responses and airways disease in mice that are sensitised and have established 
OVA-elicited airway inflammation?”. 
In this series of experiments I first tested whether established Th2 responses could be 
‘turned-off’ after airways inflammation had been established by i.n. OVA challenge.  BALB/c mice 
were sham-sensitised (unsen; saline/alum) or sensitised (sen; OVA323-339/alum) twice. Eleven days 
later, mice were exposed to intransal OVA challenges (days 25-28 & 33-36). At day 42, mice were 
irradiated (300cGy) and non-transgenic control (OVA-ve) or OVA-encoding 11c.OVA BM 
(OVA+ve) was injected i.v. Mice were rested for 4 weeks and then exposed to intransal OVA 
challenges (days 70-73 & 78-81). One day after the last intransal challenge, mediastinal lymph 
nodes, spleens, BALF, and lungs were harvested for analysis (Fig. 4.11A).  
When cultures established from MLNs were restimulated with OVA323-339, little IL-5 and IL-
13 was produced from those prepared from unsensitised mice regardless of whether they had been 
intranasally-challenged or not or from sensitised and rechallenged mice that that were not subject to 
BMT (Fig. 4.11B,D). Substantial IL-5 and IL-13 was produced in cultures from mice that were 
sensitised and received transfer of control OVA-ve BM (Fig. 4.11B,D). In cultures from recipients 
of OVA+ve BM, IL-5 IL-13 production was significantly reduced compared to cultures from those 
mice that received OVA-ve BM although this didn’t reach statistical significance for IL-5 (Fig. 
4.11B,D). When restimulated with OVA, IL-5 and IL-13 showed a similar pattern except in cultures 
from recipients of OVA+ve BM in which the cytokine production didn’t statistically differ to 
recipients of OVA-ve BM. (Fig. 4.11C,E).  
Next, cultures were established from spleen which is a site distant to that of allergen 
exposure, and therefore reflects the systemic response. Again, restimulation with OVA323-339 led to 
little IL-5 and IL-13 production from cultures prepared from unsensitised mice regardless of 
whether they were intranasally-challenged or not or from sensitised and rechallenged mice that did 
not received BMT (Fig. 4.12B,D). IL-5 and IL-13 were substantially produced in cultures from 
mice that were sensitised and received control OVA-ve BM (Fig. 4.12B,D), but cytokine levels 
were lower than in cultures of MLNs (N.B. Y-axis scale relative to Fig. 4.11). In cultures from 
recipients of OVA+ve BM, IL-5 and IL-13 levels were both significantly reduced compared to 
recipients of OVA- BM (Fig. 4.12B,D).When restimulated with OVA, IL-5 and IL-13 showed a 
similar pattern to that observed for OVA323-339-stimulated cultures (Fig. 4.12C,E). Together, these 
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data indicate OVA challenge most strongly amplifies the cytokine response in draining lymph 
nodes, but in this experimental setting also amplifies the cytokine response systemically.  
As in other series of experiments, I analysed BALF collected from allergen-challenged and 
unchallenged mice to gain insight into the status of the established airways inflammation following 
OVA-encoding BM transfer. The total number and proportion of CD4
+
 cells in BALF did not differ 
significantly across all intranasally-challenged groups and this was elevated compared to 
unchallenged controls (Fig. 4.13A,C), although the total number of cells was more variable 
between groups. The total number of eosinophils as well did not differ significantly across all 
intranasally-challenged groups although variability was observed between the groups. However, the 
proportion of eosinophils in BALF was elevated in sensitised, challenged, no BMT controls 
compared to unsensitised, challenged no BMT controls (Fig. 4.13B,D). Moreover, the proportion 
and total number of eosinophils was similar in recipients of OVA+ve BM compared to sensitised, 
challenged no BMT controls and sensitised mice that received OVA-ve BM (Fig. 4.13B,D).  
Histological analysis of lung sections showed substantial inflammatory cell infiltration near 
major and minor airways in sensitised, no BMT controls and in recipients of OVA-ve BM (Fig. 
4.14A). Recipients of OVA+ve BM typically demonstrated less inflammatory infiltration than 
sensitised, no BMT controls and in recipients of OVA-ve BM (Fig. 4.14A). As in the experiments 
described above, the presence of inflammatory infiltrates in unsensitised, challenged mice, but not 
unchallenged mice indicated the challenges themselves introduced some inflammatory cell 
infiltration. When quantitated, infiltrate scores were highest in sensitised and challenged, no BMT 
controls and recipients of OVA-ve BM and the infiltrate score was not different for the OVA+ve 
BMT group although it slightly varied (Fig. 4.15A). 
Periodic Acid Schiff’s (PAS) staining showed mucus-filled goblet cells were prominent in 
airways of sensitised challenged no BMT controls and in recipients of OVA-ve BM and some 
luminal accumulation of mucus was present (Fig. 4.14B). Recipients of OVA+ve BM typically 
demonstrated less mucus accumulation than sensitised, no BMT controls and recipients of OVA-ve 
BM (Fig. 4.14B). When quantitated, the frequency of mucus-filled cells was highest in sensitised 
and challenged, no BMT controls and recipients of OVA-ve BM and frequency was significantly 
reduced in recipients of OVA+ve BMT relative to no BMT controls (Fig. 4.15B). 
In conclusion, the reduction in IL-5 and IL-13 cytokine production in recipients of OVA+ve 
BM indicated that OVA-specific Th2 T-cell responses were largely reduced or terminated by this 
treatment. This then prevented exacerbation of eosinophilia, lymphocytic infiltration and goblet cell 
hyperplasia. In general, the eosinophil content of BALF, inflammatory infiltration, and mucus 
hypersecretion was lower in OVA+ve BM recipients than in other test groups although this was not 
always statistically significant.  
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Together, these data show that transfer, under immune preserving non-myeloablative 
conditions, of BM encoding antigen targeted to DC ‘turned off’ pre-existing and ongoing allergen-
specific T-cell responses however, this treatment appears to have a more moderate effect on 
inflammatory cell infiltration to BALF, but did quite strongly influence mucus hypersecretion 
which may be directly dependent on local cytokine production. 
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Figure 4.11 Cytokine production by MLNs of OVA+ve BM recipients as an indication of 
the reduced respiratory T-cell response to OVA323-339. 
(A) BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 
/alum) at days 0 & 14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. 
At day 42 mice were irradiated (300cGy) and non-transgenic control (OVA-) or 11c.OVA BM 
(OVA+) injected i.v.. 4 weeks later, the mice were intranasally challenged with OVA at days 70-
73 & 78-81. One day after the last i.n. challenge mice were euthanized. MLNs were collected 
and restimulated in vitro with OVA323-339 peptide or OVA. Three days later the supernatant was 
collected and (B-C) IL-5 and (D-E) IL-13 concentration was determined by ELISA. (Data are 
pooled from 3 separate experiments. Each point represents an individual mouse n=6). Statistical 
test: ANOVA followed by Tukey’s post-test. (*p<0.05, **p<0.01, and ***p<0.001) 
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Figure 4.12 Reduced cytokine production by spleen cells of OVA+ve BM recipients 
indicates diminished systemic response to OVA323-339 stimulation. 
(A) BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 
/alum) at days 0 & 14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. 
At day 42 mice were irradiated (300cGy) and non-transgenic control (OVA-) or 11c.OVA BM 
(OVA+) injected i.v.. 4 weeks later, the mice were intranasally challenged with OVA at days 70-
73 & 78-81. One day after the last i.n. challenge mice were euthanized. Spleens were collected 
and restimulated in vitro with OVA323-339 peptide or OVA. Three days later the supernatant was 
collected and (B-C) IL-5 and (D-E) IL-13 concentration was determined by ELISA. (Data are 
pooled from 3 separate experiments. Each point represents an individual mouse n=6). Statistical 
test: ANOVA followed by Tukey’s post-test. (**p<0.01, ***p<0.001, and ****p<0.0001) 
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Figure 4.13 Analysis of cellular recovery in BALF after OVA intranasal challenge. 
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 /alum) at 
days 0 & 14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. At day 42 
mice were irradiated (300cGy) and non-transgenic control (OVA-) or 11c.OVA BM (OVA+) 
injected i.v.. 4 weeks later, the mice were intranasally challenged with OVA at days 70-73 & 78-
81. One day after the last i.n. challenge mice were euthanized. BALF was collected and CD4+ T 
cells and eosinophils enumerated by flow cytometry. Representative gating strategy and FACS 
plots for CD4+ T cells and eosinophils is as shown in Fig.4.4. Total number of (A) CD4+ T cells 
and (B) eosinophils and percentage of (C) CD4+ T cells and (D) eosinophils in BALF were 
determined. (Data are pooled from 2 separate experiments. Each point represents an individual 
mouse n=6). Statistical test: ANOVA followed by Tukey’s post-test. (***p<0.001, 
****p<0.0001) 
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Figure 4.14 Effect of 11c.OVA BM on airway and lung inflammation following OVA 
intranasal challenge. 
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 /alum) at 
days 0 & 14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. At day 42 
mice were irradiated (300cGy) and non-transgenic control (OVA-) or 11c.OVA BM (OVA+) 
injected i.v.. 4 weeks later, the mice were intranasally challenged with OVA at days 70-73 & 78-
81. One day after the last i.n. challenge mice were euthanized. One day after the last i.n. 
challenge mice were euthanized lungs were collected, fixed, embedded and sectioned at 500 μm 
intervals and stained with (A) hematoxylin & eosin (H&E) or (B) periodic acid-Schiff (PAS). 
Bar=1mm (low power) and 50 μm (high power). (One lobe from an individual mouse is shown). 
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Figure 4.15 Quantitative analysis of the stained lung sections reflects the trend of decreased 
inflammation observed in 11c.OVA recipients.  
BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 /alum) at 
days 0 & 14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. At day 42 
mice were irradiated (300cGy) and non-transgenic control (OVA-) or 11c.OVA BM (OVA+) 
injected i.v.. 4 weeks later, the mice were intranasally challenged with OVA at days 70-73 & 78-
81. One day after the last i.n. challenge mice were euthanized, lungs were collected, fixed, 
embedded and sectioned at 500 μm intervals and stained with hematoxylin & eosin (H&E) or 
periodic acid-Schiff (PAS). (A) Inflammatory infiltrate score and (B) PAS+ cells/100 μm of 
basement membrane was quantitated. (Data are pooled from 2 separate experiments. Each point 
represents an individual mouse n=6). Statistical test: ANOVA followed by Tukey’s post-test. 
(*p<0.05, and **p<0.01) 
 
A) 
B) 
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4.2.4 Transfer of OVA-encoding BM Reverses airway hyper responsiveness 
Acute asthma symptoms result from airways smooth muscle hyper-reactivity within the 
small conducing airways. A strong factor implicated in the development of hyper reactivity is Th2-
mediated inflammation in these sites. Therefore, to determine whether reversing localised Th2 T-
cell responsiveness, and possibly inflammation, alleviated airways hyper-reactivity I next tested the 
effects BM transfer on airways hyper responsiveness. For this series of experiments, I modelled a 
therapeutic scenario where BALB/c mice were sham sensitised (unsen; saline/alum) or sensitised 
(sen; OVA323-339/alum) twice. Eleven days later, mice were exposed to intransal OVA challenges 
(days 25-28 & 33-36). At day 42 mice were irradiated (300cGy) and non-transgenic control (OVA-
ve) or OVA-encoding 11c.OVA BM (OVA+ve) was injected i.v. Mice were rested for 4 weeks and 
then exposed to intransal OVA challenges (days 70-73 & 78-81). Two days after the last intransal 
challenge, lungs were tested for airway hyper responsiveness (AHR) (Fig. 4.16A). OVA-ve BM 
recipients demonstrated a dose-dependent increase in airway resistance in response to methacoline 
challenge and airway resistance was significantly higher in this group than in sham-sensitised and 
OVA-challenged controls at the highest concentration tested (5mg/ml) (Fig. 4.16B). OVA+ve BM 
recipients showed an attenuated increase in airway resistance to methacoline challenge and at 
5mg/ml methacholine challenge airway resistance did not differ from the sham-sensitised and OVA 
challenged control group (Fig. 4.16B). Reduced AHR in OVA+ve recipients was also mirrored by 
increased compliance in this group in comparison to the OVA-ve BM recipient control group (Fig. 
4.16C).  
In summary, the data from all the experiments show that transfer of BM encoding antigen 
targeted to DC, under immune-preserving, non-myeloablative conditions, ‘turned-off’ pre-existing 
and ongoing allergen-specific T-cell responses and protected against allergen-induced airways 
inflammation and potentially sensitisation by respiratory-allergen challenge. However, immune 
responses are maintained to irrelevant allergens. This treatment appears to have a more moderate 
effect on inflammatory cell infiltration to BALF when airway inflammation has been established 
before BM transfer. Nevertheless it did quite strongly influence mucus hypersecretion and airway 
hyper responsiveness which may be directly dependent on local cytokine production. 
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Figure 4.16 Reduction of airway hyper responsiveness in 11c.OVA BM recipients. 
(A) BALB/c mice were sham-sensitised (unsen; saline/alum) or sensitised (sen.; OVA323-339 
/alum) at days 0 & 14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. 
At day 42 mice were irradiated (300cGy) and non-transgenic control (OVA-) or 11c.OVA BM 
(OVA+) injected i.v.. 4 weeks later, the mice were intranasally challenged with OVA at days 70-
73 & 78-81. 48hrs after the last i.n. challenge  mice were subjected to increased doses of 
methacoline for (B) transpulmonary resistance reading and (C) Dynamic compliance.(Data are 
pooled from 2 experiments; n=8). Statistical test: Two-way ANOVA followed by Tukey’s post-
test. (*p<0.05, ***p<0.001, and ****p<0.001) 
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4.3 Discussion 
Transfer of bone marrow (BM) or hematopoietic stem cells (HSC) has been utilized to treat 
hematologic malignancies. More recently, this has been adapted for autoimmune diseases and 
autologous HSCT has shown promising results. However, limitations accompany this approach due 
to the toxic effects of myeloablation, complete immune suppression, and high disease relapse rates. 
It has been shown that combining gene therapy with syngeneic HSCT might overcome these 
limitations (Coleman et al. 2012). The main idea behind this approach is that immunologic 
tolerance is achieved under immune-preserving conditions by targeting expression to differentiated 
APCs (Coleman et al. 2013). Here I tested whether 11c.OVA BM transfer reverses allergenic Th2 
responses and in doing so protects against allergen-elicited airway inflammation. Further, I tested 
the impact of 11c.OVA BM transfer on established disease. In this chapter, I show OVA-encoding 
BM transfer reverses allergic priming and, consequently, respiratory immune responses to 
respiratory OVA challenge.  
To understand the influence of OVA-encoding BMT on the systemic T-cell component of 
the allergic response, it was appropriate to study the Th2 response to allergen challenge. 
Sensitisation with OVA323-339 induced a Th2 response indicated by IL-5 and IL-13 production in 
OVA323-339 restimulated spleen cultures from the sensitised, no BMT controls as expected. 
However, looking at the systemic response of the OVA-ve and OVA+ve BM recipients there was 
no difference in IL-5 and IL-13 production in response to OVA323-339 stimulation. One explanation 
is that OVA323-339-T cells in the OVA-ve group migrated to MLNs where the OVA323-339 specific 
response is boosted by the intranasal challenges with OVA. One study demonstrated that the 
migration of antigen-specific T cells is primarily from the splenic pool from which some of them 
migrate into target tissues upon local antigen challenge (Kaminuma et al. 2001). The kinetics and 
mechanisms of the migration of those cells demonstrated in that study compensated for the gaps of 
earlier investigations. It revealed that the migrated antigen-specific cells were activated and 
proliferated in an antigen-specific manner (Kaminuma et al. 2001). However, if this is completely 
the case then it might be expected the sensitised group that received no BMT would behave 
similarly to the OVA-ve BM recipient group. A study investigating the different effects of low and 
high dose radiation on the responses of different splenocyte subpopulations showed significant 
differences between the sensitivity and viability of the cell types. Apoptosis increased in all 
splenocyte subpopulations under 2Gy exposure. Sensitivity ranged from very sensitive for CD8
+
 
and B cells to less sensitive for NK cells, DC and Tregs. However, the T-helper 1 (Th1)- and T-
helper 2 (Th2)-type cytokine-expression increased after such a dose. Interleukin 6 (IL-6) and IL-10 
were affected at different time points and IL-5 levels were consistently elevated (Bogdandi et al. 
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2010). Another study showed a greater decrease in total CD4
+
 numbers than in CD4
+
Foxp3
+
 Tregs in 
splenic lymphocyte fractions after 200cGy irradiation and concluded that Tregs are more resistant to 
irradiation and repopulate at a faster rate than CD4
+
Foxp3
-
 cells, but have a reduced suppressive 
capacity (Balogh et al. 2013). This could explain the limited response in the spleens of OVA-ve BM 
recipients in Fig. 4.3B. It is possible i) that the number of primed OVA323-339-specific T-cell 
response was reduced by irradiation, ii) that Tregs became more abundant relative to primed OVA323-
339-specific T-cell, iii) that primed OVA323-339-specific T-cell migrated to MLNs or a combination of 
these occurred. Besides, there is the consideration that sensitisation with a single peptide leads to 
weaker responses than sensitisation with whole protein. This adds to the fact that the OVA323-339 T-
cell repertoire remaining after irradiation is not sufficient to induce an immune response in the 
presence of regulatory cells. However, this wasn’t the case in Fig. 4.12 were irradiation takes place 
after the airway disease has been established. A boost in the response is seen in the OVA-ve BM 
recipients. Basic studies that evaluate the effect of low-dose irradiation on the balance between 
Th1/Th2 immune responses have led to indistinct outcomes. Some demonstrate that irradiation 
increases the Th2 response (Bass et al. 1989, Westermann et al. 1999) others that it favors the Th1 
response (Shen et al. 1991). In general, irradiation is stated to have stimulatory effects on immune 
responses demonstrated by augmented proliferation of T cells to mitogenic stimulation (Nogami et 
al. 1994), an increased primary B cell response (Anderson et al. 1979), as well as autoantibody 
production from non-irradiated lymphocytes through stimulatory effects exerted by irradiated cells 
(McGregor et al. 1979). In the context of low-dose irradiation effects on asthma in murine models, 
cytokine levels and T-cell sub-populations were the focus of evaluation in relation to pathological 
exacerbation in the study performed by Fang et al. Levels of IL-4 and IL-5 were significantly higher 
in splenocytes of an irradiated group than in a disease control group (Fang et al. 2005). On the other 
hand, γ irradiation lowered IFN-γ levels to normal values (Fang et al. 2005). In another study, IFN-γ 
levels were also shown to be lower and IL-4 levels to be significantly higher in the bronchoalveolar 
lavage fluid (BALF) of irradiated mice (Park et al. 2013). In my studies, irradiation exacerbated the 
Th2 responses only where irradiation was administered after airways disease was established. 
However, OVA+ve BMT blocked any exacerbation of the responses seen in OVA-ve BMT 
recipients.  
Investigating the response to full-length OVA restimulation in vitro, cytokine production 
was apparent in splenocyte cultures from OVA-ve recipients but not from OVA-ve recipients after 
OVA323-339 restimulation. Sensitisation to OVA through the airways could have led to migration to 
spleen of T cells specific for the several immunogenic epitopes of OVA thereby giving rise to an 
immunogenic response in the OVA-ve BMT recipients. For the sensitised group, this is seen in 
addition to the OVA323-339-specific T cell response. Another source of IL-5 and IL-13 could be from 
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a different subset of cells known as ILC2. Sensitisation through the airways is a potential inducer of 
ILC2. These cells, being the innate counterpart of the Th2 cells, likely contribute to the 
inflammation of allergic disorders at mucosal sites. ILC2 respond to IL-25 and IL-33 by producing 
high amounts of IL-5 and IL-13. Importantly, diverse cell types of immune and non-immune cells, 
including lung epithelial cells, can release IL-25 and IL-33 (Bergmann et al. 2014). Another study 
showed that the stimulation of ILC2 and Th2 cells took place by the intranasal administration of the 
protease-allergen papain. This caused an allergic lung inflammation and high IgE production. IL-13 
derived from ILC2 promoted, in this case, the activated lung DC to migrate into the draining lymph 
nodes where naïve T-cell priming and differentiation took place. Furthermore, the activation of 
ILC2 and the differentiation of Th2 cells was IL-33 dependent (Halim et al. 2014). ILC2 consist of 
various cell populations that share phenotypic features (reviewed by(Spits et al. 2012)). One of the 
cell populations are Ih2 (innate type 2 helper) cells which also play a role in type 2 immune 
responses (Price et al. 2010). Another cell population is nuocytes (as subpopulation of ILC2), which 
also play a similar role. Intranasal administration of IL-25 or IL-33 led to the infiltrate of IL-13 
producing nuocytes to the lungs and contributed to airways hyper reactivity in a study performed by 
Barlow et. al (Barlow et al. 2012). The observation of cytokine production in the unsensitised-OVA 
intranassally challenged group could be from non-specific Th2 or innate responses. The recall 
response to restimulation with OVA in the medianstinal lymph nodes in this group led to a 
profound cytokine production. However, this was not the case when restimulated with OVA323-339. 
This validates that i.p sensitisation with peptide leads to a specific T-cell response that is boosted 
locally by intranasal challenges and that sensitisation through the airways can happen and lead to 
Th2 responses to the variable epitopes of the protein. Sensitisation through the airways can have an 
effect on IL-5 and IL-13 cytokine production by the activation of innate cells as well. A major 
observation was that OVA+ve BMT blocked the response resulting from intranasal challenge itself. 
Due to the fact that Treg were not analyzed here no decisive conclusions can be made about 
the role of these cells. Based on the discussion in chapter 3, deletion or anergy were proposed as 
the key mechanisms by which DC orchestrate long-term tolerance induction. It has been shown that 
increased number of Tregs or suppressive cytokines does not underlie oral tolerance (Faustino et al. 
2012). This was shown by studying the effect of the increased infiltration of Foxp3-positive Treg 
cells in the airways of allergic mice. Treg did suppress CD4
+
 T-cell proliferation, but did not 
suppress type 2 cytokine production by Foxp3-negative CD4
+
 T cells and did not secrete Th2 
cytokines themselves (Faustino et al. 2012). As a result, Treg were not able to contribute alone to 
tolerance. The inability of CD4
+
CD25
+
 T cells to suppress Th2-cytokine release in allergic patients 
was also demonstrated in another study (Grindebacke et al. 2004). Tolerance can be driven by a 
DC/Treg mechanism. 
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Airway resistance gives provides insight into narrowing of the conducting airways and 
increasing airway resistance observed in response to increasing methacoline doses implies 
bronchoconstriction (Martin et al. 1988, Glaab et al. 2007). Compliance is also recognized as an 
important factor in alterations in AHR and reflects the elasticity of the lung parenchyma. However, 
compliance is also influenced by various factors such as surface tension, smooth muscle contraction 
and peripheral airway inhomogeneity (reviewed by (Faffe et al. 2009). It is important to consider 
that remodelling is induced in response to the mechanical stress developed during asthmatic 
bronchoconstriction (Swartz et al. 2001). OVA+ve BM transfer reduced airway hyper 
responsiveness and thus, theoretically, protected the lungs from severe damage and airway 
remodelling. In conclusion, the chronic expression of an allergen in DC in this model reduces the 
most profound pathological outcome in asthma. 
To some extent, the presence of neutrophil infiltrate in the BALF of the intranasally 
challenged mice is expected. Significantly, neutrophil infiltrates were more profound in recipients 
of OVA+ve BM which could be due to a shift in balance to a Th1 response, taking into 
consideration that the Th2 response has been reversed in those mice. Several studies demonstrate 
that a robust airway eosinophilic response is generated post challenge in OVA/alum i.p. sensitised 
mice regardless of the mouse strain (Eisenbarth et al. 2008, Conrad et al. 2009). Nevertheless, 
OVA/alum i.p. sensitised C57Bl/6 mice exhibit a mixed eosinophilic/neutrophilic inflammatory 
profile in the airways after acute antigen challenge (Zhao et al. 2013). The eosinophilic/neutrophilic 
inflammatory profile is also seen in OVA/alum i.p. sensitised BALB/c mice where equal ratios of 
eosinophils and neutrophils were recovered in the BALF (Nakada et al. 2014). This did not affect 
the inflammatory response and both antigen and adjuvant-dependent increases in AHR were 
observed due to elevated levels of IL-4 and IL-13 (Wills-Karp et al. 1998, McKinley et al. 2008, 
Nakada et al. 2014). Studies using DO11.10 mice even show that the activation of Ag-specific 
CD4
+
 T cells in the airways in response to allergen inhalation recruits neutrophils into the lung due 
to the up-regulation of neutrophil chemokines (Nocker et al. 1999, Knott et al. 2001). The impact of 
the environment, especially the effect of lipopolysaccharide (LPS) on neutrophilic influx and the 
Th2 response, in mouse models of allergic asthma has been incompletely resolved. Several factors 
such as timing, route and dose of LPS administration affect the outcome of experimental asthma. 
Low doses (<100ng) acted as an adjuvant in promoting a Th2 response (Eisenbarth et al. 2002, 
Eisenbarth et al. 2004). Intraperitoneal administration of higher doses (100ng–1μg/mouse) before 
OVA sensitisation reduced the Th2 response, but did not affect AHR even if LPS was introduced 
during OVA challenge (Delayre-Orthez et al. 2005). Moreover, concomitant delivery of LPS (20ug) 
and OVA intranasally in OVA sensitised mice did not affect AHR, but suppressed airway 
eosinophilia, mucus and Th2 cytokine production (Rodríguez et al. 2003). A more recent study has 
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shown that intranasal administration of OVA with very low doses of LPS (≤10⁻³ μg) result in longer 
lived asthma features with associated Th2 cytokines and eosinophilia. However, higher doses of 
LPS (10⁻¹ μg; still environmentally relevant) resulted in shorter lived features with the display of 
Th-17 associated neutrophilia (Whitehead et al. 2014). Another study showed that, LPS in a dose-
dependent manner increases the frequency of CD11b
+
Gr1
int
F4/80
+
( Gr1
int
 cells) cells in the lung 
tissue of mice and this is dependent on TLR4 and the TLR adaptor protein, MyD88 (Arora et al. 
2011). LPS stimulation during allergen immunotherapies were shown to normalize TLR4 
expression on DC favouring Th1 responses allergic patients (Wang et al. 2013). Potential 
implications of monitoring TLR4 expression in allergic patients could benefit from the 
compensation of TLR4 agonists to enhance allergen immunotherapies (Wang et al. 2013). 
In the experiment studying the specificity of the antigen-encoding BM transfer, a weak 
OVA323-339 response was observed. Sensitizing the mice with OVA323-339 and RGP (ryegrass) 
simultaneously could have led to this dramatic effect. RGP being a potent activator can mask the 
effect of OVA323-339 by overwhelming the response due to the diversity of signals through TLR and 
dectin receptor. Another possibility could be the protease activity of Lol p 1- a major allergen in 
RGP. At least six allergen groups are reported to be present in Lolium perenne (ryegrass). One of 
them is Lol p 1(group 1) a glycoprotein that belongs to the expansins family of papain-related 
cysteine proteinases (Grobe et al. 1999, De Canio et al. 2009). Not only has cysteine protease 
activity been detected in ryegrass pollen, also it has been shown to exhibit peptidase activity due to 
serine proteases (Raftery et al. 2003) (reviewed by(Matsumura 2012)). Spontaneous cytokine 
production is present in the un-restimulated controls of OVA323-339+RGP/alum-sensitised mice that 
were intranasally challenged with RGP. The ongoing chronic activation of the lymphocytes in vivo 
following RGP administration could lead to a strong response in which cytokine secretion continues 
in vitro even in the absence of restimulation. The uptake of RGP by DC in vivo and its presentation 
in vitro leading to the activation of the T cells even in the absence of restimulation. Nevertheless, 
the experiment answers the question concerning the specificity of OVA encoding BM transfer 
which blocks OVA-specific responses, but the response to other irrelevant antigens is maintained.  
Cell -to –cell contact is needed for T-cell activation while B cells can act as potent APCs 
and are directly activated through the antigen (Rock et al. 1984, Baumgarth 2000).It has been stated 
that in order to achieve robust tolerance, both the T-cell and B-cell compartments need to be 
successfully tolerized. Moreover, suppression by regulatory T cells might be an efficient tolerance 
mechanism for Th-1 but not Th-2 mediated B-cell responses (Baranyi et al. 2013). The degree and 
type of tolerance achieved by molecular chimerism is influenced by the site of Ag expression. 
Clonal deletion or receptor editing of autoreactive B cells in the BM is the mechanism of central B-
cell tolerance toward surface Ags (Tiegs et al. 1993, Halverson et al. 2004). Somatic hypermutation 
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in a germinal centre could also alter the persistence of particular B cell specificities. Anergy is the 
other mechanism provoked in B cells toward soluble self antigens (Goodnow et al. 1988, Hartley et 
al. 1991, Gay et al. 1993). One of the studies has suggested that the absence of T-cell help maintains 
B-cell tolerance toward intracellularly expressed Ags (Taylor et al. 2012). Baranyi et al. also 
investigated the intracellular and membrane expression of allergen and the quality of tolerance 
induced. The conclusion was that surface exposure of allergens is crucial to achieve complete B-cell 
tolerance (Baranyi et al. 2013). In a previous study, Baranyi et. al demonstrated that allergen 
expression on the surface with persistent low-level chimersim was sufficient and required to induce 
tolerance in IgE- mediated allergy (Baranyi et al. 2012). 
Taken together, the data indicate a functional role of OVA encoding BMT under non-
myeloablative conditioning in which the expression and presentation by DC of OVA-derived 
peptides reversed OVA–specific Th2 responses. Recipients of OVA+ve BM were subsequently 
protected from developing airway inflammation. However, this did not eliminate immune responses 
to irrelevant allergens. The transgenic BM also reversed OVA-specific Th2 responses after the 
disease has been established and prevented the exacerbation of the pathological symptoms. 
Moreover, AHR the most important pathological readout was reversed after OVA-encoding BM 
transfer. 
4.4  Future directions 
The treatment “turned off” pre-existing and ongoing specific T-cell responses. Although the 
treatment prevented disease exacerbation and reduced airways hyper responsiveness, it appeared to 
have a more moderate effect on inflammatory cell infiltration to BAL. It also did not quite strongly 
influence mucus hypersecretion which may be directly dependent on local cytokine production, 
possibly through the effect of the innate system. The incomplete reversal of airways inflammation 
in mice with established disease could be addressed in further experiments by extending the 
recovery time after BMT and, also, by testing the effect on inflammation without i.n. challenges to 
determine if inflammation resolves. Other experiments could include combination therapies, such as 
combining antigen-encoding BM and steroid administration, to help reduce symptoms at the early 
stages of recovery. The efficacy of OVA-encoding BM transfer using immunosuppressants or 
chemotherapeutics in place of myeleoablation could potentially eliminate the partially- 
lymphopenic state that occurs after irradiation. Future directions of this work should include the 
study of the mechanisms of tolerance after the transplantation of OVA-encoding HSPC to non-
myeleoablatively conditioned mice with and without established airways inflammation. However, 
other models that use more clinically relevant allergens may help to confirm the applicability and 
relevance of the observations from the OVA model.  
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CHAPTER 5: 
DEVELOPMENT OF A GRASS POLLEN 
ALLERGEN-ENCODING LENTIVIRAL VECTOR 
FOR GENETIC ENGINEERING OF 
HEMATOPOIETIC STEM AND PROGENITOR 
CELLS 
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5.1 Introduction 
The previous chapter established the proof-of principle that transfer of antigen-encoding BM can 
induce antigen-specific tolerance in sensitised mice. Furthermore, this treatment alleviates airways 
pathology elicited by allergen exposure. In this chapter, I establish a model of grass pollen allergy 
that is amenable to testing the therapeutic effects of gene-engineered BM transfer. In order to 
exploit this, the approach for gene-engineering of BM or hematopoietic stem and progenitors cells 
(HSPC) will be to transducer these cells with lentiviral vectors rather than use transgenically-
modified cells as described in the previous Chapters. This model can be utilized in the future to test 
the universal applicability of lentivirus-mediated treatment for allergic diseases.  
In cool temperate climates such as in southern Australia, where rain-storms and gusty winds are 
more frequent, grass pollen is a major cause of seasonal allergy (Knox et al. 1996). Surveys from 
several countries have shown that serum antibodies specific to grass pollen allergens were present 
in approximately 35% of the population of young adults ((Burney et al. 1997, Andersson et al. 
2003) and reviewed by (Davies 2014)). Murine models using pollen allergens have been developed 
to explore allergen-specific IgE responses and Th2 responses (Seitzer et al. 2003, Seitzer et al. 
2003, Scheiblhofer et al. 2007, Danilowicz-Luebert et al. 2013). The world’s most economically-
important and clinically-significant temperate grass is ryegrass (Lolium perenne) (Jauhar) and it is 
the major outdoor aeroallergen in temperate regions of Australia (Davies et al. 2012). One of the 
principal allergenic determinants in ryegrass pollen (RGP) is Lol p 1 (Freidhoff et al. 1986, Perez et 
al. 1990, IUIS/WHO 1994). Lol p 1-specific IgE is present in sera of 95% of patients allergic to 
grass pollen (Kahn et al. 1986). In humans, T-cell reactivity to Lol p 1 was investigated in a study 
which showed several regions in Lol p 1 are highly recognized by T cells with a 79% antigenic 
recognition frequency (Burton et al. 2002). Moreover, cytokine responses from allergic RGP 
individuals showed IL-5 production was induced by immunodominant Lol p 1 peptides in cultures 
of RGP-specific T-cell lines generated from PBMC of those allergic patients (Burton et al. 2002). 
Although human studies have demonstrated IgE and Th2 responses specific to RGP, only limited 
studies have been performed in murine models. An early study showed T-cell response in lymph 
node cells prepared from RGP sensitised mice upon restimulation with RGP allergens in vitro 
(Cook et al. 1988). To examine the effect of an idiotypic antibody (290A167) on allergen specific 
IgE responses, one study showed downregulation of IgE specific responses to Lol p 1 after the 
administration of anti-Lol p 1 monocolonal antibody (Boutin et al. 1995). Another study 
investigating the effect of innate type 2 responses to a fungal allergen in a model of ryegrass-
induced lung inflammation, demonstrated robust adaptive Th2-driven responses to RGP (Kim et al. 
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2014). With these considerations, development of a ryegrass pollen-based model might provide 
useful opportunities to test potential therapies.  
Targeting antigen expression to DC in steady state conditions as discussed in the previous two 
chapters is crucial to induce tolerance to reverse allergic responses while ensuring high levels of 
BM engraftment under non-myeloablative conditioning. In allergy, some studies have reported 
tolerance induction in murine models of asthma, but without restricting antigen expression to DC. 
One study showed induction of permanent tolerance to a grass pollen allergen Phl p 5 in mice that 
received retrovirally-transduced HSC that encode for untargeted membrane-expression of Phl p 5 
(Baranyi et al. 2008). This was followed by another study based on the same concept, but using an 
allergen from birch tree pollen, Bet v 1. The latter study demonstrated allergen-specific tolerance in 
mice that were treated with BM cells retrovirally-transduced to encode Bet v1-GFP (Gattringer et 
al. 2013). The two studies used untargeted allergen expression to induce tolerance under 
myeloablative conditions.  
Over the last decade, lentiviral vectors have evolved to become promising tools for stable gene 
transfer into mammalian cells. An important target cell population in gene therapy applications is 
hematopoietic stem cells (HSC). After genetic engineering and engraftment in host animals, the 
inserted genetic information is passed to progeny cells. HIV-1-based lentivirus vector transduction 
of HSC and subsequent transplantation can lead to long-term expression of transgenes in 
hematopoietic lineages (reviewed in (Cockrell et al. 2007)). For instance, transduction of HSC with 
a lentivirus containing a WT β-globin gene led to long-term expression in transplanted mice and 
elimination of sickle cell disease (Pawliuk et al. 2001). Lentiviral vector gene therapy has been the 
subject of investigation in multiple diseases over the past 10 years. Hemophilia, being one of those 
diseases, has had successful attempts of lentiviral gene therapy treatment in animal models, but no 
clinical trial reports registered (reviewed in (High et al. 2014)). Up to this date, there hasn’t been a 
study incorporating lentiviral vectors encoding targeted expression of allergen to DC into HSPC 
transfer under non-myeloablative conditioning as a potential therapeutic strategy for allergies. To 
test this in a murine model, the use of allergen-encoding lentiviral vectors is required to transduce 
HSPC that will then be injected into mice which provides long-term tolerance to the allergen of 
interest. In this chapter, Lol p 1 is the allergen of interest. 
The first goal of this chapter was to develop a robust murine model of Lol p 1-elicited airway 
inflammation in which therapeutic strategies could be tested. To define this I investigated allergen-
specific Th2 responses after ryegrass pollen sensitisation and subsequent airway inflammation that 
occurs through intranasal challenges with Lol p 1. The second goal of the studies described in this 
Chapter was to develop and produce a lentivirus vector encoding Lol p 1 which could be used to 
test therapeutic strategies in conjunction with the model developed as the first goal of these studies. 
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5.2 Results 
5.2.1 Ryegrass extract is highly allergenic in BALB/c mice 
As a first step to developing a model of Lol p 1-elicited airway inflammation, I first wished 
to determine whether Lol p1 is allergenic in BALB/c mice. To test this, BALB/c mice were sham- 
sensitised (saline/alum) or sensitised (ryegrass pollen extract (RGP)/alum) by i.p. injection. Seven 
days later, spleen cells from sham-sensitised and sensitised mice were harvested, single cell 
suspensions prepared, and these were stimulated or not with 20µg/ml or 50µg/ml of RGP and 
culture supernatants collected after 3 days (Fig. 5.1A). Restimulation with 20µg/ml or 50µg/ml of 
RGP led to low, but detectable, levels of IL-13 and IL-4 in two out of four mice in the unsensitised 
group (Fig. 5.1C,D). For IL-5, cytokine production was low and near limit of detection in cultures 
of unsensitised mice (Fig. 5.1B). Restimulation with 50µg/ml led to substantial IL-13 and 
detectable IL-4 production in cultures prepared from sensitised mice relative to unsensitised 
controls (Fig. 5.1C,D). For IL-5, high levels were detected in the sensitised group although this was 
not statistically significant most likely due to the low numbers in each group tested (Fig. 5.1B). 
Moreover, it was notable that for the 20µg/ml restimulated cultures, the sensitised group produced 
high levels of cytokines compared to the unsensitised control group although this was not 
necessarily statistically significant (Fig. 5.1 B-D).  
Together, these data indicate that in BALB/c mice, RGP is allergenic. 
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Figure 5.1 Th2 cytokine production in response to RGP stimulation.  
(A) BALB/c mice were sham-sensitised (unsens:saline/alum) or sensitised (sen: RGP/alum) by 
i.p. injection. At day 7 post-sensitisation, spleens were collected and restimulated in vitro with 
20µg/ml or 50µg/ml of RGP extract. Three days later the supernatant was collected and (B) IL-5, 
(C) IL-13 and (D) IL-4 concentration was determined by ELISA. (Data are pooled from 2 
separate experiments. Each point represents an individual mouse n=4). Statistical test: unpaired 
t-test. (*p<0.05). 
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5.2.2 Intransal challenge with Lol p 1 induces airway inflammation in RGP-sensitised 
mice. 
The previous experiment demonstrated that RGP/alum sensitisation induces a Th2 response 
in BALB/c mice. Here, I determined whether intranasal administration of the major allergen in RGP 
extract, Lol p 1, to sensitised mice induces airways inflammation in RGP-sensitised mice.  
BALB/c mice were sham-sensitised (saline/alum) or sensitised (RGP/alum) and at days 
11,12,13,14 post-sensitisation mice were intranasally challenged, either with purified Lol p 1, or 
saline. One day after the last intranasal challenge, BALF, lungs, and blood were harvested. Cellular 
infiltrate in BALF was determined by flow cytometry, lung sections examined after by hematoxylin 
& eosin (H&E) or periodic acid-Schiff (PAS) staining, and IgE concentrations by ELISA (Fig. 
5.2A).  
Th2 T-cell responses to Lol p 1 were established along with other components of RGP by 
the i.p. RGP/alum sensitisation performed. Intranasal challenge with Lol p 1, therefore, likely 
allows a measure of the scale of Lol p 1–specific Th2 responses as indicated by development of 
airways inflammation after Lol p1 challenge. BALF was collected from allergen-challenged and 
unchallenged mice. The number and proportion of CD4
+
 cells in BALF was elevated only in 
sensitised, Lol p 1 intranasally-challenged mice (Fig. 5.2D,F). Moreover, the number and 
proportion of eosinophils in BALF were elevated only in the sensitised, Lol p1 intranasally- 
challenged mice (Fig. 5.2E,G). Lol p 1 intranasal challenges thus led to the trafficking of 
eosinophils in the airways of RGP/alum-sensitised mice, indicating the expansion of the localised 
Lol p 1–specific Th2 response in those mice. 
Histological analysis of lung sections showed substantial inflammatory cell infiltration near 
airways only in sensitised, Lol p 1 intranasally-challenged mice (Fig. 5.3A). Periodic Acid Schiff’s 
(PAS) staining showed goblet cell hyperplasia was prominent in airways also only in sensitised, Lol 
p1intranasally-challenged mice (Fig. 5.3B).  
Total serum IgE concentration as determined by ELISA did not substantially increase in 
sensitised, Lol p1 intranasally-challenged mice (Fig. 5.4B) and this might reflect a requirement for 
several sensitisations to lead to high levels of IgE production (Seitzer et al. 2003).  
A single rather than double i.p. sensitisation used in the previous chapters for OVA323-339 
could explain to some extent the somewhat higher levels of variability in the in vivo responses (esp. 
IgE) to Lol p 1. 
Together, these data show that Lol p1 reliably induces airway inflammatory responses in 
RGP-sensitised mice.  
  
119 
 
 
 
 
 
  
Figure 5.2 Lol p 1 intranasal challenge leads to substantial eosinophil infiltrate after RGP 
sensitisation.   
(A) BALB/c mice were sham-sensitised (saline/alum) or sensitised (RGP/alum) by i.p. injection. 
At days 11- 14 post-sensitisation the mice were challenged intranasally with purified Lol p1 
(20µg) or saline. One day after the last i.n. challenge mice were euthanized. BALF was collected 
and CD4
+
 T cells and eosinophils enumerated by flow cytometry. Representative gating strategy 
and FACS plots for (B) CD4
+
 T cells and (C) eosinophils are shown. Total number of (D) CD4
+
 
T cells and (E) eosinophils and percentage of (F) CD4
+
 T cells and (G) eosinophils in BALF 
were determined. (Data are pooled from 2 separate experiments. Each point represents an 
individual mouse n=4-5). Statistical test: ANOVA followed by Tukey’s post-test. (*p<0.05, 
**p<0.01) 
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Figure 5.3 Inflammatory cell infiltrate and mucus hyper secretion after Lol p 1 intranasal 
challenge in RGP-sensitised mice. 
BALB/c mice were sham-sensitised (saline/alum) or sensitised (RGP/alum) by i.p. injection. At 
days 11- 14 post-sensitisation the mice were challenged intranasally with purified Lol p1 (20µg) 
or saline. One day after the last i.n. challenge mice were euthanized lungs were collected, fixed, 
embedded and sectioned at 500 μm intervals and stained with (A) hematoxylin & eosin (H&E) 
or (B) periodic acid-Schiff (PAS). Bar= 50 μm (high power). (One airway from an individual 
mouse is shown). 
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Figure 5.4 Levels of IgE detected in serum of RGP-sensitised and Lol p 1 intranasally-
challenged mice.   
(A) BALB/c mice were sham-sensitised (saline/alum) or sensitised (RGP/alum) by i.p. injection. 
At days 11- 14 post-sensitisation the mice were challenged intranasally with purified Lol p1 
(20µg) or saline. One day after the last i.n. challenge mice were euthanized. Blood was collected. 
(B) IgE concentrations were determined by ELISA. (Data are pooled from 2 separate 
experiments. Each point represents an individual mouse n=4-5). Statistical test: ANOVA 
followed by Tukey’s post-test. 
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5.2.3 Optimization for the airway inflammatory response in sensitised mice 
So far, my studies have shown that RGP is allergenic in BALB/c mice, and that Lol p 1 
intransal challenges induce an airway inflammatory response in RGP-sensitised mice. However, 
one 4-day cycle of Lol p 1 challenge did not lead to a particularly strong eosinophilic response. 
Therefore, I tested a different intransal challenging regime that could lead to more robust 
eosinophilia in the airways. 
To determine whether two 4-day cycles (2x i.n.) of Lol p 1 intranasal challenge induced a 
robust localised allergic inflammatory response to respiratory allergen challenge, BALB/c mice 
were sham-sensitised (saline/alum) or sensitised (RGP/alum) at day 0. Eleven days later mice were 
challenged intranasally either with purified Lol p 1 or saline for two 4-day cycles (Fig. 5.5A). The 
two 4-day cycle challenge regime was compared to the one 4-day cycle regime (Fig. 5.5B). One 
day after the last intransal challenge, mediastinal lymph nodes, spleens, BALF, and lungs were 
collected. In vitro restimulated cultures of MLNs and spleens were analysed by ELISA, cytokines in 
BALF by ELISA, cellular infiltrate in BALF by flow cytometry and lung sections by periodic acid-
Schiff (PAS) staining (Fig. 5.5A,B). 
When restimulated with Lol p 1, high levels of IL-5 and IL-13 were produced in cultures 
prepared from MLNs of sensitised, Lolp1 intranasally-challenged mice regardless of whether it was 
a one 4-day or two 4-day cycle challenge regime (Fig. 5.5C,E). In contrast, IL-5 and IL-13was not 
produced in cultures from mice that were sensitised, intranasally-challenged with saline or from 
unsensitised controls (Fig. 5.5C,E). When MLNs were restimulated with RGP, IL-5 and IL-13 
production showed a similar pattern as described previously with Lol p 1 restimulations (Fig. 
5.5D,F). Next, cultures were established from spleen which is distant to the site of allergen 
exposure, but may reflect the systemic response. Restimulation of spleen cells with Lol p 1 led to 
little IL-5 and IL-13 production from cultures prepared from sensitised mice regardless of whether 
they were intranasally-challenged with Lol p 1 or RGP, or whether it was a one 4-day or two 4-day 
cycle challenge (Fig. 5.6C,E). Cytokine production was lower than what was seen with cultures 
from MLNs (N.B. Y-axis scale relative to Fig. 5.5). When restimulated with RGP, IL-5 was 
detected only in sensitised, Lolp1 intranasally-challenged mice regardless of whether it was a one 4-
day or two 4-day cycle challenge regime (Fig. 5.6D). For IL-13, cytokine production was evident in 
all challenged groups (Fig. 5.6F). Together, these data indicate Lol p1 challenge strongly amplifies 
the cytokine response in draining lymph nodes, but has much less effect on the splenic cultures. 
BALF was collected from allergen-challenged and unchallenged mice. ELISA revealed a 
slight increase in IL-5 and IL-13 levels in BALF of sensitised mice that received the two 4-day 
cycle Lol p 1 challenges in comparison to sensitised mice that received the one 4-day cycle Lol p 1 
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challenges (Fig. 5.7A,B). The number of CD4
+
 cells in BALF was elevated in sensitised, Lol 
p1intranasally-challenged groups in comparison to unsensitised controls (Fig. 5.8A). There was a 
two-fold difference in the number of CD4
+
 cells in BALF of sensitised mice that received the two 
4-day cycle Lol p 1 challenges in comparison to the ones that received the one 4-day cycle Lol p 1 
challenges (Fig. 5.8A). The proportion of CD4
+
 cells on the contrary showed no differences 
between any of the groups (Fig. 5.8B). The content of eosinophils in BALF was elevated in 
sensitised, Lol p1 intransally-challenged groups in comparison to unsensitised controls. A two-fold 
difference was seen in the number and proportion of eosinophils in BALF of sensitised mice that 
received the two 4-day cycle Lol p 1 challenges in comparison to the group that received the one 4-
day cycle Lol p 1 challenges (Fig. 5.8C,D). Flow cytometry dot plots showed minimal neutrophilic 
infiltrates for all intranasally challenged groups (data not shown). PAS staining showed goblet cell 
hyperplasia was prominent in airways of sensitised, Lol p1intranasally-challenged mice in 
comparison to unsensitised controls. The two 4-day cycles of Lol p 1 challenges again had a more 
intense effect on airway pathology which showed a stronger, more robust mucus hypersecretion 
than what was seen with the one 4-day cycle Lol p 1 challenges (Fig. 5.9).  
Overall the two 4-day cycles of Lol p 1 challenges induced a robust Lol p 1-specific Th2 
response, a strong eosinophilic response, and a profound goblet cell hyperplasia in RGP/alum-
sensitised mice. Taken together, the optimised regime, using a single sensitisation and 2 cycles of 
i.n. challenge will be used in future experiments. 
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Figure 5.5 Elevated production of Th2 cytokines in the site of local challenges with the 
allergen.   
(A) Two 4-day cycles (2x i.n.): BALB/c mice were sham-sensitised (saline/alum) or sensitised 
(RGP/alum) by i.p. injection. At days 11- 14 and days 19-22 post-sensitisation the mice were 
challenged intranasally with purified Lol p1 (20µg) or saline. (B) One 4-day cycle (1x i.n.): 
BALB/c mice were sensitised (RGP/alum) by i.p. injection. At days 11- 14 post sensitisation the 
mice were challenged intranasally with purified Lol p1 (20µg). One day after the last i.n. 
challenge mice were euthanized. MLNs were collected and restimulated in vitro with 20µg/ml 
RGP or 10µg/ml Lol p 1. Three days later the supernatant was collected and (C-D) IL-5 and (E-
F) IL-13 concentration was determined by ELISA. (Data are pooled from 1 experiment. Each 
point represents an individual mouse n=3).  
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Figure 5.6 No difference in Th2 cytokine production in stimulated splenocytes regardless of 
number of Lol p1 challenges. 
(A) Two 4-day cycles (2x i.n.): BALB/c mice were sham-sensitised (saline/alum) or sensitised 
(RGP/alum) by i.p. injection. At days 11- 14 and days 19-22 post-sensitisation the mice were 
challenged intranasally with purified Lol p1 (20µg) or saline. (B) One 4-day cycle (1x i.n.): 
BALB/c mice were sensitised (RGP/alum) by i.p. injection. At days 11- 14 post-sensitisation the 
mice were challenged intranasally with purified Lol p1 (20µg). One day after the last i.n. challenge 
mice were euthanized. Spleens were collected and restimulated in vitro with 20µg/ml RGP or 
10µg/ml Lol p 1. Three days later the supernatant was collected and (C-D) IL-5 and (E-F) IL-13 
concentration was determined by ELISA. (Data are pooled from 1 experiment. Each point 
represents an individual mouse n=3).  
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Figure 5.7 Presence of Th2 cytokines in BALF of Lol p 1 challenged and RGP-sensitised 
mice.   
Two 4-day cycles (2x i.n.): BALB/c mice were sham-sensitised (saline/alum) or sensitised 
(RGP/alum) by i.p. injection. At days 11- 14 and days 19-22 post-sensitisation the mice were 
challenged intranasally with purified Lol p1 (20µg) or saline. One 4-day cycle (1x i.n.): 
BALB/c mice were sensitised (RGP/alum) by i.p. injection. At days 11- 14 post-sensitisation the 
mice were challenged intranasally with purified Lol p1 (20µg). One day after the last i.n. 
challenge mice were euthanized. 1ml of BALF collected and (A) IL-5 and (B) IL-13 
concentration was determined by ELISA. (Data are pooled from 1 experiment. Each point 
represents an individual mouse n=3). Dotted line specifies detection limit. 
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Figure 5.8 A higher eosinophil proportion with 2x Lol p 1 intranasals than with 1 x Lol p 1 
intransals.   
Two 4-day cycles (2x i.n.): BALB/c mice were sham-sensitised (saline/alum) or sensitised 
(RGP/alum) by i.p. injection. At days 11- 14 and days 19-22 post-sensitisation the mice were 
challenged intranasally with purified Lol p1 (20µg) or saline. One 4-day cycle (1x i.n.): 
BALB/c mice were sensitised (RGP/alum) by i.p. injection. At days 11- 14 post sensitisation the 
mice were challenged intranasally with purified Lol p1 (20µg). One day after the last i.n. 
challenge mice were euthanized. BALF was collected and CD4
+
 T cells and eosinophils 
enumerated by flow cytometry. Representative gating strategy and FACS plots for CD4
+
 T cells 
and eosinophils is as shown in Fig. 5.2. Total number of (A) CD4
+
 T cells and (B) eosinophils 
and percentage of (C) CD4
+
 T cells and (D) eosinophils in BALF were determined. (Data are 
pooled from 1 experiment. Each point represents an individual mouse n=3). Total cell counts of 
BAL/ 3ml BAL fluid: no i.n group = 54±16; saline 2x i.n group = 109±55; Lol p 1 1x i.n group = 
977±642; Lol p 1 2x i.n group = 5463±3487 (each number represents the mean±SD of 3 mice/ 
group). 
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Figure 5.9 Robust mucus hyper secretion after 2x Lol p 1 intranasal challenge. 
Two 4-day cycles (2x i.n.): BALB/c mice were sham-sensitised (saline/alum) or sensitised 
(RGP/alum) by i.p. injection. At days 11- 14 and days 19-22 post sensitisation the mice were 
challenged intranasally with purified Lol p1 (20µg) or saline. One 4-day cycle (1x i.n.): 
BALB/c mice were sensitised (RGP/alum) by i.p. injection. At days 11- 14 post sensitisation the 
mice were challenged intranasally with purified Lol p1 (20µg). One day after the last i.n. 
challenge mice were euthanized. Lungs were collected, fixed, embedded and sectioned at 500 
μm intervals and stained with periodic acid-Schiff (PAS). Bar=1mm (low power) and 50 μm 
(high power). (One lobe from an individual mouse is shown). 
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5.2.4 Construction of grass pollen encoding plasmids  
The overall goal of the studies described in this Chapter was to generate lentiviral vectors that 
could be used to genetically engineer HSPC to encode allergens. To take advantage of the studies to 
date, lentivectors encoding OVA and Lol p 1 were generated. Given the shortcomings I discovered 
in using a truncated OVA transgene the lentivector(s) encoding OVA were constructed to encode 
full-length native OVA. The transferrin receptor (TfR) transmembrane glycoprotein (Vidal 1984) 
was used to ensure membrane expression of Lol p 1 and OVA for B cell recognition (explained in 
discussion). Therefore, I first designed and cloned constructs encoding TfR-OVA and TfR-Lol p 1. 
TfR-Lolp1 was constructed as a synthetic mini-gene based on the isoform protein sequence of 
Griffith et al. (Griffith et al. 1991). Codon usage was optimised for mouse expression using EnCor 
Biotechnology online Codon Optimisation Calculator (Appendix Fig.I.1-I.2). All construct 
planning used the codon-optimised sequence. TfR-OVA was also constructed as a synthetic mini-
gene. 
In order to allow a thorough analysis of the lentivector-encoded constructs and to provide 
flexibility and alternatives for cell-specific targeting of allergen expression Tfr-OVA and Tfr-lop1 
were inserted into two different lentiviral vector ‘transfer plasmids’. These are the plasmids that 
encode the genetic material to be packaged in the lentivirus. The first plasmid to have either of the 
inserts cloned into was pRRLsin.CMV.IRES.GFP (Fig. 5.11A). The cytomegalovirus (CMV) 
promoter is a constitutive mammalian promoter that drives ectopic gene expression in a wide range 
of mammalian cell types(Boshart et al. 1985). In this plasmid, TfR-OVA or TfR-Lolp1 was inserted 
between the CMV promoter and an internal ribosomal entry site (IRES). When these plasmids were 
transfected into cells, Lol p1 or OVA and the green fluorescent protein (GFP) would be co-
expressed. This series of plasmids was utilized to certify whether the inserts could function to 
enable expression of the encoded protein. The second plasmid series that I constructed had allergen 
gene sequences cloned into pRRLsin.11c960.ER-SIINFEKL.IRES.GFP.EF1α.td-Tomato (Fig. 
5.12A). Here, td-Tomato is under control of the human elongation factor-1 α (EF-1 α). When 
transfected into cells the construct would drive constitutive expression of the reporter gene td-
Tomato. On the other hand, the protein of interest is under a truncated CD11c promoter (11c960) 
(Ko et al. 2011) in this vector; expression of the allergen of interest and GFP expression is restricted 
to DC.  
Two restriction sites on the donor and recipient plasmids were employed for directional cloning, 
XbaI and MluI (Fig. 5.11-12A). It is important to mention that another XbaI site is present outside 
the designed TfR-Lol p1 and TfR-OVA constructs in the pUC57.TfR-Lol p1/ pUC57.TfR-OVA 
donor plasmids. This came about as the pUC57 plasmid used as a cloning plasmid has an additional 
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distal XbaI site in the multiple cloning sites used by the supplier to insert the synthesised constructs. 
When digested with XbaI, pUC57.TfR.Lolp1 preferentially cuts at the additional distal XbaI site, 
leading to inclusion of an extra 15 bases at the start of TfR.Lolp1 sequence.  
During the first step of cloning, the holding plasmids supplied by GenScript pUC57.TfR-Lolpl, 
pUC47.TfR-OVA, and the recipient pRRLsin.11c960 ER-SIINFEKL.IRES.GFP.EF1α.td-Tomato 
were digested with XbaI and MluI restriction enzymes. The digests were run on a 0.7% agarose gel 
and the images from the gel showed that the restriction digest formed two bands from each plasmid 
(Fig. 5.10A). The bands of interest cut from the gel were the 1120bp (TfR-Lolp1), 1520bp (TfR-
OVA), and 12700bp (pRRLsin. 11c960.IRES.GFP.EF1α.td-Tomato) for DNA extraction. The DNA 
extracted from the 1120bp band was ligated with the DNA extracted from the 12700bp fragment. In 
a separate ligation, the DNA from the 1520bp band was ligated with the DNA extracted from the 
12700bp fragment. The ligated samples were then transformed into E.coli DH5α and plated on LB-
agar containing ampicilin. The colonies that formed on the plates were selected and plasmid DNA 
was isolated from them to test for the presence of Lolp1 and OVA sequences in the transformants. 
The DNA isolated was restricted with the same restriction enzymes XbaI and MluI and confirmed 
on a 1% agarose gel (Fig. 5.10B). The agarose gel image clearly confirmed the presence of the 
1120bp (TfR-Lolp1), 1520bp (TfR-OVA), and 12700bp (pRRLsin. 11c960.IRES.GFP.EF1α.td-
Tomato) bands (Fig. 5.10B). Colony #4 (pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1α.td-Tomato) 
and colony #1 (pRRLsin.11c960.TfR-Lolp1.IRES.GFP EF1α.td-Tomato) were then sequenced to 
compare to the theoretical sequence. An additional 15 bases were observed after sequencing 
pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1α.td-Tomato (Appendix Fig. I.5) and the inclusion of 
those extra bases was due to the additional XbaI site in the pUC57 plasmid as mentioned earlier 
(Fig. 5.12B). The full cloning process was also done to generate the pRRLsin.CMV.TfR-
Lolp1.IRES.GFP and the pRRLsin.CMV.TfR-OVA.IRES.GFP plasmids. 
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Figure 5.10 Agarose gels for restriction digests. 
(A) Agarose gel for restriction digest of pUC57.TfR-Lolp1, pUC57.TfR-OVA and 
pRRLsin.11c960.SIINFEKL.IRES.GFP.EF1α-tdTomato by using XbaI and MluI restriction 
sites. (B) Agarose gel for restriction digests of pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1α-
tdTomato colonies #1-#6 and of pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1α-tdTomato 
colony#1 by using XbaI and MluI restriction sites. 
 
Lane1: hyperladder 1 
Lane2: pUC57.TfR-Lolp1 (XbaI/MluI) 
Lane3: pUC57.TfR-Lolp1 (undigested) 
Lane4: pUC57.TfR-OVA (XbaI/MluI) 
Lane5: pUC57.TfR-OVA (undigested) 
Lane6: hyperladder 1 
Lane7: pRRLsin.11c960.SIINFEKL.IRES.GFP.EF1a.Tdtomato (undigested) 
Lane8: pRRLsin.11c960.SIINFEKL.IRES.GFP.EF1a.Tdtomato (XbaI/MluI) 
A) 
B) 
1: pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1a.Tdtomato (XbaI/MluI) 
2: pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1a.Tdtomato undigested 
3: pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1a.Tdtomato (XbaI/MluI) 
4: pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1a.Tdtomato undigested 
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Figure 5.11 Cloning strategy for pRRLsin.CMV.TfR-Lolp1.IRES.GFP. 
(A) Cloning of TfR-Lolp1 or TfR-OVA sequence from pUC57.TfR-Lolp1 or pUC57.TfR-OVA 
into pRRLsin.CMV.IRES.GFP by using XbaI and MluI restriction sites. (B) Actual 
pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1α-tdTomato clone after sequencing.  
TfR.Lolp1 CMV 
pRRLsin 
IRES GFP 
pRRLsin 
TfR.OVA CMV 
pRRLsin 
IRES GFP 
pRRLsin 
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Figure 5.12 Cloning strategy for pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1α-tdTomato. 
(A) Cloning of TfR-Lolp1 sequence from pUC57.TfR-Lolp1 into 
pRRLsin.11c960.SIINFEKL.IRES.GFP.EF1α-tdTomato by using XbaI and MluI restriction 
sites. (B) Actual pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1α-tdTomato clone after sequencing 
with the inclusion of extra 15bp before TfR-Lolp1.  
Additional 15 bp between the 2 XbaI 
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5.2.5 TfR-Lol p 1 and TfR-OVA is expressed in mammalian cells 
To determine whether Lol p 1 or OVA is expressed in mammalian cells from the constructs 
designed and constructed, HEK293T cells were left un-transfected or transfected with 
pRRLsin.CMV.TfR-Lolp1.IRES.GFP or pRRLsin.CMV.TfR-OVA.IRES.GFP (Fig. 5.12A). One 
day later, the cells were harvested and lysed with RIPA buffer. Supernatant from cell lysates, RGP 
extract, and OVA protein were electrophoresed and immunoblotted with an anti-Lol p 1 monoclonal 
antibody, anti-OVA immune serum (anti-OVA), anti-β-actin, or without primary antibody as a 
control for non-specific binding of the secondary antibody. Immunoreactivity was detected by 
chemiluminescence (Fig. 5.13B-E). The CMV promoter is a constitutive mammalian promoter 
which drives expression of the protein of interest in cells. The presence of Lol p 1 was observed in 
the first 2 lanes (in which pRRLsin.CMV.TfR-Lolp1.IRES.GFP transfected HEK293T lysate and 
RGP extract was loaded respectively) on the immunoblot probed with anti-Lol p1 (Fig. 5.13B). The 
molecular weight (MW) of Lol p 1 is ~33kDa ((Cottam et al. 1986) and reviewed in (Andersson et 
al. 2003)). Consistent with this, the immunoreactive band in RGP displayed an apparent MW of 
approximately 33 kDa (lane 2) whereas the immunoreactive band from pRRLsin.CMV.TfR-
Lolp1.IRES.GFP lysate (presumptive TfR-Lol p1) had an apparent MW of approximately 44kDa 
(lane 1) (Fig. 5.13B). The difference in MW is consistent with the contribution of the approximately 
10kDa TfR component in the Tfr-OVA fusion protein. When OVA protein or lysates of 
untransfected HEK293T and pRRLsin.CMV.TfR-OVA.IRES.GFP transfected HEK293T cells 
(lanes 3, 4, and 5) were blotted with anti-Lol p 1, no staining was detected (Fig. 5.13B) indicating 
specificity of the anti-Lol p 1 mAb. Next, the presence of OVA was observed in the anti-OVA 
immunoblot in lanes 3 and 4 in which lysate from pRRLsin.CMV.TfR-OVA.IRES.GFP transfected 
HEK293T cells and OVA whole protein was loaded respectively (Fig. 5.13C). The molecular 
weight of OVA is ~45kDa (lane 4) and the molecular weight of TfR-OVA is ~55kDa (lane 3) (Fig. 
5.13C). Again this difference between MW is due to the fragment of transferrin receptor which 
contributes an extra 10kDa to the fusion protein. When ryegrass pollen extract or lysates of 
untransfected HEK293T, pRRLsin.CMV.TfR-Lolp1.IRES.GFP transfected HEK293T cells (lanes 
1, 2, and 5) were blotted with anti-OVA, no staining was detected (Fig. 5.13C). This indicated that 
the anti-OVA immune serum specifically interacts with OVA and that HEK293T cells can express 
functional immunoreactive OVA when transfected with pRRLsin.CMV.TfR-OVA.IRES.GFP as in 
the case of transfection with pRRLsin.CMV.TfR-Lolp1.IRES.GFP as stated above. As a measure of 
lysate loading in lanes 1, 3, and 5, amount of β-actin protein was determined based on similar 
appearance of β -actin bands (Fig. 5.13D). The equal band thickness indicated similar loading of 
lysates. Finally, the no 1
0
 control immunoblot did not show any unspecific binding of the secondary 
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antibody (Fig. 5.13E). This indicated that the secondary antibody used in anti-OVA immune serum 
immunoblot specifically detects the OVA-antibodies. 
Taken together, detection of Lol p1 or OVA in lysates of pRRLsin.CMV.TfR-Lolp1.IRES.GFP 
or pRRLsin.CMV.TfR-OVA.IRES.GFP transfected HEK293T cells demonstrated efficient protein, 
Lol p1 or OVA, expression in those cells. 
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3 4 
lane 1:  pRRLsin.CMV.TfR-Lolp1.IRES.GFP lysate 
lane 2: RGP extract 
lane 3: pRRLsin.CMV.TfR- OVA.IRES.GFP lysate 
lane 4: OVA 
lane 5: untransfected  293T lysate  
Figure 5.13 Western blots showing expression of Lol p 1 or OVA in mammalian cells. 
HEK293T cells were plated at day 0 in T25 flasks. At day 1, cells were either left un-transfected 
or transiently transfected (A) pRRLsin.CMV.TfR-Lolp1.IRES.GFP or pRRLsin.CMV.TfR-
OVA.IRES.GFP. Cells were harvested at day 4, washed and put in RIPA buffer. Supernatant 
from cell lysates, RGP, and OVA was immunoblotted with (B) anti-Lol p 1, (C) anti-OVA, (D) 
anti-β-actin, or (E) a no primary control. 
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5.2.6 TfR-Lol p 1 and TfR-OVA is expressed on the membrane of mammalian cells 
Transfecting HEK293T cells with pRRLsin.CMV.TfR-Lolp1.IRES.GFP or pRRLsin.CMV.TfR-
OVA.IRES.GFP demonstrated Lol p 1 or OVA expression in those cells. The importance of 
membrane expression to achieve complete T and B cell tolerance was first demonstrated by 
Goodnow et al. (Goodnow et al. 1988). Baranyi (Baranyi et al. 2013) then tested this in a BMT 
setting and showed that complete T and B cell tolerance is achieved only when the antigen of 
interest is expressed on the membrane. For this reason, the Lol p 1 and OVA cDNA were fused with 
the transmembrane portion of human transferrin receptor (TfR) to study membrane expression in 
this chapter.  
First, I tested if the Lol p 1 or OVA was expressed on the cell surface as intended by the 
inclusion of the TfR signal sequence. HEK293T cells were left un-transfected or transfected with 
pRRLsin.CMV.IRES.GFP, pRRLsin.CMV.TfR-Lolp1.IRES.GFP or pRRLsin.CMV.TfR-
OVA.IRES.GFP. One day later, the cells were harvested, stained for surface expression of Lol p 1 
and OVA. The stained, unfixed and non permeabilized cells were then analysed for surface 
expression of Lol p 1 or OVA and GFP expression by flow cytometry. Untransfected controls 
showed no GFP expression or specific staining with anti- Lol p1, and anti-OVA (Fig. 5.14A,B). 
Transfection with pRRLsin.CMV.IRES.GFP, pRRLsin.CMV.TfR-Lolp1.IRES.GFP or 
pRRLsin.CMV.TfR-OVA.IRES.GFP led to high GFP expression (Fig. 5.14A,B). However, only 
transfection with pRRLsin.CMV.TfR-Lolp1.IRES.GFP led to specific staining with anti-Lol p 1 
(Fig. 5.14A) and pRRLsin.CMV.TfR-OVA.IRES.GFP to staining with anti-OVA (Fig. 5.14B). 
This showed that TfR-Lolp1 and TfR-OVA were co-expressed with GFP and, as these were not 
fixed or permeabilized cells, that the inclusion of the TfR led to surface localisation of the proteins. 
To this point, analysis had been performed analysing only ‘live’ cells defined by PI exclusion. 
Inclusion of ‘dead’ (PI+ve) cells in the analysis of pRRLsin.CMV.TfR-Lolp1.IRES.GFP transfected 
cells revealed an additional population that stained for Lol p 1, but devoid of GFP expression (Fig. 
5.15A). However, this GFP
-ve
 APC
bright
 population was not present after isotype control antibody 
staining where a GFP
-ve
 APC
intermediate
 population was observed (Fig. 5.15B). This suggests that the 
GFP
-ve
 APC
bright
 population is dead cells expressing high levels of Lol p 1 or, perhaps, cell 
membrane fragments with embedded Lol p 1. Importantly, unstained and no primary antibody 
controls revealed the APC
intermediate
 population represented dead cells non-specifically binding 
streptavidin-APC (compare Fig. 5.15B to Appendix Fig.I.3). After transfection with 
pRRLsin.CMV.TfR-OVA.IRES.GFP the majority of cells were positive for both OVA and GFP 
expression and few dead cells were present (Fig. 5.15B). Taken together, inclusion of PI
+ve
 dead 
cells showed an additional population that appeared to be dead cells staining strongly for Lol p 1 
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but without GFP fluorescence. This could be due to high levels of Lol p 1 being toxic and leading to 
cell death with GFP degradation occurring as the cells died. In conclusion, Lol p1 or OVA is 
effectively expressed on the membrane of mammalian cells. However, the data also suggest high 
expression of Lol p 1 may be toxic in mammalian cells.  
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A) 
Figure 5.14 Membrane expression of Lol p 1 or OVA in mammalian cells verified by flow 
cytometry. 
HEK293T cells were plated at day 0 in T25 flasks. At day 1, cells were either left un-transfected 
or transiently transfected (A) pRRLsin.CMV.TfR-Lolp1.IRES.GFP or (B) pRRLsin.CMV.TfR-
OVA.IRES.GFP. Cells were harvested at day 4, and analysed by FACS. PI gated  
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Figure 5.15 Not APC targeted, high- membrane expression of Lol p 1 not OVA is slightly 
toxic in mammalian cells. 
HEK293T cells were plated at day 0 in T25 flasks. At day 1, cells were either left un-transfected 
or transiently transfected (A) pRRLsin.CMV.TfR-Lolp1.IRES.GFP or (B) pRRLsin.CMV.TfR-
OVA.IRES.GFP. Cells were harvested at day 4, and analysed by FACS. 
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5.2.7 Lentivirus production  
Having shown that Lol p 1 or OVA can be expressed on the membrane of mammalian cells 
under a constitutive promoter, I then studied the expression under a cell-type specific promoter. 
Since the interest of this project is to drive allergen expression in DC to achieve immune tolerance, 
pRRLsin11c960.TfR-Lolp1.IRES.GFP.EF1α.td-Tomato was constructed as shown in Fig. 5.12. In 
this vector, Lol p1 expression is under the control of the 11c960 promoter (Ko et al. 2011) that 
drives expression specifically in DC. For the purpose of future experiments to confirm the 
applicability and relevance of the observations from the OVA model, Lol p1 encoding lentivirus 
was produced as stated in materials and methods. HEK293T cells were used as the producer cells 
and were co-transfected with pRRLsin11c960.TfR-Lolp1.IRES.GFP.EF1α.td-Tomato, or 
pRRLsin11c960.TfR-OVA.IRES.GFP.EF1α.td-Tomato and the three packaging plasmids pRSV-
Rev, pMDG, and pRRE. The virus supernatant collected was PEG precipitated and stored in 
aliquots at -80
o
C. Each of the viruses produced were titrated as described in the materials and 
methods by transducing HEK293T and detecting td-Tomato expression. This revealed a typical titer 
of approximately 8x10
4
 transducing units/ml which was lower than expected. The low titer may 
decrease the likelihood of high transduction rates. To evaluate upstream factors that may have led to 
lower packaging efficiency, I then wanted to understand the influence of construct size on virus 
titer. As shown in Table 5.1 the length of the construct had a dramatic effect on the virus titre 
recovered from the standard production conditions. The difference in the length of the constructs 
(“payload”) between the two different plasmids pRRLsin.CMV.GFP and 
pRRLsin11c960.IRES.GFP.EF1α.td-Tomato appeared to lead to a dramatic reduction in virus titre 
(Table. 5.1). The change in insert length within the same plasmid 
(pRRLsin.11c960.IRES.GFP.EF1a.td-Tomato) did not lead to a difference in virus titer (Table. 
5.2). Therefore, the “payload” associated with the considerably larger construct that contains TfR-
Lol p 1 or TfR-OVA, is what contributed to the low virus titre and not the size of TfR-Lol p 1 or 
TfR-OVA by itself. I then tested the effect of interactions between plasmids and whether altering 
the ratio of ‘transfer’ plasmid to ‘packaging plasmids’ altered the outcome. First to test the effect of 
interactions, the transfection efficiency of each of the plasmids pRRLsin.CMV.GFP, 
pRRLsinCMV.TfR-Lolp1.IRES.GFP, or pRRLsin11c960.TfR-Lolp1.IRES.GFP.EF1α.td-Tomato 
with or without the packaging plasmids was measured. Co-transfection of the pRRLsin.CMV.GFP 
or pRRLsin11c960.TfR-Lolp1.IRES.GFP.EF1α.td-Tomato plasmids with the packaging plasmids 
increased the percentage of GFP or td-Tomato positives (~95% for both) in comparison to transfer 
plasmid alone (Table. 5.3). However, pRRLsinCMV.TfR-Lolp1.IRES.GFP transfection did not 
increase with the introduction of the packaging plasmids and the transfection-rate in general was 
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lower than the other two plasmids (Table. 5.3). This could be due to the high expression of Lol p 1 
driven under the CMV promoter as shown in Fig. 5.15A leading to higher cell death. Co-
transfection with the pRRLsin.CMV.GFP plasmid and the packaging plasmids introduced on the 
first day post-transfection a GFP
bright
 population in the producer cultures which was at a higher 
proportion to what was seen with the td-Tomato
bright
 population in the producer cultures of the other 
two plasmids (Table. 5.3). Second, to test whether altering the ratio of ‘transfer’ plasmid to 
‘packaging plasmids’ altered the outcome, I modified the amount of pRRLsin11c960.TfR-
Lolp1.IRES.GFP.EF1α.td-Tomato relative to the packaging plasmids in order to match the molar 
equivalence of pRRLsin.CMV.GFP plasmid. HEK293T cells were transfected with different 
amounts of the pRRLsin11c960.TfR-Lolp1.IRES.GFP.EF1α.td-Tomato plasmid while keeping the 
amount of the packaging plasmids constant. The intention was to increase the proportion of the td-
tomato
bright
 population in the producer cultures one day post-transfection to match the GFP
bright
 
population seen with pRRLsin.CMV.GFP transfected cells. Increasing the amount of transfer 
plasmid however lowered transfection rates and did not increase the td-tomato
bright
 cell population 
(Table. 5.4). Increasing the amount of transfer plasmid was toxic to the cells and did not improve 
the quality of the cultures or transfections. 
Taken together, the length of the construct to be packaged had a major effect on the virus titer 
and increasing transfer plasmid did not alter the outcome of transfection rates or the proportion of 
the GFP
bright
 population in producer cell cultures. In conclusion, further experiments need to be 
carried out to understand the reason behind these results and to optimize virus production.  
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Plasmid 
Length of 
construct 
(‘Payload’ 
including 
LTRs) 
Length of 
plasmid (bp) 
Virus titre 
TU/ml 
pRRLsin.CMV.GFP 3973 7457 2.7x10
7
 
pRRLsin11c960.SIINFEKL.IRES.GFP. EF1α.td-
Tomato 
7880 11340 9.98x10
4
 
pRRLsin11c960.TfR-Lolp1.IRES.GFP. EF1α.td-
Tomato 
8900 12360 8.07x10
4
 
pRRLsin11c960.TfR- OVA.IRES.GFP. EF1α.td-
Tomato 
9300 12780 8.81x10
4
 
Plasmid 
Insert Size of insert 
(bp) 
Virus titre 
TU/ml 
pRRLsin11c960.SIINFEKL.IRES.GFP. EF1α.td-
Tomato 
SIINFEKL 
100 9.98x10
4
 
pRRLsin11c960.TfR-Lolp1.IRES.GFP. EF1α.td-
Tomato 
TfR-Lolp1 
1120 8.07x10
4
 
pRRLsin11c960.TfR- OVA.IRES.GFP. EF1α.td-
Tomato 
TfR-OVA 
1520 8.81x10
4
 
Table 5.2 Effect of length of insert on virus titer of pRRLsin11c960….IRES.GFP.EF1α.td-
Tomato. 
Table 5.1 Effect of length of plasmid on virus titer.  
TfR.Lolp1 11c960 
pRRLsin 
IRES GF
P 
EF1α tdTomato 
pRRLsin 
TfR. OVA 11c960 
pRRLsin 
IRES GF
P 
EF1α tdTomato 
pRRLsin 
Figure 5.16 Length of plasmid, rather than length of insert, affects virus titer. 
HEK293T cells were used as producer cells for virus production for each of the above vectors. 
The virus supernatant collected was PEG precipitated and stored in aliquots at -80
 o
C. The virus 
was later titrated by transducing HEK293T cells. Analysis was done by FACS. Virus titer was 
calculated (Transducing unit (TU)/ml) then compared to length of plasmid and length of insert.  
 
A) 
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Plasmid 
DNA 
( µg) 
GFP or 
tdTomato 
+ve
 (%) 
with plasmid 
alone 
GFP or 
tdTomato 
+ve
 
(%) 
Cell viability post-
transfection 
*GFP or 
tdTomato 
intensity 
day1 post-
transfectio
n 
pRRLsin.CMV.GFP 6.6 71.24% 97% 31% 1:1 
pRRLsinCMV.TfR-
Lolp1.IRES.GFP 6.6  35% 23% 21% 3:1 
pRRLsin11c960.TfR-
Lolp1.IRES.GFP. 
EF1α.td-Tomato 
6.6  45% 94% 25% 2:1 
Plasmid 
DNA 
(µg) 
tdTomato 
+ve
 
(%)  
Cell viability 
post-
transfection 
*tdTomato 
intensity day1 
post-
transfection 
*tdTomato 
intensity 
day3 post-
transfection 
pRRLsin11c960.TfR-
Lolp1.IRES.GFP. 
EF1α.td-Tomato 
6.6 78% 30% 2:1 1:1 
9.9 47.4% 32.55% 3:1 1:1 
13.2 21.09% 39.69% 4:1 1:1 
16.5 51.43% 21% 2:1 1:1 
Table 5.3 Rate of transfection and cell viability of the three different plasmids.  
Table 5.4 Amount of DNA effect on transfection.  
Figure 5.17 Increasing DNA amount does not lead to higher transfection rate. 
HEK293T cells were used as producer cells for virus production for each of the above vectors. 
The virus supernatant collected was PEG precipitated and stored in aliquots at -80
 o
C. The virus 
was later titrated by transducing HEK293T cells. Analysis was done by FACS. Virus titre was 
calculated and comparisons according to td-tomato or GFP expression or intensity was made. 
(analysing parallels) 
 
* Ratio of intermediate GFP/ td-Tomato expressing producer-cell to bright GFP/ td-Tomato expressing producer-cell 
* Ratio of intermediate GFP/ td-Tomato expressing producer-cell to bright GFP/ td-Tomato expressing producer-cell 
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5.2.8 HSPC transduction and in vitro DC differentiation 
Hematopoietic stem and progenitor cells (HSPCs) provide a renewable source of immune 
and blood cells that regenerates the whole hematopoietic system. Lentiviral vectors are capable 
of transducing HSPCs, thereby facilitating the introduction of a transgene of interest. Long-
term transgene expression is then ensured in differentiated cells repopulating the hematopoietic 
system in conditioned recipients (Cui et al. 2002). The lentiviruses generated encode either Lol 
p 1 or OVA under the 11c960 promoter which restricts their expression to DC. The first 
parameter to test was the capacity of the lentivirus generated to transduce HSPCs. The next to 
test was whether transduced HSPCs differentiated in vitro to DC expressed Lol p 1 or OVA. c-
kit (CD117)-enriched hematopoietic stem and progenitor cells (HSPC) (Fig. 5.18C) were left 
untransduced or transduced with one of these lentiviruses: pRRLsin.CMV.GFP, 
pRRLsin11c960.TfR-Lolp1.IRES.GFP.EF1α.td-Tomato, or pRRLsin11c960.TfR-
OVA.IRES.GFP.EF1α.td-Tomato. Cells were harvested eighteen hours post-transduction and 
levels of transduction analysed by flow cytometry. Cells were also harvested six days post 
transduction, and GFP or td-Tomato and Lol p 1 and OVA membrane expression was analysed 
by flow cytometry. Eighteen hours post transduction, GFP expression indicated ~30% 
transduction rate with GFP plasmid-derived Lentivirus and td-Tomato expression indicated 
~50% transduction-rate with either of the td-Tomato plasmid-derived Lentiviruses (Fig. 5.19). 
However, six days post transduction around 4% GFP-expressing (Fig. 5.20) and 10-15% td-
Tomato expressing cells were present (Fig. 5.21A, 5.22A). Moreover, no Lol p 1 (Fig. 5.21B) 
or OVA (Fig. 5.22B) membrane expression was observed by surface staining. This might 
indicate that even though the lentivirus transduced HSPC the transgene did not get integrated 
for long term expression. Maintenance of in vitro cultures of HSPCs, generation of innate 
immune responses, and mutations in the lentiviral backbone might all be reasons behind this 
observation. 
The lentiviral vectors generated were capable of transducing c-kit-enriched HSPCs and 
those HSPCs successfully differentiated to DC in vitro. Although GFP or td-Tomato reporter 
transgene expression was observed transiently in these cells, long-term expression was not 
maintained and no membrane expression of Lol p 1 or OVA was detected. 
In summary, the data show that the plant allergen Lol p 1 induces a robust Th2 mediated airway 
inflammatory response in RGP sensitised BALB/c mice and can be used to generate a useful 
model in which to test therapeutic strategies. Transient transfections showed the plant protein 
Lol p 1 was effectively expressed as a membrane-bound protein by mammalian cells. Finally, a 
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lentiviral vector encoding Lol p 1 was capable of transducing HSPCs in vitro was successfully 
generated, although sustained transgene or reporter expression was not detected.  
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Figure 5.18 Purity of c-kit-enriched HSPCs. 
Representative plots of flow analysis of (A) Bulk bone marrow (B) c-kit-enriched HSPCs 
negative fraction and (C) ckit
+
 fraction.  
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Figure 5.19 GFP and td-Tomato expression day one post-transduction. 
c-kit-enriched HSPCs were left 1) untransduced or transduced with either 2) 
pRRLsin.CMV.GFP, 3) pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1a.td-Tomato, or 4) 
pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1a.td-Tomato Lentivirus. 18 hours post transduction 
cells were harvested, stained with lineage mix, and analysed for td-tomato or GFP expression by 
flow cytometry. (Representing results from two experiments) 
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Figure 5.20 GFP expression a few days post-transduction. 
c-kit-enriched HSPCs were 1) left untransduced or transduced with 2) pRRLsin.CMV.GFP 
Lentivirus. 18 hours post transduction the media was replaced with medium containing cytokine 
mix (SCF, GM-CSF, and TNF-α) for DC differentiation. At day 3 post-transduction the cells 
undergo another media change. 6 days post-transduction cells were harvested, stained, and 
analysed for td-tomato or GFP expression by flow cytometry. (Representing results from two 
experiments) 
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Figure 5.21 td-Tomato expression and Lol p 1 membrane expression a few days post-
transduction. 
c-kit-enriched HSPCs were 1) left untransduced or transduced with 3) pRRLsin.11c960.TfR-
Lolp1.IRES.GFP.EF1a.td-Tomato Lentivirus. 18 hours post transduction the media was replaced 
with medium containing cytokine mix (SCF, GM-CSF, and TNF-α) for DC differentiation. At 
day 3 post-transduction the cells undergo another media change. 6 days post transduction cells 
were harvested, stained, and analysed for (A) td-tomato, GFP, or (B) Lol p1 membrane 
expression by flow cytometry. (Gating strategy as in figure 5.18) (Representing results from two 
experiments) 
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Figure 5.22 td-Tomato expression and OVA membrane expression a few days post-
transduction. 
c-kit-enriched HSPCs were 1) left untransduced or transduced with 4) pRRLsin.11c960.TfR-
OVA.IRES.GFP.EF1a.td-Tomato Lentivirus. 18 hours post transduction the media was replaced 
with medium containing cytokine mix (SCF, GM-CSF, and TNF-α) for DC differentiation. At 
day 3 post transduction the cells undergo another media change. 6 days post-transduction cells 
were harvested, stained, and analysed for (A) td-tomato, GFP, or (B) OVA membrane expression 
by flow cytometry. (Gating strategy as in figure 5.18) (Representing results from two 
experiments) 
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5.3 Discussion 
Murine models have played a crucial role in providing insights on the complex 
immunological and pathophysiological mechanisms involved in the development of allergic 
responses. Acute-phase OVA-induced asthma models have delivered substantial knowledge 
concerning the Th2 phenotype and the airway inflammatory response in this disease. However, 
differences of those models to the clinic scenario in humans emphasize the fact that allergic 
asthma is a chronic disease with features indicating structural remodeling of the lung. 
Development of chronic OVA-asthma models provided an obvious improvement to acute-phase 
models. The fact remains that these models still face some practical restrictions in which 
inflammation becomes less severe after chronic OVA exposure (Swirski et al. 2002, Van Hove et 
al. 2007) and resolves after the cessation of allergen exposure (Kumar et al. 2004). Since OVA 
models do not always reflect clinical studies, OVA has been substituted with human-relevant 
allergens such as house dust mite (Der f 1) (Cates et al. 2004), birch pollen (Bet v 1) 
(Wiedermann et al. 1999), timothy grass pollen (phl p 5) (Linhart et al. 2007), olive pollen (Ole e 
1) (Batanero et al. 2002), and others. A major structural difference to OVA is that many 
clinically-relevant allergens are multivalent (Fedorov et al. 1997) and sometimes their 
dimerization leads to exclusive recognition by membrane-bound immune globuline (Ig)E (Scholl 
et al. 2005). Also many allergens are carried as part of complex biological sources with the 
capacity to engage innate immune receptors (reviewed by (Hosoki et al. 2015)). It is important to 
mention that sensitisation with allergen extracts might more closely resemble a clinical scenario 
as allergic individuals are typically reactive to a diverse repertoire of allergens rather than a 
single allergen as in OVA models. One of the major allergic sensitisations in cool temperate 
climates is to grass pollen (reviewed in (Andersson et al. 2003)) and this affects 20% of the 
general population and 40% of atopic individuals (Burney et al. 1997, D'Amato et al. 1998). In 
parts of Australia, Lolium perenne is considered a significant source of allergens (Smart et al. 
1979). Group 1 allergens such as Lol p 1 are the most important allergenic determinants 
(Tamborini et al. 1997). Clinically, around 95% of patients sensitive to grass pollen show IgE 
specific to group 1 grass pollen allergens (Freidhoff et al. 1986) reviewed in (Weber 2003, 
Taketomi et al. 2006). Thus the need to provide new strategies in the field of immune-therapy 
using a clinically relevant allergen led to the development of a Lol p 1 model in this chapter. 
The sensitisation and challenge protocol followed in developing the Lol p -1 model 
resembled that of the OVA-model in chapters 2 and 3. Grass pollen extracts represent a complex 
mixture of biological material with a heterogeneous selection of allergens that may contain up to 
50 antigens which defines their allergenic potency (Lowenstein 1986, Hoek et al. 1988). RGP 
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extract was used for i.p sensitisations here which eliminated the need for two i.p sensitisations, in 
contrast to when OVA323-339 peptide was used, for the purpose of inducing Th2 immune 
responses. The Lol p 1 model presented in this chapter showed a strong Th2 response 
characterized by IL-5 and IL-13 increased production in spleen and MLN cultures in response to 
RGP or Lol p 1 restimulation. Comparing RGP and Lol p 1 in vitro responses indicated that 90% 
of the response observed was attributable to Lol p 1 as it is predicted to be the major 
immunodominant allergen in RGP. The levels of IL-5 and IL-13 in the optimized regime were 
equivalent to what was seen in our OVA model. Previously, some reports have mapped T-cell 
epitopes of Lol p 1using T-cell lines (TCL), T-cell clones (TCC) or PBMC (Perez et al. 1990, 
Fard et al. 1993, Bungy et al. 1994, Spiegelberg et al. 1994). However, few studies have 
explored T-cell responses to Lol p 1, one of the major allergens of RGP. Th2-type cytokines 
were shown to be produced by Lol p 1-specific CD4
+
CD30
+
 T cells from the circulation of 
patients showing allergic symptoms during the grass-pollen season (Del Prete et al. 1995). IL-5 
and IFN-γ production was induced by immunodominant Lol p 1 and Lol p 5 peptides in a study 
using short-term T-cell lines from RGP allergic patients to characterize the human T-cell 
response to those allergens (Burton et al. 2002). In mice, an enhanced allergen-specific T-cell 
response was induced in vitro after the stimulation of lymph nodes, prepared from RGP 
sensitised mice, with ryegrass pollen allergens (Cook et al. 1988). In one study comparing the 
immunological properties of recombinant Lol p 1 with its natural counterpart, the T-cell response 
in mice was similar to that observed with the natural protein (Boutin et al. 1997). The Lol p 1 
model in the present study showed a reliable Th2 response demonstrating the allergenicity of 
RGP in BALB/c mice. In contrast to using one sensitisation with grass pollen extracts to assess 
Th2 responses, several sensitisations are required for the generation of profound allergen-
specific IgE responses. One study has shown that a similar IgE reactivity pattern as seen in 
humans to P.pratense (timothy grass) major allergens was seen in mice after the 5
th
 sensitisation 
(Seitzer et al. 2003). Another study showed that BALB/c mice sensitised systemically with 
P.pratense pollen extract precipitated with alum as an adjuvant produced optimal high levels of 
IgE after the 5
th
 sensitisation. Moreover, a non-specific IgE production, in those mice, was 
provoked by the adjuvant alone (Seitzer et al. 2005). This requirement for several allergen 
exposures for IgE development explains the absence of a strong IgE response in the model 
developed here where one or two exposures were used.  
Symptoms of allergic inflammation are also very important to be taken into account during 
the development of a model of allergy. In an rPhl p5/alum model, intraperitoneal sensitisations 
followed by intranasal Phl p 5 extract challenges induced a prominent airways inflammatory 
profile in BALB/c mice (Fuchs et al. 2008). A model of ryegrass-induced lung inflammation also 
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led to a profound eosinophilic lung inflammatory profile. This model implemented the 
intraperitoneal route for sensitisation of BALB/c mice with ryegrass/alum; sensitisation was later 
followed by intranasal administration of ryegrass extract. The protocol used in that model led to 
an increase in IL-5and IL-13 levels in BALF of those mice in addition to the development of 
robust airway eosinophilia, peribronchial infiltrate, and mucus production (Kim et al. 2014). My 
model showed similar outcomes which revealed the importance of RGP/alum sensitisation prior 
to intranasal challenges in order to drive an adaptive Th2 immune response.  
Delivering antigen(s) to steady state DC via the DEC-205, adsorptive endocytosis receptor 
(Jiang et al. 1995), which efficiently internalizes and delivers the antigen for MHC II 
presentation (Mahnke et al. 2000), led to T-cell unresponsiveness (Hawiger et al. 2001). B cell 
responses can be controlled, in some circumstances, by limiting T-cell help (Li et al. 2008). 
However, this is not always the case and cell intrinsic peripheral B-cell tolerance can be induced 
by expression of cognate antigen (Basten et al. 1991, Brooks et al. 1991). Membrane-bound 
expression of hen egg lysozyme was found to most effectively achieve peripheral B cell 
tolerance (Hartley et al. 1991). The study indicated that the complexity of the antigen recognized 
by B cells, whether it is monomeric or oligomeric, soluble versus highly multivalent and 
membrane-bound antigens, dictates the degree of antigen-receptor crosslinking on those cells 
(Hartley et al. 1991). Distant signalling consequences result in response to the various cross-
linking which lead to different cellular responses (Harnett et al. 1988, Ransom et al. 1988, Gold 
et al. 1990). In another study, peripheral B cell tolerance was also induced by membrane-bound 
H-2Kb targeted expression on liver and kidney cells in Fas-deficient MRL/ lpr.H-2(d) 
autoimmune-prone mice (Kench et al. 1998). It was inferred as well that different regulation 
processes take place to B cells that react to membrane autoantigens to those that have specific 
receptors to nuclear antigens (Kench et al. 1998). B cell activation can directly occur through the 
antigen itself (Rock et al. 1984, Baumgarth 2000). It was conferred in one of the studies that in 
an allergy model, B cells played a role in antigen presentation, and membrane expression of 
allergens on BM cells was crucial to induce complete B cell tolerance in addition to T-cell 
tolerance (Baranyi et al. 2013). The inclusion of the transmembrane portion sequence of the 
human membrane transferrin receptor upstream of the Lol p 1 sequence in the plasmid construct 
allowed for the membrane expression of Lol p 1 in pRRLsin.CMV.TfR-Lolp1.IRES.GFP 
transfected 293T cells. The human transferrin receptor (hTfR) is a type 2 transmembrane 
glycoprotein which binds and internalizes transferrin, the serum iron transport protein, for iron 
uptake into the cells (Vidal 1984). This transmembrane receptor is efficiently internalized and 
transported to endosomal compartments to be recycled (Dautry-Varsat et al. 1983, Stoorvogel et 
al. 1996). Thus, in the presented model, the TfR will insure membrane expression of Lol p 1 to 
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achieve B cell tolerance, in addition to the internalization of the allergen to be processed and 
presented on MHC II molecules for the induction of T-cell tolerance. High levels of Lol p 1 
expression driven under the CMV promoter was toxic to cells after plasmid transfection. The 
CMV promoter is known to drive strong constitutive expression in various mammalian cell lines 
(Boshart et al. 1985, Furth et al. 1991, Fitzsimons et al. 2002). However, for the purpose of gene 
therapy applications, a more controlled and cell specific promoter is favoured. The CD11c 
promoter, for instance, drives expression of transgenes in a regulated DC-specific manner 
(Brocker et al. 1997, Corbi et al. 1997, Jung et al. 2002). This defined the purpose of using the 
11c960 promoter (Ko et al. 2011) in the construction of the pRRLsin.11c960.TfR-
Lolp1.IRES.GFP.EF1a.td-Tomato plasmid to achieve tolerance due to targeted expression to 
DC. 
Lentiviruses have been used as tools for gene delivery and analysis of gene functions in both 
dividing and non-dividing cells. Recently, lentivirus-based gene delivery vectors became popular 
in the field of gene therapy mainly for their ability to deliver and integrate transgenes into non-
dividing primary cells resulting in sustained long-term expression. Lentiviruses have the capacity 
to accommodate transgenes up to ~10 kilobases (Kb) (De Meyer et al. 2006). However, the 
larger the insert, the lower the vector titers (May et al. 2000, Sinn et al. 2005) as seen with the 
pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1a.td-Tomato lentivirus generated in this chapter. 
Despite the low titer, the transduction efficiency of AUTOMACS enriched HSPCs with the 
pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1a.td-Tomato and the pRRLsin.11c960.TfR-
OVA.IRES.GFP.EF1a.td-Tomato vectors was >25% which is comparable to transduction 
efficiencies demonstrated in other studies (Di Nunzio et al. 2007, Su et al. 2008). However, GFP 
expression and td-Tomato expression was not maintained across the five-day in vitro cultures. 
Several reasons could be behind the loss of expression. Loss of expression, for instance, could 
have been due to the non-expressing population proliferating, overwhelming, and masking the 
expressing population. In the case of the pRRLsin.CMV.GFP lentivirus, another explanation 
could be introduced concerning the loss of GFP expression. The use of the cytomegalovirus 
(CMV) promoter has been shown to induce methylation-associated silencing leading to low-level 
GFP expression in some studies (Miyoshi et al. 1999, Brooks et al. 2004). Moreover, it has been 
shown that the strength of the CMV promoter varies between cell types (Qin et al. 2010), which 
to some extent explains it being silenced in some cells (Brooks et al. 2004, Meilinger et al. 
2009). Transcriptional silencing though does not explain the decrease in td-Tomato expression 
which is driven under the human elongation factor-1 α (EF-1 α) promoter. EF-1 α gene has 
housekeeping functions in all cells and induced-expression under this promoter does not 
stimulate physiological changes in cells thus avoiding the silencing effect seen with CMV viral-
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promoter (Kim et al. 1990, Wakabayashi-Ito et al. 1994, Goldman et al. 1996, Gopalkrishnan et 
al. 1999, Teschendorf et al. 2002). If promoter silencing is not the reason behind the dramatic 
decrease in GFP and td-Tomato expression, then opens a different area of discussion 
incorporating non-integrating lentiviral vectors and ex vivo maintenance of hematopoietic stem 
cells. First, lentiviral vectors have been shown to efficiently and stably introduce genes into cells 
for sustained expression. The genes become integrated into the host genome by the insertion of 
specific viral genomic sequences called long terminal repeats (LTR) recognized by the virus-
encoded integrase (reviewed in (Kulkosky et al. 1994, Hindmarsh et al. 1999)). Mutations in the 
integrase gene (Wiskerchen et al. 1995) or modifications of the LTR by methylation (Challita et 
al. 1995) lead to non-integrating vectors. One study has shown transient eGFP expression using 
non-integrating lentiviral vectors in which eGFP expression initially started at high levels and 
decreased to background in less than 30 days (Nightingale et al. 2006). Transient expression was 
also demonstrated in another study with the use of integrase-minus lentiviral vectors in which 
GFP expression dramatically decreased after transduction in two weeks (Farazmandfar et al. 
2012). Additionally, maintaining hematopoietic stem cells in vitro for transduction has been 
shown to have its own challenges. The main difficulty is preventing their differentiation in order 
to prevent the loss of the primitive HSC population in culture and compromise their 
reconstituting capabilities (Barquinero et al. 2000, Glimm et al. 2000). The possibility of 
preserving long-term HSC has been successfully achieved in a recent study utilizing an inhibitor 
which prevented the differentiation-associated trigger in those cells (Liu et al. 2015). Use of 
serum-free medium in HSC cultures is another way to avoid reduction in their multi-potency 
capabilities since the addition of serum was linked to the induction and acceleration of HSC 
differentiation (Barria et al. 2004, He et al. 2010). However, other issues concerning prolonged 
ex vivo cultures of HSPC and efficient gene transfer through lentiviral transductions have been 
discussed in a recent review (Kajaste-Rudnitski et al. 2015). These authors propose innate 
immune responses could be triggered by lentivirus transductions in HSPC thus leading to 
reduced transduction efficiency and poor gene transfer. Innate-immune mechanisms of activation 
rely on antiviral factors known as restriction factors (RFs) present in HSPC (Bieniasz 2004, 
Strebel et al. 2009). Restriction factors are known to be either expressed ubiquitously or are 
induced by danger signals mediated by toll like receptors (TLRs) and their activation affects the 
viral life cycle and the biological properties of the host cell (Kajaste-Rudnitski et al. 2010); also 
reviewed in (Yan et al. 2012, Towers et al. 2014). Taken together, the absence of integration, the 
rapid hematopoietic progenitor cell differentiation, or the induction of innate immune responses 
could potentially explain the dramatic loss of GFP or td-Tomato expression in Figure 5.17-5.22 
which imply either transient transfection of the lentiviral vectors or the transduction into cells 
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other than HSC which led to the loss of the transgene due to their lack of reconstitutive 
properties. Non-stable or failed integration of the transgene could be the reason behind the 
absence of Lol p 1 or OVA expression since no surface staining with anti-Lol p 1 or anti-OVA 
was observed. The antibodies used for surface staining can be considered as a better indicator of 
expression than GFP as a marker of expression in the pRRLsin.11c960.TfR-
Lolp1.IRES.GFP.EF1a.td-Tomato and the pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1a.td-
Tomato vectors. Firstly, GFP in this vector follows the reporter gene internal ribosome entry site 
(IRES). IRES-dependent second gene expression was shown to be variable (6 to 100%) and less 
efficient than cap-dependent first gene expression (Mizuguchi et al. 2000). Secondly, expression 
of Lol p 1 or OVA is induced by the 11c960 promoter which is truncated from the full CD11c 
promoter. Efficient expression of other proteins has been demonstrated using the CD11c 
promoter (Brocker et al. 1997, Kenna et al. 2010) although it wasn’t as strong as expression 
using the MHCII promoter (Kouskoff et al. 1993). Nevertheless, the 11c960 promoter hasn’t 
been tested in a lentiviral setting to assess its strength and functionality in inducing the 
expression of a plant allergen. The combination of all these factors make it difficult to point out 
the exact reason as to why GFP and td-Tomato was not sustained and Lol p 1 or OVA expression 
not detected. In conclusion, efficient lentiviral transduction and integration of the transgene in 
HSC is essential to achieve long-term expression in DC to induce tolerance. 
This chapter demonstrated that RGP is highly allergenic in BALB/c mice and that Lol p 1 is 
capable of inducing airways inflammation when introduced intranasally in RGP sensitised mice. 
IL-5 and IL-13 production indicated strong Th2 responses, while eosinophilia and mucus 
production verified airways inflammation development as a result of allergen challenge. In 
addition, an optimized sensitisation and challenge regime was generated in this chapter setting 
the base for a robust Lol p 1 model. The construction of Lol p 1 and OVA fused with the 
transmembrane portion of the human transferrin receptor, to insert into a self-inactivating (SIN) 
vector for the generation of a lentivirus encoding for expression under the 11c960 promoter, was 
achieved. The constructs were first tested using a plasmid with a constitutive promoter (CMV) 
and showed efficient surface expression when transfected into HEK293T cells. However, when 
it came to producing the lentivirus encoding allergen expression under the 11c960 promoter and 
testing its ability to induce membrane expression in DC a few issues were encountered. The first 
was the low virus titer. Other issues were the short term expression of the marker genes GFP and 
td-Tomato, and the absence of Lol p 1 and OVA surface expression in ex vivo HSPC cultures. 
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5.4 Future directions 
For future progress of the presented model sustained membrane expression of Lol p 1 is 
required to achieve long-term tolerance. Investigations are required to understand the reasons 
behind the issues observed in this chapter in order to accomplish the desired outcome. The EF1a-
Tdtomato portion in the pRRLsin.11c960.IRES.GFP plasmid can be cut off to reduce the size for 
a more efficient virus titer. The virus titer can then be determined by qPCR or ELISA. Another 
experiment that could be done is use pRRLsin.CMV.GFP vector from a different source to 
transfect HEK293Ts and check for sustained expression over several generational splits. Also a 
parallel analysis to be done would be to check for the presence of the transgene by qPCR to 
verify integration. As for HSPC cultures, different serum-free culture conditions can be tested to 
maintain those cells in the undifferentiated state as long as possible. Finally, the best experiment 
to conduct is to transfer the transduced HSPCs encoding the allergen of interest in mice and 
check for membrane expression of the allergen of interest in vivo. After showing that long-term 
expression can be achieved in vivo, the therapeutic aspect of this project can be tested to 
demonstrate the induction of tolerance in this model. 
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CHAPTER 6: 
CONCLUDING REMARKS 
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Allergic asthma is an inflammatory airway disease which results from dysregulated type 2 
immunity (reviewed by (Lloyd et al. 2010)). Exposure of the airways to aeroallergens such as house 
dust mites and pollens leads to the activation of Th2 CD4
+
 cells which secrete cytokines, such as 
IL-4, 5, and 13 that orchestrate the sequence of inflammatory responses that occur in atopic asthma 
(Larche et al. 2003). A crucial population of cells responsible for initiating the response to allergens 
is DC (Lambrecht et al. 2000). These antigen presenting cells normally exist as non-activated cells 
under steady-state conditions (Wilson et al. 2003). Only in the presence of sufficient maturation 
signals do they become activated to fully stimulate T cells (Garza et al. 2000, Sporri et al. 2005). In 
the absence of activation signals DC induce T-cell tolerance (Belz et al. 2002, Steinman et al. 
2003). Induction of immune tolerance has become a primary mechanism for the treatment of 
autoimmune diseases (reviewed in (Ten Brinke et al. 2014)). Allergen-specific immunotherapy has 
been used as a treatment for allergies for more than 100 years. However, this therapy does not 
effectively eliminate the cause of the disease which is the presence of the allergen-specific effector 
and memory T-cell repertoire. In addition it has other disadvantages one of which is noncompliance 
of patients to the treatment (Reisacher et al. 2013, Bender et al. 2014). The work described in this 
thesis addressed the possibility of a new tolerance-inducing gene-therapy based on targeting the 
allergen of interest to steady-state DC to eliminate allergen-specific T cells that underpin allergic 
airways disease. The current project investigated this concept in a clinically-oriented (ie 
therapeutic) approach which incorporated the use of allergen-encoding BM transfer under non-
myeloablative conditions. The present study also aimed to develop a grass pollen allergen-encoding 
lentiviral vector for genetic engineering of hematopoietic stem and progenitor cells for potential 
tolerogenic gene-therapy applications. 
The findings here proved the applicability of the approach tested. In Chapter 3, targeting 
OVA expression to DC prevented the induction of Th2 responses and protected mice from 
developing an allergic response to OVA challenge. This was extended in Chapter 4 by 
demonstration that transplantation of BM encoding OVA targeted to DC inactivated OVA-specific 
Th2 responses and reduced the symptoms of airway pathology and most importantly airway hyper 
responsiveness. Finally, in Chapter 5, the initial steps for the development of a new experimental 
model were established that permits future testing of the therapeutic effect for a clinically-relevant 
allergen, in this case Lol p 1. Robust Th2 and airway inflammatory responses were initiated in RGP 
sensitised and intranasally challenged mice with Lol p 1. The construction and use of the CMV 
promoter-controlled TfR-Lolp1 construct led to high membrane expression of this plant allergen in 
mammalian cells. As for the development of lentiviral vector encoding TfR-Lolp1 under the 11c960 
promoter, production of the lentivirus resulted in low virus particle titers. However, in vitro HSPC 
transductions with this lentiviral vector were successful despite reporter gene (Ef1α) expression not 
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being sustained in the cultures which aimed to differentiate those HSPC into DC. As this process 
has its own challenges it needs to be optimized for future experiments as discussed in Chapter 5. 
Several avenues still need to be explored to define the mechanisms of tolerance induction 
and the potential for therapeutic treatment of allergies, or as studied here, allergic airways disease. 
In Chapters 3 and 4, a minute Th2 response and eosinophilia was observed in 11c.OVA mice after 
OVA intranasal challenges, which was attributed to the development of a response to the portion of 
OVA (OVA1-118) not expressed as a transgene. One of the studies investigating OVA T-cell 
epitopes in BALB/c mice identified four new MHCII binding peptides, other than 323-339, one of 
which was in the region aa39-50 of the OVA molecule (Yang et al. 2009). Another study showed 
potential OVA T-cell epitopes, one being OVA26-40 (Mackenzie et al. 2013). The possibility of such 
determinants contributing to a Th2 response could have accounted for the low levels of cytokine 
production and eosinophilia upon OVA challenges in some instances. In order to overcome 
unwanted sensitisation (as seen in Chapters 3 and 4) to the portion of OVA (OVA1-118) that is not 
contained within the expressed fusion protein, future experiments testing the mechanisms of 
tolerance should be conducted with transgenically-expressed full-length OVA. Additionally, 
another factor to explore in future experiments would be the time required for the inflammatory 
response to resolve in the airways after BM transfer and the option of steroid administration for a 
short period as a combinational therapy. 
The clinical outcome of tolerance is the prevention of allergic symptoms upon allergen 
exposure. Allergen-specific immunotherapies can mainly induce tolerance by generating 
suppressive B cells and Treg (Akdis et al. 2014). Allergen specific Th2 cells skewed to Treg and the 
production of IL-10 from both Bregs and Treg can count for the decrease in IgE/IgG4 ratio during 
therapy (Akdis et al. 1998, van de Veen et al. 2013, Suarez-Fueyo et al. 2014). In addition to Treg 
induction, allergen immunotherapy was reported in some cases to reduce allergen-specific T-cell 
proliferation in HDM-allergic patients (Gardner et al. 2004). However, an important observation in 
atopic individuals which restricts efficacy of therapy through the effect of Tregs production is the 
difficulty in controlling proliferation of allergen-specific T cells and maintaining their unresponsive 
state (Jutel et al. 2003, Ling et al. 2004). One of the advantages of the approach explored 
experimentally in this thesis is eliminating those allergen-specific T cells, thus ensuring robust 
tolerance. In a recent study investigating the Timothy grass (TG) pollen proteins, 64 previously 
undescribed proteins, that were not allergens, were shown to induce Th2 responses independently of 
IgE reactivity (Schulten et al. 2013). Although T-cell and IgE reactivity often correlate 
(Hamelmann et al. 1997), studies have shown that in some instances they do not necessarily link to 
each other. Furthermore, antigen-specific IgE titers reported in some human studies were not 
associated with detectable T-cell responses (Wurtzen et al. 1998, Oseroff et al. 2012, Oseroff et al. 
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2012). The issue of whether additional T-cell epitopes could function separately to IgE reactive 
epitopes associated with an underlying T-cell response could have a major effect on the outcome of 
tolerance. For example, the development of allergic airway hyper responsiveness was induced by T 
cells in mice in the absence of IgE (Mehlhop et al. 1997, Vijayanand et al. 2012).This stresses the 
importance of eliminating the allergen-specific T-cell repertoire for example by using the approach 
discussed in this thesis without their necessarily being a need to eliminate all allergen-specific B 
cells, but rather eliciting B cells that produce IgG(4) blocking Ab.  
Antigen expression by DC is not restricted to specific DC subsets in the current study.  
While distinct differences exist in the capacity of different DC subsets to induce tolerance 
(reviewed in section 1.2.2) the findings of the current study indicate that the outcomes are 
independent of subset-specific effects. Future experiments could be performed, for instance, by 
targeting antigen to DEC205
+ 
(Ring et al. 2013). However, targeting antigen generally to all DC and 
rather than subsets may reduce the complexity of therapy. Antigen-specific tolerance has been 
demonstrated in studies targeting antigen generally to DC without specifically targeting any subset 
(Steptoe et al. 2007). Chapters 3 and 4 also showed the profound effect of targeting an antigen to 
DC and the transfer of transgenic BM in alleviating the symptoms of experimental allergic asthma. 
The major interest, however, is translating this strategy for practical, clinical application. Retroviral 
transduction of bone marrow cells and their transfer shown to induce tolerance for a range of 
antigens including allergens (Baranyi et al. 2008), neoantigens (Ally et al. 1995), alloantigens 
(Bagley et al. 2002), and self-antigens (Ko et al. 2010). However, lentiviral vectors may be more 
advantageous than retroviruses. Lentiviral vectors have the ability to integrate genetic material into 
non-dividing cells, such as quiescent HSC, with the result of want transgene expression (Ramezani 
et al. 2000, Salmon et al. 2000). Lentiviruses may be more suitable for future gene therapy although 
their use has been limited to date. The use of DC-specific lentiviral vectors has been demonstrated, 
in a mouse model, to induce antigen-specific using CD4
+
 TCR transgenic achieved cells (Dresch et 
al. 2008, Ko et al. 2011). Many questions, though, still need to be investigated for lentivirus use, at 
least for allergy treatments. Grass-allergic patients are typically sensitised to multiple pollen 
allergens. Two of the most frequently recognised temperate grass pollen allergens are group 1 (beta-
expansin proteins) and group 5 (ribonuclease) allergens (reviewed in (Andersson et al. 2003, 
Taketomi et al. 2006)). Tolerance induction in the diverse allergen-specific T-cell repertoire would 
require insertion of multiple allergens into a single lentiviral vector or the use of other strategies. 
IgE cross-reactivity between epitopes of allergens belonging to the same group usually exists 
depending on the degree of sequence homology between the molecules (Schenk et al. 1995, Weber 
2004). Taking advantage of this, inserting a common allergen for which there is cross-reactivity 
could be beneficial for the lentiviral strategy. One can justify the choice of group 1 allergen because 
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it is known to be a founder allergen; that is, it is one of the first allergens to elicit an IgE response 
prior to the onset of symptoms and disease progression (Hatzler et al. 2012). Group 1 allergens are 
also one of the most frequently recognised (Tripodi et al. 2012). To reduce the load on the lentiviral 
vector, what if one common immunodominant epitope is enough to induce tolerance to the several 
allergic responses? Is there a necessity to encode immunogenic determinants from several 
allergens? As discussed above, the T-cell and B-cell response is not restricted to only one 
immunodominant peptide in an allergen. The T-cell response is generated against a wide range of 
peptides and the diversity of the T and B-cell response might vary between individuals depending 
on HLA haplotypes and other variables. Other pertinent questions remain. Will the therapy be 
beneficial to the patients that have IgE specific to one allergen or to those that have IgE specific to 
different allergens? Finally, how likely would it be allowed to introduce a foreign antigen integrated 
into human cells and will patients with severe asthma be willing to go through that therapy? 
Many challenges to a clinically-approved lentiviral therapy for atopic asthma remain, but 
successful transplantation of lentiviral-transduced, syngeneic HSCT encoding DC-targeted antigen 
expression is achievable. Previous and current knowledge provided from experimental studies and 
clinical trials pave the way to a promising treatment to cure this complex disease. This thesis 
supported many previous findings and but also provided new and valuable information to build on. 
It also generated prospects to address and explore in the future. 
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1 TCTAGACGGG ACGGAGGACG CGCTAGTGTT CTTCTGTGTG GCAGTTCAGA 
51 ATGATGGATC AAGCTAGATC AGCATTCTCT AACTTGTTTG GTGGAGAACC 
101 ATTGTCATAT ACCCGGTTCA GCCTGGCTCG GCAAGTAGAT GGCGATAACA 
151 GTCATGTGGA GATGAAACTT GCTGTAGATG AAGAAGAAAA TGCTGACAAT 
201 AACACAAAGG CCAATGTCAC AAAACCAAAA AGGTGTAGTG GAAGTATCTG 
251 CTATGGGACT ATTGCTGTGA TCGTCTTTTT CTTGATTGGA TTTATGATTG 
301 GCTACTTGGG CTATTGTAAA GGGGTAGAAC CAAAAACTGA GTGTGAGAGA 
351 CTGGCAGGAA CCGAGTCTCC AGTGAGGGAG GAGCCAGGAG AGGACTTCCC 
401 TGCAATCGCC AAGGTGCCCC CCGGCCCCAA CATCACCGCC GAGTACGGCG 
451 ACAAGTGGCT GGACGCCAAG AGCACCTGGT ACGGCAAGCC CACCGGCGCC 
501 GGCCCCAAGG ACAACGGCGG CGCCTGCGGC TACAAGGACG TGGACAAGGC 
551 CCCCTTCAAC GGCATGACCG GCTGCGGCAA CACCCCCATC TTCAAGGACG 
601 GCAGAGGCTG CGGCAGCTGC TTCGAGATCA AGTGCACCAA GCCCGAGAGC 
651 TGCAGCGGCG AGGCCGTGAC CGTGACCATC ACCGACGACA ACGAGGAGCC 
701 CATCGCCCCC TACCACTTCG ACCTGAGCGG CCACGCCTTC GGCAGCATGG 
751 CCAAGAAGGG CGAGGAGCAG AAGCTGAGAA GCGCCGGCGA GCTGGAGCTG 
801 CAGTTCAGAA GAGTGAAGTG CAAGTACCCC GACGGCACCA AGCCCACCTT 
851 CCACGTGGAG AAGGCCAGCA ACCCCAACTA CCTGGCCATC CTGGTGAAGT 
901 ACGTGGACGG CGACGGCGAC GTGGTGGCCG TGGACATCAA GGAGAAGGGC 
951 AAGGACAAGT GGATCGAGCT GAAGGAGAGC TGGGGCGCCG TGTGGAGAAT 
1001 CGACACCCCC GACAAGCTGA CCGGCCCCTT CACCGTGAGA TACACCACCG 
1051 AGGGCGGCAC CAAGAGCGAG GTGGAGGACG TGATCCCCGA GGGCTGGAAG 
1101 GCCGACACCA GCTACAGCGC CAAGTGAACG CGT 
 
Start Lol p 1 
sequence 
TfR translation start 
MLUI restriction site 
XbaI restriction site 
Start of Transferrin receptor gene construct (5’UTR) 
Figure I.1 Annotated TfR-Lolp1 sequence. 
TfR-Lolp1 sequence is codon optimised for mouse using EnCor Biotechnology online Codon 
Optimisation Calculator for the Griffith isoform protein sequence (Griffith et al., FEBS, 
279:210-25 (1991)). All construct planning has used the codon-optimised sequence. 
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MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVT
KPKRCSGSICYGTIAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGTESPVREEPGE
DFPAIAKVPPGPNITAEYGDKWLDAKSTWYGKPTGAGPKDNGGACGYKDVDKAPFNG
MTGCGNTPIFKDGRGCGSCFEIKCTKPESCSGEAVTVTITDDNEEPIAPYHFDLSGH
AFGSMAKKGEEQKLRSAGELELQFRRVKCKYPDGTKPTFHVEKASNPNYLAILVKYV
DGDGDVVAVDIKEKGKDKWIELKESWGAVWRIDTPDKLTGPFTVRYTTEGGTKSEVE
DVIPEGWKADTSYSAK 
 
Figure I.2 Translated TfR-Lolp1 sequence. 
Translation of TfR-Lolp1 sequence. Note: Blue highlight is Transferrin receptor. 
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Un-stained 
(CMV.TfR-Lolp1.IRES.GFP) 
No 1
0
+streptavidin APC 
(CMV.TfR-Lolp1.IRES.GFP) 
Un-stained 
(CMV.TfR-OVA.IRES.GFP) 
No 1
0
+streptavidin APC 
(CMV.TfR-OVA.IRES.GFP) 
A) 
B) 
Figure I.3 Non-specific binding of streptavidin-APC to PI
+ve
 HEK293T cells. 
HEK293T cells were plated at day 0 in T25 flasks. At day 1, cells were either left un-transfected 
or transiently transfected (A) pRRLsin.CMV.TfR-Lolp1.IRES.GFP or (B) pRRLsin.CMV.TfR-
OVA.IRES.GFP. Cells were harvested at day 4, and analysed by FACS. 
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Figure I.4 Sequencing analysis of pRRLsin.11c960.TfR-OVA.IRES.GFP.EF1α.td-Tomato 
Sequence analysis confirms the inserted construct sequence conformed to the designed sequence.  
MluI restriction site 
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Theoretical sequence 
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Figure I.5 Sequencing analysis of pRRLsin.11c960.TfR-Lolp1.IRES.GFP.EF1α.td-Tomato 
Sequence analysis confirms the inserted construct sequence conformed to the designed sequence 
except for the inclusion of the 15 bp outside the TfR-Lolp1 coding region. 
MluI restriction site 
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XbaI restriction site 
Theoretical sequence 
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Start Lol p 1 
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Figure I.6 Sequencing analysis of pRRLsin.CMV.TfR-Lolp1.IRES.GFP. 
Sequence analysis confirms the inserted construct sequence conformed to the designed sequence.  
MluI restriction site 
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Figure I.7 Sequencing analysis of pRRLsin.CMV.TfR-OVA.IRES.GFP. 
Sequence analysis confirms the inserted construct sequence conformed to the designed sequence. 
MluI restriction site 
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Table I.1 Total BAL counts for Figure 3.12. 
 no sens/ no i.n no sens/ OVA i.n sham/OVA i.n OVAp/alum 
OVAi.n 
Non-transgenic 153±110 941±781 627±502 4564±3817 
Transgenic 137±92 1008±656 1422±1493 850±948 
 
  
Figure I.8 Total BAL counts. 
Non-transgenic or transgenic (11c.OVA) mice were sensitised with OVA323-339 (OVAp)/alum at days 
0 &14. Mice were then intransally challenged with OVA at days 25-28 & 33-36. One day after the 
last i.n. challenge mice were euthanized. Bronchoalveolar lavage fluid was collected and BAL cells 
enumerated by flow cytometry. Total BAL counts in 3 ml BAL fluid were determined. (Data are 
pooled from 4 separate experiments. Each value represents the mean±SD value of 6-12 mice per 
group).  
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Table I.2 Summary of results for Chapter 3. 
Group* 
1xOVA i.p 
 
1xOVA i.p 
 
1x OVA323-339 i.n. 
1xOVA i.p 
 
1x OVA i.n. 
2xOVA323-339 i.p 
 
 Non-
transgenic 
transgenic 
Non-
transgenic 
transgenic 
Non-
transgenic 
transgenic 
Non-
transgenic 
transgenic 
IL-5 
 
390±340 
pg/ml 
(SPL) 
141±117 
pg/ml 
(SPL) 
    102±46 
pg/ml 
(SPL) 
10±9.6 
pg/ml 
(SPL) 
IL-13 
 
304±194 
pg/ml 
(SPL) 
140±41 
pg/ml 
(SPL) 
    1308±1768 
pg/ml 
(SPL) 
253±154 
pg/ml 
(SPL) 
Eos #   0.4±0.15  1051±804    
CD4 #   1.02±0.21  94±34.8    
Eos%   0.8±0.4  62±9.4    
CD4%   1.5±0.5  6.2±1.4    
Total 
BAL 
counts 
  
81±55 
 
1620±913 
   
 
Group* 
2xOVA323-339 i.p 
 
1x OVA i.n. 
2xOVA323-339 i.p 
 
1x OVA i.n 
1x OVA323-339 i.n 
2xOVA323-339 i.p 
 
2x OVA323-339  i.n 
 
2xOVA323-339 i.p 
 
2x OVA i.n 
 
 Non-
transgenic 
transgenic 
Non-
transgenic 
transgenic 
Non-
transgenic 
transgenic 
Non-
transgenic 
transgenic 
IL-5 
 
      
245±191 
pg/ml 
(SPL) 
1435±1413
pg/ml 
(MLNs) 
 
11.1±4.9 
pg/ml 
(SPL) 
27±8.2 
pg/ml 
(MLNs) 
 
IL-13 
 
  
188±90 
pg/ml 
(SPL) 
157±40 
pg/ml 
(MLNs) 
77±20 
pg/ml 
(SPL) 
100±0 
pg/ml 
(MLNs) 
1179±619 
pg/ml 
(SPL) 
250±138 
pg/ml 
(MLNs) 
86±3.5 
pg/ml 
(SPL) 
87±0pg/ml 
(MLNs) 
1808±1181
pg/ml 
(SPL) 
11417±117
54 pg/ml 
(MLNs) 
125±51 
pg/ml 
(SPL) 
311±385 
pg/ml 
(MLNs) 
Eos # 23±13.5  289±370 0.7±0.08 76±153 0.8±0.08 
2944±333
8 
73±110 
CD4 # 18.4±14  90.7±95.7 1.9±0.5 28.5±33.6 1.4±0.3 328±215 105±158 
Eos % 7±2.6  25±19.2 0.75±0.2 13±18 1.5±1.2 47±22 7±5.8 
CD4% 6.3±2.8  12.2±3.3 2.7±1.5 11±9.1 3.2±2.5 8±2.4 11±6.7 
Total 
BAL 
counts 
266±84  746±787 79±27 270±180 69±65 
1119±126
1 
735±900 
 Figure I.9 Summary of Th2 cytokine responses and BAL cell counts and percentages. 
Each value represents the mean±SD value of mice per group (*only sensitised mice OVA/alum or 
OVA323-339/alum i.p. and intranasally challenged for non-transgenic and transgenic controls as 
indicated in the table) for the different sensitisation and challenge combinations. SPL=spleens; # = 
number; Eos=eosinophils; Eos # = eosinophil number; CD4 # = CD4
+
 T cell number; Total BAL 
counts = Total CD45.2
+
 cells in 3ml of BALF. IL-5 and IL-13 displayed from OVA323-339 
restimulated cultures. 
